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ABSTRACT 
Adenovirus E1A (AdE1A) is a viral oncoprotein that targets many cellular proteins and 
pathways, mainly those involved in transcriptional regulation. Proteasomes represent the 
major non-lysosomal mechanism responsible for protein degradation. Following 
interferon-γ treatment, three proteasome subunits are replaced by immunosubunits LMP2, 
LMP7 and MECL-1 producing immunoproteasomes. The proteasome and 
immunoproteasome generate peptide antigens for MHC class I presentation to cytotoxic 
T-cells. In this study, the effect of AdE1A on human immunoproteasomes as well as MHC 
class I and class II cell surface expression was examined. 
It was found that AdE1A interacts with the immunoproteasome subunit MECL-1 through 
its N-terminal and CR3 regions. AdE1A also down-regulated all three immunosubunit 
expressions during adenovirus infection, transformation and AdE1A transfection, with the 
exception of Ad5-transformed cells where immunosubunit expression remained 
unchanged. Furthermore, MHC class I expression remained unaffected in the same three 
backgrounds. However, in the Ad12 transformants MHC class I was generally reduced 
prior to IFNγ treatment but was expressed after. MHC class II surface expression, in 
contrast, was down-regulated in all cases, except in Ad5 infected cells. Similarly, AdE1A 
reduced IFNγ-stimulated STAT1 phosphorylation and transcriptional response to IFNγ. 
And finally, T-cell recognition of target cells was reduced in the presence of AdE1A. 
In conclusion, AdE1A targets the human immunoproteasome, both through direct binding 
and down-regulation of expression. It also targets the expression of MHC class I and class 
II surface expression. 
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1.1 Cancer 
Cancer is a disease that generally occurs as a result of damage to genes encoding 
components of the highly regulated pathways of cell proliferation and cell death. This 
involves genetic mutations that lead to the stabilisation and gain of function of oncogenes 
or the inactivation and hence loss of function of tumour suppressors. Evidence shows that 
cancer is a multistep process where the accumulation of multiple mutations in key 
regulatory genes that control cell proliferation, differentiation and survival, drives a normal 
cell to a “cancer state” (Vogelstein and Kinzler 1993; Hartwell and Kastan 1994; Hahn and 
Weinberg 2002). There are more than 100 distinct types of cancer and during their 
development, most cancer cells have acquired six capabilities; namely self-sufficiency in 
growth signals, insensitivity to anti-growth signals, evasion of apoptosis, unlimited 
replication,  sustained angiogenesis and local tissue invasion leading to metastasis 
(Hanahan and Weinberg 2000; Hanahan and Weinberg 2002;  Hanahan and Weinberg 
2002).  
 
1.2 DNA tumour viruses 
DNA tumour viruses are a diverse group of viruses that can cause transformation and in 
some cases cancer by targeting common cellular proteins involved in tumour suppressor 
activity and/or growth regulation. It has been found that 15-20% of global cancer incidence 
is linked to viral infection (zur Hausen, 1991; Pagano et al., 2004; McLaughlin-Drubin and 
Munger, 2008). Examples of DNA tumour viruses include adenovirus (Berk 2007), 
Hepatitis B virus, HBV (Seeger et al., 2007), human papillomaviruses, HPV (Howley and 
Lowy 2007; Beaudenon et al., 1986, de Villiers et al., 2004). Other DNA tumour viruses 
also include certain members of the Herpes family of viruses such as Epstein-Barr virus, 
EBV (Epstein et al., 1965, de-The et al., 1978; Kieff and Rickinson 2007), 
Cytomegalovirus, CMV (Mocarski et al., 2007) and Kaposi’s sarcoma-associated 
herpesvirus, KSHV (Ganem 2007; Arvanitakis et al., 1997; Bais et al., 1998), as well as 
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members of the polyomavirus family, for instance, Merkel Cell polyomavirus (Houben et 
al., 2009), simian virus 40 (SV40; Ahuja et al. 2005), BK and JC (John Cunningham) 
viruses (Imperiale and Major 2007).  
DNA tumour viruses have long been useful tools in the study of cellular transformation 
and understanding the biology of cancer. Two important tumour suppressor proteins 
retinoblastoma (pRB) and p53 are targeted by oncoproteins produced by most DNA 
tumour viruses. In addition, other cellular regulatory and transcriptional proteins are also 
deregulated through the activities of their tumour antigens. To state a few examples, the 
p53 pathway is targeted by HPV E6. HPV E6, in cooperation with a cellular protein termed 
E6 associated protein (E6-AP), target the p53 protein for very rapid ubiquitin-dependent 
degradation (Scheffner et al., 1993), as a result eliminating the transcriptional repression 
and pro-apoptotic effect of p53.  p53 is also targeted by adenovirus E1B 55k and E4ORF6 
for ubiquitin dependent degradation (Querido et al., 2001; Harada et al., 2002; Blanchette 
et al., 2008; Steegenga et al., 1998). Additionally, HPV, adenoviruses and SV40 drive 
quiescent cells into the proliferative state by inactivating pRB signalling through their 
oncoproteins thus allowing replication of the viral genome (Dyson et al., 1989; Munger et 
al., 1989, Massimi and Banks, 1997). EBV latent membrane protein 1 (LMP1) induces the 
expression of the anti-apoptotic genes Bcl-1 and A20, thus inhibiting p53 induced 
apoptosis (Fries et al., 1996) and also repressing p53 dependent DNA repair, 
subsequently affecting genome stability, as a result contributing to oncogenesis (Liu et al., 
2005). The SV40 T antigen binds and inactivates the transcriptional transactivation 
function of p53 (Mietz et al., 1992; Lane and Crawford, 1979; Linzer and Levine, 1979). It 
also binds and inactivates Rb protein thus inhibiting its function as a promoter of cell cycle 
arrest (Lee and Cho 2002). The LANA protein expressed by KSHV can bind p53 hence 
reducing the activation of p53 mediated gene expression increasing resistance to p53-
dependent apoptosis (Friborg et al., 1999).  LANA also binds to pRB, functionally 
inactivating it, as demonstrated by the increased upregulation of E2F in LANA-transfected 
cells (Radkov et al., 2000). Direct mechanism of how the HBV virus contributes to 
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hepatocellular carcinoma is not entirely known. However, there is evidence that 
integration of HBV DNA into the cell genome (Esumi et al., 1986), as well as the anti-DNA 
repair and anti-cell cycle control activities of the viral protein HBx (Lee et al., 1995; 
Sitterlin et al., 2000; Kim et al., 1991) may contribute to the oncogenesis. Merkel Cell 
polyomavirus large T-cell antigen targets pRB function by directly binding to it as it 
possesses an LXCXE motif (Feng et al., 2008).  Similarly, BK and JC viruses, express the 
small and large T-antigens, that target pRB and p53 proteins, deactivating them and 
eventually forcing the cell to enter the S-phase (Imperiale and Major 2007; Moens et al., 
2007; Caracciolo et al., 2006). And very recently, cytomegalovirus (CMV) has been 
implicated in mucoepidermoid carcinoma of salivary glands (Melnick et al., 2011), and 
hence labelled a DNA tumour virus. The adenovirus E1A protein is also known to bind to 
the transcriptional regulators p300, p400, CtBP and pRB family members p107 and p130 
(Turnell and Mymryk 2006), overall promoting cell growth. More details of adenovirus and 
its biological activity will be discussed in the following sections. These different viral 
manipulations eventually lead to the promotion of viral replication in a lytic infection or 
interference with the cell’s ability to regulate and control its division and growth during 
transformation. 
 
1.3 Adenovirus (Ad) 
Adenoviruses are medium sized, non-enveloped icosahedral viruses that are composed of 
a nucleocapsid and a DNA genome (Berk 2007). They were first discovered and 
characterised in the 1950s (Row et al., 1953, Hilleman and Werner 1954, Huebner et al., 
1954) and named because they were initially found in human adenoid tissue (Enders et 
al., 1956). Adenovirus is a frequent cause of acute respiratory tract as well as 
gastrointestinal tract infections, and this is especially common in children. Studies show 
that 5-15% of acute upper respiratory tract infections and about 5% of lower respiratory 
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tract infections are caused by adenoviruses (Avila et al., 1989; Edwards et al., 1985; 
Gardner, 1968; Hong et al., 2001; Kim et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While these infections are generally of a mild nature in immunocompetent individuals, they 
can cause severe forms of diseases such as childhood bronchiolitis, asthma and chronic 
obstructive pulmonary disease (COPD) in adults as well as acute febrile pharyngitis and 
pharyngeal-conjunctival fever in infants (Matsuse et al., 1992; Macek et al., 1994; Elliot et 
al., 1995; Vitalis et al., 1998). Other infections caused by adenoviruses include acute 
follicular conjunctivitis, keratoconjunctivitis cystitis, tonsilitis and gastroentitis (Figure 1.1). 
Adenovirus infection can be transmitted via respiratory droplets, conjunctival and faecal-
oral route with incubation periods ranging from 2 to 14 days. 
 
 
 
Figure 1.1 Adenovirus infection symptoms 
 
A:    Electron micrograph of Adenovirus 
B.   Conjunctivital haemorrhage on the left eye 
from an adenoviral infection (from 
http://www.eyeupdate.com/pages/adenoviral_in
fections.html) 
C:   A case of Tonsilitis - inflammation of the 
tonsils (from http://www.consultantlive.com) 
A B 
C 
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1.3.1    Classification 
The family Adenoviridae is comprised of five clades (groups of viruses sharing a common 
ancestor) (Davison et al., 2003). Members of the Mastadenovirus genera infect mammals 
including humans; Aviadenovirus genera infects birds; Atadenovirus genera (possess 
unusually high A + T content) infects reptiles, birds, a marsupial and mammals; 
Siadenovirus genera infects reptile and birds; and finally a new proposed clade that 
infects a sturgeon. There are now over 50 human adenovirus serotypes based on their 
resistance to neutralization by anti-sera (Rosen 1960) and DNA sequencing. These 
different serotypes are in turn classified into six species (Table 1.1) on the basis of their 
ability to agglutinate red blood cells in haemagglutination reactions testing the binding of 
the central shaft of the viral fibre protein to erthrocytes (Hierholzer, 1973; Ben Israel and 
Kleinberger, 2002). The reaction is inhibited using antisera that are specific for viruses of 
the same type but not inhibited by antisera to viruses of different types (Rosen 1960). 
Adenovirus serotype 5 (Ad5) and its closely related serotype 2 (Ad2) from group C and 
adenovirus serotype 12 (Ad12) from group A have been the primary focus of most studies 
surrounding adenoviruses. 
 
1.3.2    The biology of adenoviruses 
As discussed earlier in the chapter, adenoviruses frequently cause acute respiratory tract 
as well as gastrointestinal tract infections generating immune responses to inflammation. 
Additionally, some adenoviruses can also induce tumours in animals by a process 
comparable to cellular transformation in vitro (Green and Pina 1964). Table (1.1) shows 
the different adenovirus serotypes and their appropriate sub-groups. Across these 
serotypes, there is a varying degree of oncogenicity. For instance, group A adenoviruses 
such as Ad12 are highly oncogenic (Trentin et al., 1962; Yabe et al., 1962, 1964), with the 
ability to induce tumours in new born rodents within four months. On the other hand, 
group B adenoviruses are weakly oncogenic, and finally group C, E and F viruses are not 
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known to be oncogenic. However, it has been shown that the cells transformed by non-
oncogenic adenoviruses can cause tumours in immunocompromised host (Gallimore 
1972, Gallimore et al., 1977, Van der Eb 1977), indicative of the host immune system 
rejecting those transformed by the non-oncogenic adenoviruses. Importantly, cultured 
rodent cells can be transformed by both tumourigenic and non-tumourigenic 
adenoviruses, for example Ad12 and Ad5 respectively. The adenovirus E1 genes that 
encode for AdE1A and AdE1B proteins are required for the transforming capability of the 
virus (Gallimore et al., 1974; Graham et al., 1974). Both AdE1A, in cooperation with 
AdE1B, de-regulate cell growth by targeting key cellular regulators that control 
transcription, cell cycle progression and DNA synthesis. This will be discussed in the 
Section 1.3.5. However, alternative novel mechanism for adenovirus-mediated 
transformation was discovered in members of species D adenoviruses, namely Ad9 and 
Ad10. Both viruses were found to exclusively cause estrogen-dependent mammary 
tumours in rats (Ankerst and Jonsson 1989; Ankerst et al., 1974; Javier et al., 1991). 
Unlike the other adenovirus serotypes like Ad5 and Ad12 where the cellular 
transformation and tumourigenesis is mediated by AdE1A and AdE1B oncoproteins; Ad9 
adenovirus relies instead on the viral E4 region-encoded reading frame 1 (E4-ORF1) 
oncoprotein (Thomas et al., 1999; Javier 1994). In fact, Ad9 lacks the requirement for E1 
region-encoded gene products for tumourigenesis (Thomas et al., 1999; Javier 1994). The 
12kDa E4-ORF1 protein transforms by activating the protein kinase mammalian target of 
rapamycin (mTOR) (O’Shea 2005). Activation of mTOR leads to a stimulation of protein 
synthesis and entry to the S phase (Hay and Sonenberg 2004; Martin and Hall 2005; Lane 
et al., 1993). E4-ORF1 activates mTOR by strongly activating phosphatidylinositol 3-
kinase (PI3K) through associations with PDZ-domain containing proteins at the plasma 
membrane (Frese et al., 2003).  
Research into adenoviruses therefore has helped us understand the mechanisms of 
transformation and oncogenesis. Through dissecting the processes by which adenovirus 
manipulate and exert their effect on the host cell system, we have been able to 
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understand much better the processes of cellular gene expression and regulation, DNA 
replication, cell cycle control and apoptosis. 
Adenoviruses have also been a useful tool in the study and application of gene therapy. 
Recombinant virus vectors have been produced where they have been made replication 
defective by the deletion of the early genes (E1 or E1/E3 region), allowing space for the 
insertion of foreign DNA into the adenoviral genome (Bett et al., 1994). 
  
Table 1.1 Classification of human adenoviruses 
                                   (Modified from Berk 2007) 
 
1.3.3    Virus structure  
Adenoviruses are the largest of the non-enveloped viruses. They are of icosahedral shape 
and medium sized around 70-100nm in diameter. This structure is composed of 20 
triangular surfaces and 12 vertices (Horne et al., 1959; Cusack, 2005; Saban et al., 2005) 
The virus particles consist of 13% DNA and 87% protein with no membrane or lipid 
(Green and Pina, 1963). The surrounding protein shell (capsid) is composed of 252 
subunits, namely 240 hexons and 12 pentons (Ginsberg et al., 1966, van Oostrum and 
Burnett 1985) (Figure 1.2). Within this capsid and the core proteins, there is a double 
Species Types Oncogenicity 
A 12, 18, 31 High 
B 3, 7, 11, 14, 16, 21, 34, 35, 50 Moderate 
C 1, 2, 5, 6 Low or none 
D 8-10, 13, 15, 17, 19, 20, 22-30, 32, 33, 
36-39, 42-49, 51 
Low or none 
(mammary 
tumours) 
E 4 Low or none 
F 40, 41 Not reported 
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stranded linear DNA genome which is around 34-36kb in size depending on the serotype. 
Also in the capsid are nine viral proteins and four other proteins connected with the a 
double stranded DNA including polypeptides V, VII, mu and terminal protein. These  
proteins may serve as a histone-like around which the viral DNA is wrapped and also as a 
bridge between core and capsid (Maizel, Jr. et al., 1968; Russell et al., 1968; Robinson et 
al., 1973, Anderson et al., 1989; Mirza and Weber 1982; Chatterjee et al., 1986; 
Hosakawa and Sung 1976).   
The adenovirus genome contains five early transcription units (E1A, E1B, E2, E3 and E4), 
three delayed early units (E2L, IX and IVa2), one major late unit (ML), and also the VA 
genes (Shenk 1996).  With the exception of the latter, which are transcribed by RNA 
polymerase III, all of the remaining genes are transcribed by host RNA polymerase II. Due 
to differential splicing, each of these viral genes encode multiple mRNAs with different 
sedimentation coefficients. AdE1A is the first protein to be expressed, followed by E4. The 
expression of those two protein leads to the transcriptional activation of E1B and E2 
respectively. 
 
 
 
 
 
 
 
 
Figure 1.2.  Adenovirus Structure 
A. A three-dimensional image on the structure of an intact adenovirus particle (from 
http://www.macroevolution.net/) 
B. Generalised schematic cross-section of wild type adenovirus capsid, depicting the 
structural components and DNA genome (from Glasgow et al., 2006: 
Transductional targeting of adenovirus vectors for gene therapy).   
 
  
A B 
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1.3.4    Replication 
The different stages in the successful infection of a permissive cell involves virus 
attachment, endocytosis, production of progeny, virion release and cell lysis (Figure 1.3A). 
A typical productive infection of cultured cells takes 20-30hrs following a very high 
multiplicity of infection, however, in vivo host infection is very much prolonged as the level 
of viral exposure is much lower, in comparison to direct infection of cultured cells. The 
adenovirus first binds to cell surface receptors on the target cell. Contact begins when the 
adenovirus fibre protein attaches to cellular receptors, for instance the Coxsackievirus B3 
and Adenovirus receptor (CAR) (Lonberg-Holm and Philipson, 1969; Shenk 1996), while 
the penton base protein binds to vitronectin-binding integrins (Wickham et al., 1993). Both 
interactions are required for virus attachment and endocytosis (Meier and Greber 2003). 
The virus-receptor complex is internalised by endosomes, and in sequential uncoating 
steps the virus particle is released into the cytoplasm and is eventually transported into 
the nucleus by association with the cellular microtubules (Dales and Chardonnet 1973; 
Luftig and Weihing 1975). The viral capsids inject the viral DNA through the nuclear pore. 
Thirty minutes after internalisation, most of the viral DNA reaches the inside of the 
nucleus. Naked adenovirus DNA is incorporated by host cell histones and core adenovirus 
proteins into the chromatin. The viral DNA is transcribed by the host cell machinery to 
express both the early and late genes (Figure 1.3B). The early region genes code for non-
structural, regulatory proteins (E1A, E1B, E2, E3 and E4), that re-programme host cell 
transcription to create a favourable environment for virus replication (Shenk 1996, Burgert 
et al., 2002). E1A promotes cell cycle progression and DNA synthesis by targeting cellular 
proteins involved in transcription regulation (refer to section 1.3.5.1). E1B functions 
include (during infection) targeting and degradation of cellular proteins that may negatively 
affect viral replication such as p53 and MRN complex (refer to section 1.3.5.2). The E2 
gene comprises of E2A and E2B regions that encode for proteins vital for DNA replication 
(Challberg and Kelly 1979; Hay et al., 1995; Berk 2007). E2B encodes for precursor 
terminal protein (80kDa) and viral DNA polymerase, AdPol (140kDa), while E2A gene 
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product is a 72kDa nuclear ssDNA binding protein, DBP (Challberg et al., 1982; Cleat and 
Hay 1989; Ikeda et al., 1982; Stillman et al., 1981; Stuiver and van der Vliet 1990). All 
three proteins collaborate in viral DNA replication. Due to alternative splicing events, the 
E4 gene produces an array of mRNAs which in turn encodes several different proteins 
(Virtanen et al., 1984). For instance, both E4-ORF1 and E4-ORF4 activate mTOR protein 
kinase in the absence of mitogenic and nutrient signaling (O’Shea et al., 2005). Activation 
of mTOR leads to a stimulation of protein synthesis and entry to the S phase (Hay and 
Sonenberg 2004; Martin and Hall 2005; Lane et al., 1993). E4-ORF4 can also activate 
mTOR independently of E4-ORF1 (O’Shea 2005). E4-ORF3 interferes with the function of 
MRN complex inhibiting cellular DNA damage response (Evans and Hearing 2005; 
Stracker et al., 2002). E4-ORF6 is also involved in the inhibition of the DNA damage 
response (Boyer et al., 1999; Carson et al., 2003). It does this by interacting with E1B to 
cause the proteasomal degradation of the MRN complex and p53 (Stracker et al., 2002) 
(see also section 1.3.5.2).    
10-14hr following high multiplicity infection, the late phase of adenovirus infection begins. 
The late phase genes (major late promoter) code for structural proteins and others 
involved in the packaging of viral DNA. The host cells’ machinery is redirected towards the 
packaging and assembly of progeny viruses. These are released following the weakening 
of the cytoskeleton by the viral proteinases, eventually followed by cell death initiated by 
adenovirus death protein (ADP) (Shenk 1996; Tollefson et al., 1996). 
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Figure 1.3 : Adenovirus, replication and genome 
A     Diagram depicting replication cycle of an adenovirus: Adenovirus binds to the cell 
receptors on the surface of the host cell, entering the cell via endocytosis. The virus 
escapes the endosome then enters the nucleus. Transcription of the early and late viral 
genes occur, and regulatory and structural proteins are expressed. New viral progeny are 
assembled and they exit the cell through cell lysis (From Wagner E., Hewlett M.J., Bloom 
D.C., Camerini D. 2008. Basic Virology. Blackwell Publishing., M.A. 452 pp). 
 
B     Gene expression profile of the adenovirus genome. E refers to early region genes 
while L for the late proteins. 
 
 
A 
B 
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1.3.5    Adenovirus E1 region 
The adenovirus E1 region constitutes two transcriptional units that encode the major 
proteins that are crucial for the progression of infection, namely E1A and E1B. These are 
discussed in detail below.   
 
1.3.5.1 Adenovirus early region 1A   
Adenovirus early region 1A (AdE1A) is first viral protein to be expressed following 
infection.  The AdE1A gene is situated within the first 1500bp of the viral genome. It is 
essential for viral infection and is involved in the induction of cell cycle progression, DNA 
synthesis and the positive and negative regulation of cellular transcription (Frisch and 
Mymryk 2002; Gallimore and Turnell 2001; Ben Israel and Kleinberger 2002). It also 
regulates the expression of other adenovirus early region genes (Nevins 1981; Berk et al., 
1979; Jones and Shenk 1979).  Additionally, with a cooperating oncogene like AdE1B or 
mutated Ras it has the capacity to transform both primary human and rodent cells (Ruley 
1983).  
As a result of differential splicing of the primary transcript, AdE1A exists in various 
isoforms with mRNAs 12S and 13S being the most abundant and transcribed early in 
infection while 9S, 10S and 11S are present at minor levels and accumulate at later 
stages of infection (Stephens and Harlow 1987; Ulfendahl et al., 1987; Boulanger and 
Blair 1991). The 12S and 13S mRNAs encode 243 and 289 amino acid proteins, 
respectively in Ad2/Ad5. Both proteins are identical in all serotypes except that in 
13SAdE1A there is an additional conserved region 3 (CR3) that is situated towards the C 
terminus; this region acts as a transcriptional activation domain (Berk et al., 1979; Jones 
and Shenk 1979; Ablack et al., 2010). The size of AdE1A is about 26 to 32kDa in 
molecular weight, with the pI being around 4-5 depending on the serotype (Bayley and 
Mymryk 1994) and is localised roughly equally between the cytoplasm and nucleus (Rowe 
et al., 1983; Grand and Gallimore 1984) It is degraded rapidly with a half-life of 20-80mins 
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in infected cells (Spindler and Berk 1984). AdE1A functions primarily through a complex 
series of protein-protein interactions targeting various regulatory host proteins involved in 
cell cycle progression, DNA synthesis, apoptosis and differentiation by activating or 
repressing their expression at a transcriptional level. For instance, transcriptional co-
repressors such as the Rb family and CtBP, co-activators such as p300 and CBP, and 
proteins involved in chromatin modification such as TRRAP and p400 all interact with 
AdE1A. These are discussed in detail in section 1.3.5.1.2. AdE1A is possibly the most 
studied viral oncogene, and it had an important role in the identifying and understanding 
cellular proteins crucial in the various regulation processes in the cell.  
 
 
1.3.5.1.1  Structure of AdE1A 
Comparison of AdE1A amino acid sequences from the different adenovirus serotypes of 
human and simian origin has helped identify 4 highly conserved regions CR1, CR2, CR3 
and CR4 (Kimelman et al., 1985; Avvakumov et al., 2002, 2004). These regions are 
distributed throughout the protein and comprise about half the residues (Avvakumov et al., 
2002, 2004). They encompass amino acid positions 42-72, 113-137, 144-191, and 240-
288 respectively in the Ad513SE1A protein (Figure 1.4). Between the different serotypes, 
CR1 is found to be the most highly conserved while CR4 is the least. There is also an N-
terminal region, amino acids 1-39 (in Ad5), known to be weakly conserved between the 
different adenovirus serotypes with the exception of a conserved three amino acid 
sequence ILE at residues 18-20 (Gedrich et al. 1992), as well as M1, R2, L4 and L7 
residues (Rasti et al., 2005; Avvakumov et al., 2002) that exists within a predicted ɑ-
helical structure that spans residues 13-29 in Ad2/5 (Rasti et al., 2005; Pelka et al., 2008; 
Grand and Molloy 2009). The conserved regions, in addition to the N-terminal region, are 
the binding sites for almost all of AdE1A’s binding partners. 
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                                                                                    Modified from Gallimore and Turnell 2001 
Figure 1.4. Representation of 12S and 13S AdE1A showing conserved 
regions, associated cellular binding proteins and functional domains. 
Schematic diagram displaying the positions of the regions conserved across the different 
serotypes: CR1, CR2, CR3 and CR4 as well as the N-terminus region. The interacting 
cellular proteins for the corresponding region are also shown, in addition to the structural 
motifs (zinc finger) and other features, Nuclear localisation region (NLS) and acetylation 
site. Also depicted are the functional domains of AdE1A that involve in transcriptional 
repression/activation, transformation and repression of differentiation. 
Functional  
Domains 
Ad 13S E1A 
Ad 12S E1A 
CR1 CR2 CR3 CR4 
CR1 CR2 CR4 
AP-1 
CBP/p300 
P/CAF 
Dr1 
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Id-1, -2 
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p27kip1   
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Transcriptional 
activation/repression 
 
Suppression of 
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Transcriptional 
activation 
 
Acetylation site 
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E1B 
~ 16 ~ 
 
Studies on AdE1A secondary structure noted the possibility of one or two ɑ-helices in 
CR1, and two within CR3 and one in CR4 (Avvakumov et al., 2002; Pelka et al., 2010; 
Grand and Molloy 2009). The CR3 of the 13S E1A has two domains: a zinc finger 
structure (residues 147-177) (Culp et al., 1988) and a carboxyl domain (183-188) – Figure 
1.5. Mutational analysis revealed that 16 residues within the CR3 are crucial for its 
transactivation function. The four cysteine residues binding the Zn2+ atom: C154, C157, 
C171 and C174; H160 which is part of the zinc finger loop; S172, Y175 and R177 that are 
positioned at the C terminal side of the loop; V147 and P150 are in the N-terminus of the 
zinc finger region and finally the six residues at 183-188 that form part of the carboxyl 
region of the CR3 (Webster and Ricciardi 1991).  
 
 
 
 
 
 
 
 
 
 
                                                                        
 
                                                                       Modified from Sanchez et al., 2000 
Figure 1.5 Schematic representation of CR3 of adenovirus E1A 13S 289R 
An illustration of the CR3 of 13S AdE1A, showing the zinc finger and carboxyl region; also 
shown are the four cysteine residues that bind the Zn2+ and the crucial residues involved 
in its transactivation function (in red). 
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Ad5E1A also has multiple phosphorylation sites, at serine residues 89, 219, 132, 185, 188 
and 231 (Whalen et al., 1997). It was observed that mutations at these sites caused 
modest effects on AdE1A functions which may indicate that phosphorylation could 
regulate AdE1A activity to some extent (Whalen et al., 1996, 1997; Mal et al., 1996). 
However, the exact biological function of these has yet to been determined. AdE1A can 
also be acetylated at a lysine residue (Zhang et al., 2000; Molloy et al., 2006; Madison et 
al., 2002). One report has found that acetylation of lysine residue 285 and 261 (in Ad5E1A 
and Ad12E1A respectively) and lysine residue 239 may interfere with its association with 
the transcriptional co-repressor CtBP (carboxyl-terminal binding protein) (Zhang et al., 
2000; Molloy et al., 2006). However, this was contradicted by another study that showed 
that acetylation of lysine 239 does not disrupt binding to CtBP (Madison et al., 2002) 
however it affects its distribution between the nucleus and cytoplasm; with acetylated 
AdE1A being enriched in the latter and excluded from the nucleus (Madison et al., 2002). 
Similarly, at the carboxyl terminus of AdE1A, there is a pentapeptide (Lys-Arg-Pro-Arg-
Pro) which serves as a signal for the import of E1A to the nucleus (Lyons et al., 1987). 
Despite this, it has been found that E1A proteins are present equally in both cytoplasm 
and nucleus (Rowe et al., 1983, Grand and Gallimore 1984; Turnell et al., 2000).  
AdE1A has evolved to contain a number of motifs which can mimic the binding sites of 
certain cellular proteins (See table 1.2). It has been presumed that AdE1A binds to a 
particular host protein with a motif that is similar or identical to the host protein’s original 
partner thus displacing or preventing the normal interaction, eventually leading to the 
deregulation of that pathway. An example of this is the binding of AdE1A to the 
retinoblastoma (Rb) protein through the LXCXE motif, which is also present in the 
transcription factor E2F (Fattaey et al., 1993; Ikeda and Nevins 1993). These interactions 
will be discussed in the next section. 
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Table 1.2: AdE1A motifs present in cellular proteins 
Sequence 
AdE1A 
Location 
Examples of Cellular 
proteins with the motif 
Binding protein 
YxxxExAxS/TLLxxxL NTR APC5, APC7 CBP/p300 
LxxLIxxxL NTR NCoR Thyroid hormone receptor 
LLxxLxxLL NTR/CR1 
ACTR, TIF-2, Ets-1, Ets-
2 
CBP 
LxD/ELY/F CR1 E2Fs Rb, p107, p130 
FxD/ExxxL CR1 APC5, APC7 CBP/p300 
LxCxE CR2 
CtIP, cyclinD, MDM2, 
BRM, BRG1 
Rb, p107, p130 
PxDLS CR4 
CtIP, ZF217, HDAC, Net, 
ZEB, Ikaros, FOG-2 
CtBP1 + 2 
 
Modified from Grand and Molloy 2009 
As mentioned previously, the oncogenicity of adenoviruses depend on the serotype. Ad12 
is known to be oncogenic whereas Ad2/Ad5 is not. The sequences of both serotypes are 
about 50% identical; however there is an alanine-rich region within Ad12 E1A between 
CR2 and CR3, that is not present in Ad5 E1A, known as the oncogenic spacer region, and 
thus appears be partly responsible for the ability of Ad12 E1A to induce tumours (Telling 
and Williams 1994, Jelinek et al., 1994, Williams et al., 1995). 
With regards to the secondary and tertiary structure of AdE1A, there is so far no published 
structure. Several failed attempts have been made by various labs using crystallography 
or nuclear magnetic resonance (NMR). As a result, it was concluded that AdE1A is largely 
disordered (Pelka et al., 2008). The AdE1A sequence has a high percentage of proline 
residues that are distributed throughout the primary sequence, which probably prevents 
extensive secondary structure formation (reviewed by Frisch and Mymryk 2002, Pelka et 
al., 2008).  Additionally, other studies have hypothesized that some structure may be 
limited to parts of the conserved regions. For instance, in Ad4E1A, the protein is unfolded 
apart from the CR3 and a short region in CR4. In Ad3, Ad5, Ad9 and Ad12, structure was 
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limited to the N terminus and CR3. This disordered structure is one feature exhibited by 
hub proteins. Most cellular proteins interact with one or two other proteins, however, a 
minority bind to tens or even hundreds of other proteins to form a network hub with 
multiple interaction partners (Pelka et al., 2008). This unfolded conformation may allow 
AdE1A to bind to multiple proteins where the intrinsic disordered structure allows the 
flexibility for multiple protein interactions. A virally-encoded hub protein like AdE1A can 
reprogramme aspects of cell function and behaviour by disrupting the cellular protein 
interaction network (Pelka et al., 2008).  
 
1.3.5.1.2  Interactions of AdE1A 
 AdE1A protein is crucial for both infection and adenovirus-mediated transformation. 
AdE1A itself does not bind to DNA even though some ionic interactions between 
phosphodiester backbone of DNA and a basic region at residues 201-218 were reported. 
(Avvakumov et al., 2002). There have also been suggestions that AdE1A associates with 
other cellular DNA binding domains and hence is recruited to various promoters (Liu and 
Green 1994) although supporting evidence is limited. It binds to key proteins involved in 
transcriptional regulation and cell growth such as co-activators, co-repressors, cell cycle 
regulatory proteins and parts of the transcriptional machinery (reviewed in Berk 2005; 
Gallimore and Turnell 2001; Frisch and Mymryk 2002). Some of these interactions will be 
discussed in the next section. Transcriptional activation is mediated largely by the CR3 
region of 13SAdE1A while transcriptional repression is mediated by the N-terminal region 
of both 12S and 13S AdE1A (Pelka et al., 2009). The N-terminus and the highly 
conserved regions (CR1, CR2, CR3 and CR4) all contribute towards the AdE1A-mediated 
transformation. Figure (1.4) shows the different array of cellular proteins and their binding 
sites within AdE1A. Nearly 30 different cellular proteins bind within this sequence of less 
than 300 amino acids, as a result sabotaging the cell’s ability to control cell cycle, 
transcription and gene expression. The majority of AdE1A targets are located in the 
nucleus with a few exceptions such as the cytoplasmic proteins Sug1 (S8) and S4 (Grand 
~ 20 ~ 
 
et al., 1999; Turnell et al., 2000; Zhang et al., 2004) that are components of the 
proteasome and RACK1 (a protein kinase C scaffolding protein) (Sang et al., 2005) and 
IRS-4 (Shimwell et al., 2009). Due to its ability to bind to multiple proteins and complexes 
with its multiple binding sites, AdE1A has been classified as a “hub” protein (Pelka et al., 
2008; Keskin and Nussinov 2007, Grand and Molloy 2009) that can undergo both 
simultaneous and consecutive interactions (Pelka et al., 2008). By reprogramming host 
cell transcription, AdE1A not only creates an environment suitable for viral replication but 
also, in combination with AdE1B and mutant activated Ras, can potentially immortalise 
and transform cells. It has been shown that Ad5E1A and Ad12E1A expression alone can 
promote transformation in baby rat kidney cells (BRKs) however these quickly die through 
apoptosis (Shiroki et al., 1979; Houweling et al., 1980; Gallimore et al., 1985). The 
collaboration of AdE1B aids stable transformation when co-expressed with AdE1A as it 
inhibits E1A-induced apoptosis (Bernards et al., 1986; White and Cipriani, 1990; Rao et 
al., 1992; Debbas and White 1993; Lowe and Ruley, 1993).  
 
1.3.5.1.3 Transcriptional activation by AdE1A 
AdE1A promotes DNA synthesis and entry into S-phase in quiescent cells by interactions 
with at least two cellular protein families, the retinoblastoma tumour suppressor protein 
pRB and CBP/p300 (Howe et al., 1990). AdE1A binds to CBP/p300 through both its N-
terminal and the CR1 region while it binds pRB through CR1 and CR2 region (Barbeau et 
al., 1992; Dyson and Harlow 1992; Cobrinik 2005). CR2 contains an LXCXE motif, a 
sequence conserved in oncoproteins from small DNA tumour viruses such as HPV E7 
proteins and SV40 large T antigen (Whyte et al., 1988, Dyson et al., 1989, 1990, 1992; 
Munger el al 1989; Chellappan et al., 1992; Knudsen and Wang 1998). E2F binds to the 
pRB pocket via its own LXCXE motif.  In normal cells, pRB in its dephosphorylated state, 
inhibits DNA replication and cell cycle entry by binding to and inhibiting the transcription 
factor E2F (Nevins et al., 1997; Dyson 1998; Nevins 2001; Trimarchi and Lees 2002). The 
activity of E2F family of transcription factors can push a cell into S-phase. High affinity 
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binding of E1A through its LXCXE motif to the same “pocket domain” that pRB binds to in 
E2F displaces pRB releasing E2F (Nevins et al., 1997; Ghosh and Harter 2003) to 
become active eventually pushing the cell into the cell cycle by activating the transcription 
of genes involved in DNA synthesis such as cyclin-dependent kinase CDK2 and cyclins E 
and A (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 AdE1A disrupts retinoblastoma (pRB)  and E2F interaction 
At the G0 phase, the hypophosphorylated pRB binds to the transcription factor E2F/DP 
preventing it from activating transcription. For the progression through the cell cycle, 
cyclin-cyclin dependent kinases (CDKs) phosphorylate pRB hence releasing E2F to 
activate transcription of target genes required for the S-phase. This is counteracted by 
CDK inhibitors that bind to cyclin-CDK complex to prevent it from phosphorylating pRB. 
The presence of AdE1A disrupts this regulated cell cycle control by binding to 
hypophosphorylated pRB and thus disrupting its interaction with E2F, releasing the latter 
to initiate transcription. 
 
AdE1A also interacts with the Rb homologous proteins p107 and p130 through CR1 and 
CR2 (LXCXE motif) to relieve transcriptional repression (Ewen et al., 1991, Cobrinik et al., 
1993, Hannon et al., 1993; Li et al., 1993). p107 and p130, together with pRB, form  a 
retinoblastoma family of transcriptional regulators, also known as “pocket proteins” 
(Classon and Dyson 2001). p107 and p130 are structurally and functionally related to 
pRB, one prominent shared function between all three proteins being the negative 
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regulation of E2F (Grana et al., 1998;  Classon and Dyson 2001). Similar to pRB, the 
phosphorylation status of p107 and p130 is modulated during the cell cycle (Grana et al., 
1998; Classon and Dyson 2001), where the hyperphosphorylated forms do not associate 
with E2F (Beijersbergen et al., 1995; Mayol et al.,1996; Xiao et al.,1996). As with pRB, 
AdE1A binds to p107 and p130 through its CR1 and CR2 regions (Dyson et al., 1992), 
disrupting their binding to E2F. Furthermore, AdE1A also blocks hyperphosphorylation of 
p107 and p130, without affecting the phosphorylation status of pRB (Parreno et al., 2000). 
It was suggested that this selective targeting of p107 and p130 hyperphosphorylation may 
indicate that both proteins may have an additional function that is not shared by pRB 
(Parreno et al., 2000), but whose inactivation is important for the biological effect of 
AdE1A (Parreno et al., 2000).  Perhaps, this function may potentially be as a CDK 
inhibitor (Zhu et al., 1995), as it has been shown that p107 and p130 form stable 
complexes with cyclin A/E-dependent kinases (Ewen et al., 1992; Faha et al., 1992; Lees 
et al., 1992). 
Besides inhibiting E2F activity, pRB also recruits histone-directed deacetylases (HDACs) 
to the promoter of its target genes (Lai et al., 1999; Brehm et al., 1998; Magnaghi-Jaulin et 
al., 1998). When histones are deacetylated, they bind tightly to DNA, blocking accessibility 
to transcription factors hence blocking DNA synthesis (Luo et al., 1998, Ferreira et al., 
1998, Magnaghi-Jaulin et al., 1998).  Though HDACs also have an LXCXE motif, they 
appear to bind pRB through the bridging protein RBP1 (Suryadinata et al., 2010). Hence 
AdE1A interaction with pRB also influences histone and chromatin structure.  
Another role of AdE1A in chromatin structure control includes association with CBP/p300 
protein through its CR1 domain (Stein et al., 1990; Barbeau et al., 1992; Wang et al., 
1993; Arany et al., 1995). CBP/p300 is a multi-domain protein known to possess HAT 
(histone acetyltransferase) activity (Chan and La Thangue 2001; Vo and Goodman 2001; 
Iyer et al., 2004). It acetylates various proteins such as p53 (Gu and Roeder 1997; Ito et 
al., 2001), MyoD (Polesskaya and Harel-Bellan 2001) and histones (Bannister and 
Kouzarides 1996; Ogryzko et al., 1996). The acetylation of histone proteins causes the 
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loosening of DNA from the structure, hence rendering it more accessible to transcription 
factors. Ad12 AdE1A stimulates this HAT activity and recruits CBP/p300 for promoter 
activation (Fax et al., 2000). This activation of HAT together with AdE1A’s interaction with 
pRB, leads to the activation of genes required for S-phase entry. CBP/p300 is also a 
recruiter of basal transcription machinery including RNA polymerase II, TFIIB and TBP 
(Nakajima et al., 1997, Kee et al., 1996, Yuan et al., 1996, Kwok et al., 1994) leading to 
activation of the target genes.  However research from other laboratories has shown that 
AdE1A can also inhibit CBP/p300 activity (Frisch and Mymryk 2002) (Refer to 1.3.5.1.4). 
There is still no agreement on the exact effect of AdE1A on CBP/p300 and little 
understanding as to how inhibition of HAT activity promotes entry into S-phase. However, 
it has been reported that inhibition of p300 expression leads to a marked increase in Myc 
expression as well as activation of cyclin E and cyclin A/cyclin dependent kinase (CDK) 
activity, in turn driving G0 cells into S-phase. This shows that AdE1A inhibition of p300 
function may drive entry into S-phase due to the increase in Myc expression and 
cyclin/CDKs (Kolli et al., 2001, reviewed by Berk 2005). However, the mechanism of 
inhibition of p300 and subsequent increase in Myc expression is still not clear.  
Additionally, CBP/p300 is reported to promote transcription of genes involved in cellular 
differentiation (Goodman and Smolik 2000), suggesting that AdE1A inhibition of 
CBP/p300 may inhibit the expression of genes involved in differentiation and cell cycle exit 
(Frisch and Mymryk 2002). Other chromatin-remodelling complexes associated with 
AdE1A are p400 (Fuchs et al., 2001; Flinterman et al., 2007; Tworkowski et al., 2008) 
which contains a DNA helicase domain, P/CAF (Lang and Hearing 2003) and TRAPP 
which is a component of three HAT complexes TIP60, hGen5 and P/CAF HAT complexes 
in human cells (Deleu et al., 2001; Fuchs et al., 2001; Nikiforov et al., 2002; Sterner and 
Berger 2000).  
The TATA box is a 25 to 30bp DNA sequence found in the promoter region of many viral 
and cellular genes. It has been reported that approximately 24% of human genes have the 
TATA sequence as part of their core promoter (Yang C et al., 2007). It is therefore, one of 
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the most important elements of transcriptional activation. It is now known that 13S AdE1A 
can promote transcription through the TATA box by interacting with TBP (TATA-binding 
protein) which is a transcription factor that binds directly to the TATA sequence. AdE1A 
binds TBP through its N-terminal domain and CR3. TBP along with other TBP-associated 
factors (TAFs), make up the basal transcription factor IID (TFIID), the first protein complex 
to bind to DNA during the formation of the pre-initiation transcription complex at a 
promoter of a gene (Horikoshi et al., 1991, Lee et al., 1991, Geisberg et al., 1994). The 
tumour suppressor protein p53 can bind to TFIID causing transcription repression. It binds 
to a domain in TBP that overlaps with the AdE1A binding site. Thus AdE1A interaction 
probably displaces p53, disrupting p53 mediated repression (Horikoshi et al., 1995).   
CR3, the transactivation domain of AdE1A, can also interact with various DNA-binding 
transcription factors such as the Activating transcription factor - 2 (ATF-2), Specificity 
protein - 1 (SP1), Upstream stimulatory factor (USF) (Liu and Green 1990, 1994) and TBP 
associated factor (TAF) (Mazzarelli et al., 1997; Geisberg et al., 1995). This enables 
AdE1A to stimulate transcription from a variety of genes that lack a common promoter 
element (Liu and Green 1990, 1994). 
AdE1A is also found to bind to a cellular transcription factor Yin Yang 1(YY1) (Lewis et al., 
1995). YY1 is a multifunctional, zinc finger-containing, transcription factor that represses 
transcription if bound upstream of heterologous basal promoters. Two regions within YY1 
are required for its repression activity: the N terminal (residues 54-260) and the carboxyl 
region (residues 332-414). It has been shown that AdE1A binds to those two regions, 
affecting YY1 function and relieving transcriptional repression (Lewis et al., 1995). AdE1A 
binds YY1 through its N terminal and CR3 regions. Another transcriptional repressor Dr1 
functions by binding to TBP, preventing it from associating with TFIIA (involved in RNA 
polymerase II dependent transcription of DNA). Through its N terminal region, AdE1A 
binds to Dr1 disrupting its association with TBP, releasing it to associate with TFIIA 
(Inostroza et al., 1992, Kraus et al., 1994; Shenk 1996).  
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The chromatin remodelling factors TRRAP and p400 are also targeted by AdE1A during 
cellular transformation (Fuchs et al., 2001; Deleu et al., 2001). In fact, in addition to 
disrupting Rb and p300/CBP function, AdE1A must also recruit TRRAP to transform cells 
(Deleu et al., 2001). TRRAP is an adaptor protein that links Myc with histone acetylases 
(McMahon et al., 2000). Myc is an oncoprotein transcription factor that regulates the 
expression of 15% of genes including ones involved in cell division, cell growth and 
apoptosis (Gearhart et al., 2007). Myc recruits TRRAP to target chromatin and induces 
localised histone acetylation (Bouchard et al., 2001; Frank et al., 2001) activating the 
transcription of Myc-target genes. As with Myc, AdE1A also binds TRRAP through its N-
terminus, involving it in cell transformation (Deleu et al., 2001). AdE1A can also regulate 
Myc via the chromatin regulator p400. In normal cells, Myc is present at low levels and its 
expression highly regulated, through, for instance, ubiquitin-mediated proteolysis (Gregory 
and Hann 2000). AdE1A stabilises Myc by interfering with its ubiquitylation (Tworkowski et 
al., 2008; Chakraborty and Tansey 2009). In addition AdE1A interaction with p400 
promotes interaction with Myc hence the formation of more Myc-p400 complexes 
(Chakraborty and Tansey 2009; Tworkowski et al., 2008), and these complexes in turn go 
on to activate Myc-target genes (Chakraborty and Tansey 2009). 
In both infected and transformed cells, AdE1A also binds to MED23 (also called SUR-2), a 
part of the Mediator that is a multiprotein complex involved in the transcriptional activation 
(Boyer et al., 1999, Wang and Berk 2002). AdE1A binds to the Mediator through the CR3 
zinc finger region and recruits it to activate transcription. 12S AdE1A, lacking CR3, does 
not bind to Mediator complex. Studies from AdE1A transformed cell lines, for instance 
293, showed that much of the AdE1A bound to the Mediator is also in a stable complex 
that includes RNA polymerase II, which led to the belief that AdE1A-CR3/Mediator 
interaction stabilised Mediator/polymerase interaction, and contibutes to transcriptional 
activation (Wang and Berk 2002). Similarly, AdE1A, through the CR3 domain, promotes 
the assembly of transcription preinitiation complexes (PICs) (Roeder 1998) that includes 
RNA polymerase II and its general transcription factors (Cantin et al., 2003), and this 
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assembly is stimulated by AdE1A by its association with Mediator complex (Cantin et al., 
2003). 
Another role of AdE1A contributing to the initiation of the cell cycle is their binding to the 
CDK inhibitors (CKIs) p21 (Chattopadhyay et al., 2001) and p27 (Mal et al., 1996; 
Alevizopoulos et al., 1998; Nomura et al., 1998) preventing them from binding to  CDK-
cyclin complexes therefore promoting the cell cycle. CKIs repress the activity of CDK-
cyclin complexes which are regulators of cell cycle progression, helping drive each stage 
through the cell cycle in response to a variety of growth factors (Pines 1999). Another way 
that AdE1A targets the CKI p21 is by inhibiting its transactivation by p53 via sequestering 
CBP/p300 that are required for p53 function (Somasundaram and El-Deiry 1997). 
 
 
1.3.5.1.4 Transcriptional repression by AdE1A  
 AdE1A, in particular 12S, can also repress transcription of many cellular genes, such as 
those involved in cell differentiation and p53 expression. The N-terminus and the CR1 
region are crucial for AdE1A transcriptional repression (Song et al., 1995), and a number 
of proteins are involved in mediating this repression. In the previous section, it was shown 
that AdE1A associates with CBP/p300 for transcriptional activation. In contrast, it was also 
found by other laboratories to inhibit CBP/p300 activity (Howe et al., 1990; Stein et al., 
1990; Mymryk et al., 1992; Eckner et al., 1994; Lundbad et al., 1995; Giles et al., 1998; 
Lipinski et al., 1999; Hamamori et al., 1999; Giordano and Avantaggiati 1999). Through 
the N-terminal region and CR1, AdE1A binds the TRAM domain (transcriptional adaptor 
motif) of the CBP/p300 (O’Connor et al., 1999) inhibiting its HAT activity (Chakravarti et 
al., 1999; Ait-Si-Ali et al., 1998), as well as disrupting its ability to recruit the basal 
transcription components, hence repressing transcription (Arany et al., 1995, Goodman 
and Smolik 2000). Additionally, as CBP/p300 is also known to possess HAT activity, this 
binding to AdE1A can also disrupt this function, preventing accessibility of target 
promoters to transcription factors, leading also to repression of transcription activity 
(Bannister and Kouzarides 1996; Yang et al., 1996; Ogryzko et al., 1996, Ait-Si-Ali et al., 
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1998, Reid et al., 1998; Chakravarti et al., 1999). P/CAF (CBP/p300-associated factor) is 
a mammalian acetyl transferase that interacts with CBP/p300 (Yang et al., 1996). The N-
terminal and CR3 regions of AdE1A bind to P/CAF through its HAT domain (Reid et al., 
1998) thus disrupting its association with CBP/p300 and inhibiting its HAT activity along 
with P/CAF mediated transcriptional activation (Figure 1.7B) (Reid et al., 1998; 
Chakravarti et al., 1999). However, in addition to histones, P/CAF also acetylates p53 in 
response to DNA damage which leads to the enhancement of p53 binding to promoters of 
genes such as those encoding p21 (CDK inhibitor) (Liu et al., 1999; Sakaguchi et al., 
1998). It also acetylates MyoD (a protein involved in the regulation of muscle 
differentiation), inducing MyoD dependent gene expression and p21 expression finally 
leading to cell cycle arrest (Puri et al., 1997; Sartorelli et al., 1999). AdE1A binding to 
P/CAF therefore represses cell cycle exit and cell differentiation.  
The tumour suppressor protein p53, which is commonly mutated in many cancers, is also 
targeted by AdE1A. It is known that CBP/p300 binding to p53 is required for its function, 
(Lill et al., 1997, Levine 1997, Prives and Hall 1999, Lowe 1999) as well as CBP/p300 and 
p53 both being able to activate transcription synergistically (Gu et al., 1997). Additionally, 
CBP/p300 also regulates p53 allowing to accumulate stability by directly interacting with 
the protein (Lowe and Ruley 1993, Querido et al., 1997a, Chiou and White 1997, Yuan et 
al., 1999). p53 is normally unstable and degraded by the ubiquitin-proteasome pathway. 
CBP/p300 mediates binding between p53 and MDM2 which is an E3 ubiquitin ligase that 
recruits E2, an ubiquitin conjugating enzyme, that, in turn, ubiquitinates p53 for 
degradation by the 26S proteasome. As a result of binding to CBP/p300, AdE1A 
represses p53 transactivation (Song et al., 1995), and by disrupting p53 ubiquitination, 
prevents its degradation, hence p53 allowing to accumulate in the cell (Figure 1.7A). 
Similarly, AdE1A induces cellular p53 levels through the tumour suppressor p19ARF (de 
Stanchina et al., 1998).  AdE1A inactivates Rb and this leads to the accumulation of 
p19ARF, which in turn leads to the prevention of MDM2-mediated proteolytic degradation 
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and thus accumulation of p53 protein (Pomerantz et al., 1998; Zhang et al., 1998). Rising 
p53 levels leads to cell cycle arrest and apoptosis. 
We have seen that AdE1A either blocks CBP/p300-dependent transcription or activates it 
through redirecting its HAT activities to other regulatory proteins like pRB and cellular 
promoters. AdE1A might mediate these functions through the use of different binding 
proteins in a large multi-protein complex with CBP/p300 (Gallimore and Turnell 2001).  
Another transcriptional co-activator with HAT properties is P/CAF (CBP/p300-associated 
factor) (Yang et al., 1996).  
Another AdE1A target for transcriptional repression is the TATA binding protein TBP. It 
was noted in the previous section that 13S AdE1A can promote transcription through the 
TATA box by interacting with TBP transcription factor. TBP along with other TBP- 
associated factors (TAFs), make up the basal transcription factor IID (TFIID), the first 
protein complex to bind to DNA during the formation of the pre-initiation transcription 
complex at a promoter of a gene (Horikoshi et al., 1991, Lee et al., 1991, Geisberg et al., 
1994). On the contrary, AdE1A can also repress transcription by binding to TBP through 
its N-terminal region. It has been reported that the N-terminal region in the 12S AdE1A 
can bind independently to TBP (Geisberg et al., 1994; Song et al., 1997). However, this 
binding affinity is five times greater in 13S AdE1A than in 12S AdE1A. AdE1A binding to 
the TBP prevents it binding to the TATA box thus interrupting transcription initiation.   
Both TBP and CBP/p300 are required in p53 transactivation, so AdE1A association with 
both protein enables it to control and regulate p53 activity and transactivation. Complete 
repressive activity of AdE1A requires the association with both TBP and CBP/p300 (Boyd 
et al., 2002).  
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Figure 1.7  AdE1A interactions with CBP/p300. 
A    AdE1A frees E2F transcription factor from pRB. Then in cooperation with CBP/p300 
acetylates p53. This promotes its association with MDM2 oncoprotein, which then in turn 
binds and forms a complex with p53. This protects p53 from degradation, as well as its 
transcriptional activation and its function in growth arrest. However it still can induce 
apoptosis and transcriptional repression. 
B        P/CAF and CBP/p300 aid transcription by acetylating histone proteins allowing 
accessibility by transcription factors (TF) which may in turn be also acetylated to stabilise 
protein-protein binding to optimise transcription. The presence of AdE1A inhibits P/CAF 
and CBP/p300 function, hence blocking this process and inhibiting transcriptional initiation 
by TFs.    
 
 
AdE1A is also shown to interact with the C-terminal binding protein (CtBP) (Boyd et al., 
1993; Schaeper et al., 1995; Poortinga et al., 1998); causing a negative effect on the 
transforming activity of AdE1A. CtBP is a 48kD transcriptional co-repressor; it represses 
transcription by recruiting proteins that modify the chromatin structure (Turner and 
Crossley 2001; Chinnadurai 2007). It interacts with proteins that contain the PXDLS motif 
(Turner and Crossley 2001; Chinnadurai 2007), including AdE1A which possesses this 
motif close to its C-terminus at residues 234-240 and 279-286 of Ad5 E1A 12S and 13S 
 
 
A B 
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respectively (Molloy et al., 1998, 2000; Schaeper et al., 1995). Binding of AdE1A to CtBP 
causes an inhibition of AdE1A-mediated transactivation. CtBP binding to the PXDLS motif 
of 12SAdE1A causes the inhibition of CR1 transcriptional activity (Sollerbrant et al., 1996). 
CtBP also binds to the CR3 region of the 13SAd5E1A, thus repressing Ad5E1A CR3-
dependent transcriptional activation (Bruton et al., 2008). It has been hypothesized that 
this action of CtBP may be required for subtlety of transcriptional regulation of AdE1A 
(Bruton et al., 2008). Additionally, the effect of CtBP’s interaction with AdE1A is context-
dependent; for instance, deletion of the CtBP binding motif PXDLS increases frequency of 
AdE1A/activated Ras-transformation, whereas it reduces AdE1A/AdE1B-mediated 
transformation (Boyd et al., 1993; Subramanian et al., 1989, 1991; Douglas and Quinlan 
1995). The reasons behind this contrasting function of CtBP are yet to be determined.   
 
1.3.5.2 Adenovirus early region 1B  
The second protein that is expressed by the AdE1 transcription unit (besides AdE1A) is 
the adenovirus early region 1B (AdE1B). Due to alternative mRNA splicing, AdE1B gene 
encodes at least five different gene products, but the two major ones are the 19K and 55K 
proteins (Sieber and Dobner 2005).  
Compared to AdE1A, the functions of AdE1B-55K are less straightforward as it exhibits 
differing roles depending on the setting of either infection or transformation (Blackford and 
Grand 2009). During infection, AdE1B-55K activity can be divided into early and late 
functions. The early functions include the targeting and degradation of cellular proteins 
that may negatively affect viral replication such as members of the cellular DNA damage 
response, i.e. p53, DNA ligase IV and the MRN complex (heterotrimeric protein complex 
comprising of Mre11, Rad50 and Nbs1) (Baker et al., 2007; Querido et al., 2001; Stracker 
et al., 2002). This occurs due to the interaction of AdE1B-55K and Ad E4 open reading 
frame 6 (E4-ORF6) protein, to form an E3 ubiquitin ligase complex, comprising the cellular 
proteins cullin 5, RING-box1 and elongins B and C (Harada et al., 2002; Querido et al., 
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2001) – Figure 1.8A. This ligase complex ubiquitylates target proteins for degradation by 
proteasomes. The late functions involve the inhibition of cellular mRNA export and 
promotion of viral mRNA export and translation (Blackford and Grand 2009). E1B-55K/E4-
ORF6 complex ubiquitylates cellular proteins that are involved in the mRNA transport, 
leading to their degradation by the proteasome (Berk 2005). 
During AdE1-mediated transformation, AdE1B-55K cooperates with AdE1A (in the 
absence of E4-ORF6) to enhance cellular transformation (Houweling et al., 1980; 
Bernards et al., 1983; Gallimore et al., 1985; Yew and Berk, 1992). In AdE1 transformed 
cells AdE1B-55K protein is found to bind to p53 (figure 1.8B) resulting in the inhibition of 
p53 transactivation and apoptosis (White 1996). Most importantly, AdE1B inhibits 
apoptosis induced by AdE1A (White et al., 1991).  As mentioned earlier in the chapter, 
AdE1A stabilises p53 by disrupting its ubiquitylation, and degradation by the 26S 
proteasomes. This causes p53 levels to rise, which can induce apoptosis when DNA is 
damaged (Grand et al., 1994, Teodoro and Branton 1997; Prives 1998; Lowe and Ruley 
1993; Debbas and White 1993). To prevent this, AdE1B-55K binds and inactivates p53 
(Zantema et al., 1985b, van den Heuvel et al., 1990, Grand et al., 1995; Martin et al., 
1998) by inhibiting its association with its promoters hence repressing p53 activated 
transcription. Additionally, the binding with AdE1B-55K causes the p53 to be translocated 
to the cytoplasm (Zantema et al., 1985), neutralising the transcriptional activity of p53. 
Thus, during viral infection, p53 is degraded by the E1B-55K/E4-ORF6 E3 ubiquitin ligase, 
whereas in transformed cells, p53 is inhibited without being degraded by direct binding 
and relocalisation.  
 Ad5E1B-55K is a cytoplasmic protein as it has no nuclear localisation signal (NLS) 
(Zantema et al., 1985), requiring binding to E4-ORF6 to be transported to the nucleus 
during infection (Dobbelstein et al., 1997; Goodrum et al., 1996; Ornelles and Shenk 
1991) . However, it has been revealed that Ad5E1B-55K may possess a well-defined 
nuclear export signal (NES), similar to that of human immunodeficiency virus type 1 Rev 
protein (Dobbelstein et al., 1997; Dosch et al., 2001; Kratzer et al., 2000).  On the other 
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hand, Ad12 E1B 54K already has NLS so it is present in the nucleus independently of 
Ad12 E4-ORF6 (Grand et al., 1999). This may explain the nuclear and cytoplasmic 
localisations of the Ad12E1B-55K and Ad5E1B-55K respectively in AdE1 transformed 
cells (Zantema et al., 1985; Blair-Zajdel and Blair 1988).  
The smaller AdE1B-19K is a homologue of Bcl2, (Rao et al., 1992; Farrow et al., 1995). In 
normal cell conditions, Bcl2 binds to the pro-apoptotic Bax on the mitochondrial and 
endoplasmic reticulum membranes, keeping it inactive. High levels of nuclear p53 triggers 
apoptosis by transcriptionally activating Bax and other related pro-apoptotic proteins, 
AdE1B-19K binds to Bax keeping it inactivated to prevent AdE1A induced apoptosis 
during infection (Chen et al., 1996; Han et al., 1996a). It also blocks p53-independent 
apoptosis mediated by tumour necrosis factor-α (TNF- α) and Fas ligand (Hashimoto et 
al., 1991). 
 
 
 
 
 
 
 
 
 
                                                                                         
 
 
 
 
 
 
1.3.5.3 Adenovirus early region 3  
The adenovirus early transcription unit 3 (AdE3) encodes three proteins with 
immunosubversive functions: E3-19K, E3-14.7K and E3-10.4K/14.5K (RID, receptor 
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Figure 1.8 Inhibition of p53 
function by AdE1B-55K . 
 
A.  During infection, AdE1B-
55K, E4-ORF6, Cullin 5, 
Elongin BC, Rbx1complex to 
form an E3 ubiquitin ligase that 
targets and ubiquitylates p53 
and other proteins for 
degradation by the 
proteasome. 
 
 
 
 
B.   AdE1B-55K binds to p53 
and hence blocks 
transcriptional activation. 
AdE1B-55K prevents p53 
interaction with transcriptional 
co-activators. It also increases 
the affinity of p53-DNA binding 
sites 
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internalisation and degradation). They are not essential for viral replication although they 
play an important role in facilitating the establishment and persistence of adenovirus 
infection in vivo. They reduce the recognition of infected cells by the host immune system, 
allowing the viability of the cell while the viral replication continues. 
E3-19K down-regulates cell surface MHC class I expression by inhibiting its transport from 
the endoplasmic reticulum to the plasma membrane, where it normally presents peptides 
for recognition to cytotoxic T lymphophcytes (CTL) (Burgert et al., 1987; Wold et al., 1999, 
reviewed by Horwitz 2004).  E3-gp19K also inhibits the processing of peptides by tapasin, 
as a result reducing the amount of peptide presented by MHC class I in infected cells 
(reviewed by Horwitz 2004; Bennett et al., 1999). AdE3-14.7k is a 128 amino acid protein 
that inhibits TNF-induced apoptosis (Gooding et al., 1988). E3-10.4K/14.5K (RID) is a 
protein complex, consisting of RIDα and RIDβ polypeptides (Tollefson et al., 1991), which 
was found to downregulate fas receptors of the death ligands, FAS-L and TRAIL by 
internalisation into cell and degradation in lysosomes, thus prohibiting apoptosis (Shisler 
et al., 1997, Tollefson et al., 1998). It also inhibits TNF-induced apoptosis (Gooding et al.,  
1991), degrades the epidermal growth factor receptor (EGFR) from the cell surface 
(Tollefson et al., 1991; Carlin et al., 1989) as well as inhibiting TNF-induced NF-Kb signal 
transduction (Friedman and Horwitz 2002). Both AdE3-14.7K and RID inhibit TNF-α-
induced secretion of arachidonic acid, a 20 carbon unsaturated fatty acid involved in the 
inflammatory immune response (Zilli et al., 1992; Krajcsi et al., 1996). The three E3 
proteins prevent the infected cell’s recognition by the immune system. There is an 
additional Ad E3 protein called the AdE3-11.6K (also known as the adenovirus death 
protein, ADP) (Tollefson et al., 1996). This protein is not expressed at the early promoter, 
at the same time as the other E3 proteins, but synthesized later in infection from the major 
late promoter, seemingly during the death and lysis of the cell when the newly formed 
virus progeny are released (Tollefson et al., 1996).   
All the mechanisms of E3 protein function described above, was largely derived from the 
study of adenovirus serotype 2 and 5 of species C. Various E3 proteins from other 
~ 34 ~ 
 
adenovirus serotypes have been identified (see Table 1.3, Figure 1.9) (Windheim et al., 
2004). However, the functionality of only four of these proteins have been confirmed so 
far, namely, 19K, 10.4K, 14.5K and 49K. With the exception of adenoviruses from species 
A and F, E3-19K is expressed in all human adenoviruses (Blusch et al., 2002). E3-19K 
from Ad7, Ad35, Ad5, Ad2, Ad37 and Ad4 and their interactions with MHC class I 
molecules were examined (Fu et al., 2011). The E3-19K proteins of species B, C, D and E 
display allele-specific interactions with varying binding affinities with MHC class I 
molecules. The said species showed stronger binding to HLA-A molecules compared to 
HLA-B, and no interactions with HLA-C molecules (Fu et al., 2011). Binding was strongest 
between Ad4 E3-19K and HLA-A MHC class I and weakest between Ad37 E3-19K and 
HLA-A (Fu et al., 2011). It was also shown that the binding affinity negatively correlate 
with levels of MHC class I surface expression in infected cells (Fu et al., 2011). Another 
protein E3-49K is expressed by Ad19 of the species D. This species is associated with 
epidemic keratoconjuntivitis (EKC) (Deryckere and Burgert 2002). A novel 
immunomodulatory function is demonstrated by this protein. E3-49K may not act on 
infected cells but rather on cells of the immune system. After synthesis, E3-49K is 
extensively modified at the Golgi then enters the secretory pathway where they are 
packed in secretory vesicles destined for the plasma membrane (Windheim et al., 2004). 
Proteolytic cleavage takes place releasing the N-terminal ectodomain at either the cell 
surface, in secretory vesicles or endosomes. The protein is secreted followed by binding 
to NK cells (Windheim et al., 2004).  
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Table 1.3: E3 proteins from the different species of adenovirus 
 
                                                                                      Modified from Windheim et al., 2004 
  
 
 
 
 
 
 
 
                                                                                                  Windheim and Burgert 2002 
 
Figure 1.9:  Compositions of the E3 region 
From species C(Ad2), B (Ad3), D (1d19) and E (Ad4). The top scale indicates size of base 
pairs. ORFs are denoted as bars and drawn to scale. Shading code is shown below the 
figure. 
 
Protein Species Serotype 
19K B 
C 
D 
E 
Ad3 
Ad2 
Ad19 
Ad4 
16K B 
B 
B 
Ad3 
Ad7 
Ad35 
22K D Ad19 
23K E Ad4 
6.7K C Ad2 
20.1K B Ad3 
20.5K B Ad3 
24.8K E Ad4 
49K D Ad19 
11.6K C 
C 
C 
C 
Ad2 
Ad5 
Ad2 
Ad5 
9K B 
B 
Ad3 
Ad7 
31.6K D Ad19 
29.7K E Ad4 
Protein Species Serotype 
31.6K D Ad19 
29.7K E Ad4 
29.4K A Ad12 
19.4K F Ad40 
30.7K A Ad12 
31.6K F Ad40 
10.4K A 
B 
C 
D 
E 
F 
Ad12 
Ad3 
Ad2 
Ad19 
Ad2 
Ad40 
14.5K A 
B 
C 
D 
E 
F 
Ad12 
Ad3 
Ad2 
Ad19 
Ad4 
Ad40 
14.7K A-E  
12.5K A-E  
6.3K E Ad 4 
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1.3.6 The effect of AdE1A on components of the antigen presentation 
machinery. 
It is known that viruses have evolved mechanisms to prevent the detection of infected or 
transformed cells by the host immune system, producing ways to evade recognition by 
cytotoxic T lymphocytes (CTL) and natural killer (NK) cells (Alcami and Koszinowski 
2000). These mechanisms involve targeting multiple components of the antigen 
processing machinery such as proteasomes, transporter associated with antigen 
processing (TAP) and the MHC complexes (Alcami and Koszinowski 2000). 20S 
proteasome and immunoproteasomes are discussed in section 1.4.   
 
 
1.3.6.1  Major histocompatibility complex (MHC) class I and II and transporter 
associated with antigen processing (TAP) 
On the surface of CTLs, T cell receptors (TCRs) recognise antigenic peptides presented 
by the major histocompatibility complex (MHC) molecules on the target cells (Kindt et al., 
2007).  Proteins are continuously synthesized and destroyed in cells. Those proteins can 
be cellular proteins or those derived from pathogens. MHCs are heterodimeric 
glycoproteins whose function is to display fragments of processed proteins on the surface 
to be recognised by the surveilling immune cells, such as CTLs (Janeway et al., 2004).  If 
the CTLs recognise the presented peptide/MHC complex, they initiate an immune 
response against the cell (Corse et al., 2011). Due to the large diversity of microbes in the 
environment, MHC has evolved to be able to present a wide range of peptides. This is 
because the MHC locus is polygenic and highly polymorphic (Janeway et al., 2004). MHC 
genes are codominantly and concomitantly expressed. There are two classes of MHC 
molecules: MHC class I and II.  MHC class I proteins are present on the surface of most 
nucleated cells while MHC class II are present constitutively on the surface of only  
immune cells, specifically on antigen presenting cells like dendritic cells. MHC class I 
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comprises an α chain that is composed of three domains: α1, α2 and α3; and, in 
association wih β2-microglobulin, they protrude from the cell surface (Figure 1.10A) 
(Bjorkman and Parham 1990; Janeway et al., 2004). The whole structure is anchored on 
the cell membrane through a hydrophobic transmembrane region in the α3 domain. MHC 
class I specifically presents peptides of cytosolic or viral origin to CD8+ CTLs (Bjorkman 
and Parham 1990).  After a viral infection, the host cell presents non-self peptides through 
the MHC class I complex present on the cell surface where CTLs recognise the peptide 
fragment derived from pathogens. The CTLs in turn become activated stimulating an 
immune response in the process (Pamer and Cresswell 1998).  
MHC class II proteins are composed of α and β poly-peptide chains, each one consisting 
of two domains: α1 and α2, β1 and β2 (Figure 1.10A). Each polypeptide chain is anchored 
to the cell membrane via a hydrophobic transmembrane region (Janeway et al., 2004). 
MHC class II is present on the surface of antigen presenting cells like dendritic cells and 
macrophages; however, they can be induced in most other cells by exposure to interferon 
gamma (IFNγ). MHC class II presents processed peptides of extracellular origin (e.g. 
endocytosed bacterial pathogens) to CD4+ T cells (helper T lymphocytes) (van den Hoorn 
et al., 2011). Extracellular proteins are endocytosed, digested in the lysosome then loaded 
onto MHC class II molecules before being transported to the cell surface (van den Hoorn 
et al., 2011). 
Antigenic peptides of viral or cellular origin that are loaded onto the MHCs are generated 
by the proteasomes in the cytoplasm (see section 1.4). These peptides are then pumped 
into the lumen of the endoplasmic reticulum (ER) by an active transport mechanism 
carried out by a protein complex termed “transporter associated with antigen processing” 
(TAP) (Lankat-Buttgereit and Tampe 1999), which utilises ATP for its function. TAP 
consists of two subunits: TAP1 and TAP2. TAP is essential for antigen presentation as 
cells mutant for TAP have their levels of surface MHC class I greatly reduced (Van Kaer et 
al., 1992).  In the ER lumen, with the aid of several chaperones that assemble the newly 
formed MHC class I, and tapasin (TAP-associated glycoprotein) to aid loading, peptides 
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associate with the newly synthesized MHC class I molecules. The MHC class I and 
peptide complex are then finally transported to the cell surface to be presented to CD8+ 
CTLs (Figure 1.10B) 
 
 
 
 
1.3.6.2  The effect of AdE1A on the antigen processing components 
AdE1A targets multiple components of this antigen processing machinery, and the extent 
of this effect determines adenovirus oncogenicity.  The level of cell surface MHC class I 
molecules are down-regulated in Ad12 E1A transformed human (Bottley et al., 2005; 
Vasavada et al., 1986) and rodent cells (Schrier et al., 1983, Ackrill and Blair 1988), but 
not in cells transformed by the non-oncogenic Ad2/5. The biological function of this was 
demonstrated by the inability of influenza specific CTLs to recognise and lyse influenza 
virus infected Ad12 transformed mouse cells in comparison to the less resistant Ad5 
transformed cells (Yewdell et al., 1988). Thus, reduced levels of MHC class I expression 
enables Ad12 transformed cells to evade the immune system. This effect is reversed by 
either the treatment of the cells with IFNγ or transfection of heterologous class I heavy 
chain gene (Yewdell 1988; reviewed by Blair and Blair-Zajdel 2004). The overall effect of 
Ad12 E1A on the level of surface MHC is at the level of transcription (Proffitt et al., 1994; 
Ackrill and Blair 1988). Similarly, Ad5 transformed but not Ad12 transformed cells are 
eradicated by E1A specific CTLs in mice (Kast et al., 1989). 
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This is because in Ad5 transformed cells, antigenic peptides can be derived from a non-
conserved C-terminal region of the E1A (residues 232-247 of 13S Ad5 E1A) and 
presented to the CTLs by the MHC class I. However, it was speculated that in Ad12 E1A 
the corresponding peptide inefficiently binds or fails to be recognised by CTL. This and the 
reduced level of surface MHC class I may by responsible for the oncogenic nature of 
Ad12 transformed cells (reviewed by Blair and Blair-Zajdel 2004).  
Ad12 E1A also inhibits the expression of other genes from the MHC locus, namely TAP1, 
TAP2, and the immunoproteasome subunits LMP2 and LMP7 in Ad12 transformed cells 
 
 
A 
B 
Figure 1.10: Components 
of the antigen processing 
machinery. 
 
A Schematic diagram 
showing the structures of the 
major histocompatibility 
complex (MHC) class I and 
MHC class II (from 
Immunobiology: the immune 
system in health and disease 
(6th edition) by Janeway et al. 
2004. 
 
 
 
B    Proteins of viral or cellular 
origin are degraded by 
proteasomes. They are then 
pumped into the lumen of the 
endoplasmic reticulum (ER) 
by the transporter associated 
with antigen processing (TAP) 
complex. In the ER, with the 
aid of chaperones, the 
peptides are loaded into 
newly synthesized MHC class 
I molecules, then eventually 
transported to the surface to 
be recognised by cytotoxic 
CD8+  T-cells (CTLs) (from 
Yewdell et al., 2003) 
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(refer to section 1.5 for details), but not in those transformed by Ad5 (Rotem-Yehudar et 
al., 1994, 1996; Vertegaal et al., 2003). 
With regards to the effect of AdE1A on the level of surface MHC class II, very few studies 
have been undertaken so far. A study by Ackrill et al., 1991 showed that Ad5E1A 
represses MHC class II expression due to it inhibiting the induction by IFNγ (see section 
1.5). 
 
1.4 The Immunoproteasome 
1.4.1 The 20S proteasome  
Proteasomes are proteolytic complexes that are involved in regulated degradation of 
intracellular proteins, and they are also involved in the production of peptides for antigen 
presentation via the MHC class I pathway (Groettrup et al., 1996; York et al., 1999; 
Yewdell et al., 1999). The proteasome exists in two forms: the 20S complex that degrades 
proteins, independently of ubiquitin and is based on a proteolytic mechanism involving a 
threonine binding site (Figure 1.10D) (Dahlmann 2005; Coux et al., 1996). The 26S 
proteasome, which comprises one 20S core particle and one or two 19S regulatory caps, 
degrades ubiquitinated target substrates (Figure 1.12).   
The 20S proteasome has a barrel shaped structure consisting of four stacked rings: two 
outer α and two inner β rings (Figure 1.11A) . Each ring has seven subunits (α1-7 or β1-7) 
and proteolysis occurs in the central channel (Lowe et al., 1995; Groll et al., 1997; 
Baumeister et al., 1998; Coux et al., 1996). The molecular structure of the α and β 
subunits of the 20S proteasome consist of two layers of five-stranded β-sheets that are 
sandwiched between two helices at either side (Figure 1.11B) (Dahlmann 2005). 
However, the N-terminus of the α-subunits has an extra helix that fills the cleft between 
the two layers of β-sheets. Similarly, the helices mediate interaction between the α and β 
as well as β and β subunits (Dahlmann 2005). Amino acids at the extreme N-terminal 
region of the α-subunits form a lattice that gate the central pore of the α-ring (Figure 
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1.11A). In vivo, the 19S complex docks to the 20S proteasome in a ATP-dependent  
process, where it then controls access to the lumen (see below). 
The proteolytic activity of the 20S proteasome is due to three β subunits: β1, β2 and β5. 
β-subunits lack the extra helix and their N-terminal threonine is positioned at the open cleft 
between two layers of  β-sheets (Dahlmann 2005). The N-terminal threonine is exposed to 
the inner lumen of the proteasome (Figure 1.11C), hence forming an active site, serving 
as a catalytic nucleophile and primary proton acceptor (Figure 1.11D). Although these 
subunits have a common catalytic mechanism, they have different substrate specificities. 
β1 possesses “caspase-like” activity which cleaves after acidic residues, β2 has “trypsin-
like” activity that cleaves after basic residues and β5 “chymotrypsin like activity” that 
cleaves after hydrophobic amino acids (reviewed in Rivett and Hearn 2004, Groettrup et 
al., 2001). Each of these subunits has their active sites facing inside the lumen of the 
cylinder where the proteolytic activity takes place (Baumeister et al., 1998; Groll et al., 
1997). This is to protect other cytosolic proteins from uncontrolled degradation. The 
access to the lumen is controlled by the 19S cap, a proteasome regulatory sub-complex 
with ATPase activity that is involved in functions such as unfolding and translocating 
protein substrates and ubiquitin recognition.  The 19S complex is composed of 20 
subunits which constitute a “lid” and a “base”. The six ATPases are incorporated in the 
“base” that is in direct contact with the outer α rings of the 20S proteasome and two other 
subunits involved in the binding of ubiquitin-like domains (Hendil and Hartmann-Petersen 
2004). The 19S cap, in combination with the 20S proteasome core forms the complete 
26S proteasome (Figure 1.12) (Marteijn et al., 2006; Baumeister et al., 1998). 
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Figure 1.11: Structure and catalytic mechanism of the 20S proteasome 
A. ribbon diagram of the yeast 20S proteasome. B. Schematic drawing of an α- and β-
subunit of eukaryotic 20 S proteasomes. C. Longitudinal view of the 20S proteasome. The 
N-terminal threonine residues of the β-subunits are shown in blue circles. These are 
exposed to the lumen for catalysis of peptide bind hydrolysis. Substrate entry and exit is 
through the ring pores (Dahlmann 2005). D. The N-terminal threonine of a proteasome β-
subunits faces the lumen of the proteasome cylinder. It acts as a catalytically active 
nucleophile. The hydroxy group attacks the carbonyl group of the substrate peptide bond, 
while its proton is delocalized to the threonine amino group. As a result, a tetrahedral 
intermediate is formed, followed by peptide-bond cleavage and release of the N-terminal 
fragment of the substrate protein. Hydrolysis of the acyl-enzyme intermediate releases the 
C-terminal substrate fragment (Dahlmann 2005). 
 
Dahlmann 2005 
D 
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                                                                                                                                       Modified from Brooks 2010 and Marteijn et al., 2006 
Figure 1.12: Structure of the 26S proteasome 
26S proteasome degrades proteins that have been ubiquitinated. They consist of the 20S proteasome core and the 19S sub-complex lid. 
The catalytic domain is within the 20S core while the 19S recognises ubiquitylated proteins, unfolds them while also removing the ubiquitin. 
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 1.4.1.1  AdE1A and the 20S proteasome 
AdE1A also targets parts of the 20S proteasome, binding to the ATPase (S4 and S8) and 
non-ATPase (S2) components of the 19S regulatory complex (Grand et al., 1999; Turnell 
et al., 2000; Zhang et al., 2004) leading to the decrease in their ATPase activity. Through 
its CR3 transactivation domain, AdE1A also binds to several α subunits of the 20S 
proteasomes (Rasti et al., 2006). In addition, the expression of the chaperone tapasin and 
the immunoproteasome components MECL-1, PA28α and PA28β was much lower in 
Ad12 transformed rat cells compared to Ad5 transformed cells enabling escape from 
recognition by CTLs as the generation of peptides and loading onto MHC complex require 
those components (Vertegaal et al., 2002).  
AdE1A also recruits 20S proteasomes and the 19S ATPase, S8, a component of 19S 
ATPase proteins independent of 20S (APIS) to viral promoters to aid transcription of early 
region proteins (Rasti et al., 2006). They bind specifically to the AdE1A transactivation 
domain CR3 enhancing its ability to stimulate transcription. Both S8 and 20S proteasome 
are required for the process. 
 
1.4.2   The Immunoproteasome  
1.4.2.1 Formation and assembly 
In the presence of Interferon gamma (IFNγ) (resulting from cellular stimulation during host 
infection), each of the three catalytic subunits of the 20S proteasome β1, β2 and β5 are 
replaced by their inducible homologous subunits LMP2 (β1i), MECL1 (β2i) and LMP7 (β5i) 
respectively, to form the immunoproteasome (Hisamatsu et al., 1996) – (Figure 1.13).  
Immunoproteasomes are expressed constitutively in cells of lymphoid origin such as 
spleen, lymph node and thymus (Stohwasser et al., 1997) as well as immune cells such 
as dendritic cells. Immunoproteasomes are enriched at the endoplasmic reticulum (ER) 
(Brooks et al., 2001), where they may provide peptides directly to the TAP complex. The 
peptides are then pumped into the ER lumen, finally binding to the MHC.  Even though the 
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efficiency of the immunoproteasome to degrade proteins is the same as the 20S 
proteasome, the former has different cleavage preferences (see next section), and hence 
a different spectrum of peptides are produced which may potentially enhance antigen 
presentation (Groettrup et al., 2001; Ehring et al., 1996; Gaczynska et al., 1996; Cascio et 
al., 2001; Cerundolo et al., 1995).  
 
 
 
 
 
 
 
 
 
                                                                                         Modified from Kukan 2004 
 
 
Figure 1.13: The formation and structure of the immunoproteasome 
Upon IFNγ exposure, the constitutive 20S catalytic subunits β1, β2 and β5 are replaced 
by their IFNγ inducible homologes LMP2, LMP7 and MECL1 respectively. The 
immunoproteasome has different cleavage preferences. 
 
 
LMP2 and LMP7 genes are located adjacent to the TAP1 and TAP2 genes in the MHC 
locus (Figure 1.14) (reviewed in Rivett and Hearn 2004; Glynne et al., 1991; Martinez and 
Monaco 1991; Ortiz-Navarrete et al 1991), whereas the MECL-1 gene is found separately  
in a locus on human chromosome 16q22.1 (Larsen et al 1993).  
TAP1 and LMP2 genes are located in close proximity to each other separated by their 
common 593bp bidirectional promoter; this may potentially indicate coordinate regulation 
(Wright et al., 1995) (Figure 1.15). The expression of the three immunosubunits is 
mediated by IRF-1 after IFNγ stimulation (Namiki et al., 2005; Foss and Prydz 1999; 
Chatterjee-Kishore et al., 2000) – (see section 1.5). 
 
IFN γ 
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Figure 1.14:  The MHC locus: The location of the LMP and TAP genes within the 
MHC locus II.  Boxes represent the approximate position of the genes.  
 
 
 
 
 
 
 
                                                                              Chatterjee-Kishore et al., 1998  
 
Figure 1.15: The LMP2/TAP1 bidirectional promoter: a 593bp bi-directional 
promoter shared by LMP2 and TAP1. The diagram also shows transcription factor binding 
sites.  
 
 
The assembly of immunoproteasomes and the mechanisms by which the inducible 
immunosubunits replace their constitutive homologues is poorly understood. However, 
evidence so far supports the cooperative model for assembly. It has been shown that the 
incorporation of MECL1 is strictly and mutually dependent on LMP2 but not LMP7 
(Groettrup et al., 1997), and LMP2 is also not incorporated in the absence of MECL1 
(Griffin et al., 1998; Kingsbury et al., 2000, Groettrup et al., 1997).  This idea of 
interdependent cooperation is further supported by the observation that both LMP2 and 
 
 
 
Lankat-Buttgereit  and Tampé 2002 
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MECL1 are direct neighbours in the β-ring (Dahlmann et al., 1999). LMP7 seems to 
incorporate into immunoproteasomes independently of the other two subunits (Kingsbury 
et al., 2000), and is separated from LMP2 and MECL1 by two β-type subunits: β3 and β4 
(Dahlmann et al., 1999). Additionally, LMP7 is required for maturation, where it removes 
the amino-terminal propeptide of MECL1 and LMP2 to liberate their active sites. Due to 
the independent nature of LMP7, it may be possible that in certain cells, populations of 
proteasomes contain LMP7 together with the two other constitutive subunits, β1 and β2 
(Gaczynska et al., 1994; Boes et al., 1994). The functional significance of these 
proteasomes is not known, although, there are suggestions the resulting diversity of 
“mixed proteasome” populations could translate into a larger array of peptides produced 
(reviewed in Groettrup et al., 2001). 
IFNγ exposure also induces PA28 (also known as 11S), a protein regulator complex that 
enhances the activity of the proteasome core in both the 20S and the immunoproteasome 
(Baumeister et al., 1998; Groettrup et al., 1995; Dick et al., 1996). Like the 19S complex in 
the 26S proteasome, it controls access to the lumen; however, it is in an ATP-independent 
manner and it mediates the degradation of non-ubiquitinated short peptides. There have 
also been reports of PA28 promoting immunoproteasome assembly (Preckel et al., 1999), 
although this was not supported by other reports which showed that PA28 is not required 
for assembly and that its effect is independent of the proteasome (reviewed by Van den 
Eynde and Morel 2001; Schwarz et al., 2000; van Hall et al., 2000). 
 
 
1.4.2.2 Catalytic activity and antigen processing 
The immunosubunits have different proteolytic activities in comparison to the 20S 
proteasome. Trypsin-like (cleavage after basic residues) and chymotrypsin-like activities 
(cleavage after hydrophobic residues) are stimulated whereas caspase-like activity 
(cleavage after acidic residues) is suppressed (Aki et al., 1994; Driscoll et al., 1993; 
Gaczynska et al., 1993). This is possibly due to the incorporation of LMP2 that possesses 
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chymotrypsin-like activity to substitute for the caspase-like β1 subunit (Groettrup et al., 
1995; Gaczynska et al., 1994; Schmidtke et al., 1998). TAP and MHC class I molecules 
are reported to strongly prefer peptides with carboxyl terminal, hydrophobic and basic 
residues over acidic ones, making the immunoproteasome-processed peptides more 
favourable for presentation. However, the view that the immunoproteasome is more 
efficient at producing peptides for presentation has been challenged. A study using LMP2 
and LMP7 knockout mice showed that while presentation of certain epitopes was reduced, 
others were still processed and presented (Fehling et al., 1994; Van Kaer et al., 1994), 
revealing that the immunoproteasome is not a necessity for antigen presentation. In fact, 
the majority of MHC class I epitopes known are processed by the standard proteasome. 
Similarly, some epitopes are processed more effectively by the 20S proteasome than the 
immunoproteasome (Gaugler et al.,1994; Morel et al.,1999; Van den Eynde et al., 1995). 
Examining the protein origins of these epitopes reveals that the immunoproteasome 
epitopes are derived mainly from infectious agents like viruses, whereas 20S proteasome 
epitopes are derived from self proteins (reviewed by Van den Eynde and Morel et al., 
2001). Examples of such epitopes and their origins are summarized in Table 1.4 and 1.5. 
So in conclusion, the notion that immunoproteasomes are more efficient at producing 
epitopes for MHC class I presentation remains correct as far as epitopes derived from 
infectious organisms in particular. This appears to make sense, in view of its presence in 
antigen presenting cells and in response to IFNγ produced during infection (reviewed by 
Van den Eynde and Morel et al., 2001). However, it was recently suggested that 
immunoproteasomes may also play a primary role in the maintenance of protein 
homeostasis and preservation of cell viability under inflammatory conditions of IFN-
induced oxidative stress by rapidly degrading nascent oxidant-damaged proteins (Seifert 
et al., 2010).  
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       Table 1.4 Epitopes preferentially processed by cells carrying immunoproteasomes - Van den Eynde and Morel (2001) 
 
     Table 1.5  Epitopes poorly processed by cells carrying immunoproteasomes- Van den Eynde and Morel (2001) 
 
Protein 
 
MHC 
restriction 
Peptide sequence 
Amino acid 
positions and 
epitopes 
References 
Viral (mouse)     
Influenza NP (strain A/NT/60/68) H-2Db TRGVQI ASNENMDAM ESSTLE 366-374 Cerundolo et al., 1995 
Influenza NP (strain A/PR/8/34) H-2Db TRGVQI ASNENMETM ESSTLE 366-374 Van Kaer et al., 1994 
LCMV NP H-2Ld KIMRTE RPQASGVYM GNLTAQ 118-126 Schwarz et al., 2000 
Mo MuLV gag H-2Db CCSIVL CCLCLTVFL YLSENM 75-83 Van Hall et al., 2000 
Adenovirus E1B-19K H-2Db YKISKL VNIRNCCYI SGNGAE 192-200 Sijts et al., 2000 
Viral (human)     
Influenza M1 HLA-A2 LSPLTK GILGFVFTL TVPSER 58-66 Luckey et al., 1998; Gileadi et 
al., 1999 
HIV-1 RT HLA-A2 KQNPDI VIYQYMDDL YVGSDL 346-354 Sewell et al., 1999 
HBV core Ag HLA-A68 PNAPIL STLPETTVVRR RGRSPR 141-151 Sijts et al., 2000 
Self (Mouse)     
H-Y H-2Db n.d. n.d. Fehling et al., 1994 
Tumoral (human)     
MAGE-A3 HLA-B60 ALSRKV AELVHFLLL KYRARE 114-122 Schultz, van der Bruggen 
(unpublished data) 
Protein MHC restriction Peptide sequence 
Amino acid 
positions and 
epitopes 
References 
Self (human)     
RU1 HLA-B51 ETGSTA VPYGSFKHV DTRLQN 34-42 Morel et al., 2000 
Melanoma differentiation (human)     
Melan-AMART1 HLA-A2 SYTTAE EAAGIGILTV ILGVLL 26-35 Morel et al., 2000 
gp100Pmel17 HLA-A2 SSSAFT ITDQVPFSV SVSQLR 209-217 Morel et al., 2000 
Tyrosinase HLA-A2 HNALHI YMDGTMSQV QGSAND 369-377 Morel, Van den Eynde 
(unpublished) 
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1.4.3  The Relationship between viral proteins (other than AdE1A) and the 
immunoproteasome. 
Due to their role in antigen processing and presentation, proteasomes are known to be 
targeted by various viruses that are capable of establishing persistent infections. 
Proteasomes are not only involved in the production of peptides for antigen presentation, 
but they also involved in the degradation of key cellular regulatory proteins such as p53 
and Rb (Maki et al., 1996; Sdek et al., 2005; Ciechanover et al., 1991; Boyer et al., 1996; 
Wang et al., 2001). The interaction between viral proteins and the proteasomes can affect 
not only recognition of the infected cell by the immune system but also the events that 
lead to cell transformation and apoptosis. Interactions between viral proteins and 
components of the 20S/26S proteasome as well as immunoproteasome have been 
studied. As mentioned in the previous section, immunoproteasomes are more efficient 
than 20S proteasomes in processing antigens of viral origin, so they will form potential 
targets for viral manipulations as part of a strategy to evade the immune system. 
The E7 protein of the high-risk human papillomavirus (HPV) type 18 is reported to repress 
the bidirectional promoter that encodes the expression of the immunoproteasome subunit 
LMP2 as well as TAP1 (Georgopoulos et al., 2000), hence affecting immunoproteasome 
composition and activity. Similarly, the low-risk HPV 6b E7 protein also repressed the 
TAP1/LMP2 promoter; potentially explaining the ability of low-risk HPV to induce benign 
tumours (Georgopoulos et al., 2000).  
Research into the effect of human immunodeficiency virus type 1 (HIV-1) p24 on antigen 
presentation showed that the viral protein down-regulated the expression of PA28α, 
MECL1 and LMP7 in primary dendritic cells. In addition, PA28β and MECL1 expression 
was reduced in the dendritic cell line JAWS II (Steers et al., 2009), as a result interfering 
with the immunoproteasome complex. However, this effect was reversed by pre- 
treatment of cells with IFN γ. Furthermore, HIV-1 Tat protein was found to bind to LMP2 
and LMP7, in addition to α4 and α7 (therefore interfering with the binding of PA28 to the 
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alpha ring) plus six β subunits of the constitutive 20S proteasome leading to the inhibition 
of immunoproteaosme and 20S proteasome activity (Apcher et al., 2003). 
NS3, a non-structural protein of the Hepatitis C virus (HCV) also affects 
immunoproteasome activity by directly binding to the immunsubunit LMP7, repressing its 
peptidase activity, potentially interfering with the processing of viral antigens to MHC class 
I (Yee-Ling Khu et al., 2004). 
  
 
1.5 Interferon gamma and the JAK/STAT1 signalling pathway 
 Interferons are cytokines that are released by lymphocytes in response to viral and 
bacterial infections. They are known as interferons for their ability to “interfere” with viral 
replication. They have antiviral, antiproliferative and immunomodulatory effects, 
stimulating the immune system, leading to the expression of anti-viral genes. They 
activate immune cells such as macrophages and natural killer cells, enhance antigen 
presentation to CTLs and increase the ability of uninfected cells to resist infection. 
There are two types of interferons: type I and type II. Type I interferon includes IFN α and 
IFN β. Most types of cells express type I interferons. On the other hand, type II IFN has 
one member: Interferon gamma (IFNγ). IFNγ is produced only by cells of the immune 
system such as natural killer cells as well as CD4+ and CD8+ T-cells. All IFNs mediate 
their effect by association with type-specific cell surface receptors that set into motion a 
complex series of signalling pathways that lead to the eventual expression of IFN 
stimulated genes (ISG).The pathway through which IFNγ activates gene transcription is 
called the Janus kinase/signal transducer and activator of transcription-1 (JAK/STAT1) 
pathway (Figure 1.16). IFNγ is a homodimeric soluble cytokine that has a crucial role in 
activating an array of immune responses.  
It does not have a marked structural homology with type I interferons (Pestka et al., 1987, 
2004, 1997; Chen et al., 2004; Platanias and Fish 1999; Parmar and Platanias 2003). It  
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Figure 1.16: The JAK/STAT1 pathway. 
The binding of IFNγ ligand to its receptor causes the activation of the JAKs, which results 
in the phosphorylation of a residue at the cytoplasmic tail of the IFNγ receptors. This then 
serves as a docking site for STAT1 proteins which in turn get phosphorylated and 
activated. The STAT1 dimerse and translocate to the nucleus and initiates the 
transcription from gene promoters that GAS element (primary response). IRF-1 become 
expressed and in the secondary response, IRF-1 activates transcription various genes, 
with or without association with the STAT1 homodimers (modified from Shawn P. Murphy 
et al., 2009 and Melanie Newport: 
http://journals.cambridge.org/fulltext_content/ERM/ERM5_06/S1462399403005908sup00
4.htm)  
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binds to the cell surface IFNγ receptor (IFNγR) (Pestka et al., 1997; Bach et al., 1997) 
through which it activates the JAK/STAT signalling pathway. 
The IFNγR consists of a heterodimer of two chains: α (IFNγR1), and β chain (IFNγR2). 
These are 90 and 60-67kDa glycoproteins respectively that mediate binding with IFNγ 
(Farrar and Schreiber 1993; Soh et al., 1994; Hibino et al., 1991; Celada 1988; Bach et 
al., 1997).  IFNγR1 and IFNγR2 are not associated with each other in unstimulated cells; 
however, they are constitutively bound to members of the Janus family of protein tyrosine 
kinases, JAK1 and JAK2 that mediate IFNγR signalling activation following ligand binding. 
JAK1 and JAK2 bind to specific residues/motifs on the cytoplasmic tails of the IFNγR1 and 
IFNγR2 respectively (Farrar et al., 1991; Kotenko et al., 1995; Kaplan et al., 1996). 
Binding to the ligand leads to oligomerisation with two IFNγR1 molecules associating with 
one IFNγ homodimer. This is then followed by the recruitment of the two IFNγ R2 chains 
to the complex (Kotenko et al.,1995; Windsor et al., 1996; Marsters et al., 1995; 
Greenlund et al., 1993, 1994; Bach et al., 1996; Fountoulakis et al., 1992). This 
association brings the two inactive JAKs into close proximity where they transactivate one 
another through phosphorylation. It has been suggested that JAK2 first 
autophosphorylates, followed by phosphorylation of JAK1 (Bach et al., 1997; Briscoe et 
al., 1996; Igarashi et al., 1994). Subsequently, the  activated JAK1 phosphorylates a 
tyrosine residue pair present near the C-terminus of each of the IFNγR1 chains (Y440) 
(Farrar et al., 1992; Igarashi et al., 1994; Greenlund et al., 1994; Hershey et al., 1990), 
which is within a recognition sequence – 440YDKPH444 – that  serves as a docking site for 
STAT1, a member of the Signal Transducers and Activators of Transcription family of 
latent cytoplasmic proteins (Farrar et al., 1992; Greenlund et al., 1994, 1995; Hein et al., 
1995). After STAT1 docks and binds to the sequence in the IFNγR complex, it becomes 
activated by phosphorylation of tyrosine residue Y701 by JAK2 (Shuai et al., 1992, 1993; 
Schindler et al., 1992). After phosphorylation, STAT1 homodimerises and translocates to 
the nucleus where it binds to a nine nucleotide consensus sequence TTNCNNNAA, which 
is also known as GAS (gamma-activated site) element (Tau and Rothman 1999, Darnell 
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et al., 1994; Schindler and Darnell 1995, Sekimoto et al., 1997; Tessitore et al., 1998). 
This sequence is present in the regulatory DNA sequences of more than 200 genes. Thus 
the binding of STAT1 homodimers activates the expression of a whole array of proteins 
that are involved in immune effects of IFNγ (Boehm et al., 1997) – Figure 1.16.  Such 
genes include the transcription factor interferon regulatory factor 1 (IRF-1), a master 
regulator for the concerted expression of immunoproteasome subunits (Namiki et al., 
2005, Boehm et al., 1997; Stark et al., 1998). IRF-1, in turn, activates several genes, such 
as those encoding MHC class Ia, by binding to IFNγ response elements (IRE) or 
cooperates with STAT1 to form a complex that binds to IRE/GAS elements of promoters 
in TAP1, TAP2 , immunoproteasome subunits and CIITA (MHC class II) to activate 
transcription.  
CIITA is the MHC class II master regulator, which, in collaboration with 19S ATPases, is 
recruited to the MHC class II promoter where it orchestrates various transcription factors 
and co-factors leading to the initiation of transcription (Bhat and Greer 2011) – Figure 
1.17.  In addition, even though TAP1 and LMP2 share a bidirectional promoter, both 
proteins have differential cellular expression. TAP1 is expressed constitutively and LMP2 
is induced following exposure to IFNγ. This is because the binding of either IRF-1 or 
STAT1 to the IRE/GAS element of promoter is sufficient to initiate transcription of TAP1, 
both proteins are required for LMP2 transcription (Chatterjee-Kishore et al., 1998). 
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                                                                                                                                                                   Bhat and Greer 2011 
Figure 1.17: Regulation of MHC class II transcription by the 26S proteasome 
After IFNγ stimulation, 19S proteasome binds to promoters and recruits histone modifying enzymes to open chromatin to allow access for 
transcription factors. MHC class II regulator CIITA which is now induced (from Figure 1.12) is phosphorylated at S280 and this results in its 
mono-ubiquitination.  CIITA then, with a collaboration from 19S ATPases is recruited to the MHC class II promoter where it coordinates the 
assembly of transcription factors and co-factors to initiate transcription.  The APIS complex detaches from CIITA and transcription elongation 
continues. After prolonged cytokine stimulation, CIITA is poly-ubiquitinated and degraded by the 26S proteasome.
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1.5.1   The effects of AdE1A on IFNγ signalling 
As mentioned previously, IFNγ stimulates the immune response and enables uninfected 
cells to resist infection, as well as increasing the recognition of infected cells by the 
immune system. Viruses, including adenoviruses, have evolved a mechanism to 
counteract this response in order to support viral replication and disrupt the antiviral action 
of IFNγ (Anderson and Fennie 1987; Kalvakolanu et al., 1991; Katze et al., 2002). Most 
adenovirus resistance to IFNγ is attributable to AdE1A (Anderson and Fennie 1987; 
Kalvakolanu et al., 1991; Ackrill et al., 1991; Gutch and Reich 1991).  
In some studies, in AdE1A expressing cells, the level of STAT1 protein was particularly 
reduced (Leonard and Sen 1996). During the course of early infection, AdE1A directly 
binds to STAT1 homodimer through its N-terminus, thus disrupting transcriptional initiation 
and its association with CBP/p300 (Look et al., 1998) (Figure 1.18). AdE1A also represses 
STAT1 activity by targeting CBP/p300. Upon IFNγ stimulation, the activated STAT1 
homodimer binds to the GAS sequence and interacts with CBP/p300 which in turn recruits 
the basal transcription complex (Zhang et al., 1996). In section 1.3.5.1.3 / 4, it was stated 
that CBP/p300 is a target of AdE1A, affecting the transcription of many genes. In fact, 
both STAT1 and AdE1A bind to the same domain on CBP/p300 (Zhang et al., 1996), so 
there may be a direct competition between STAT1 and AdE1A for binding with CBP/p300, 
therefore affecting the anti-viral effect of IFNγ (Zhang et al., 1996; Look et al., 1998) 
(Figure 1.18). Phosphorylation of STAT1, which leads to the formation of activated STAT1 
homodimer prior to transcription initiation, is inhibited by AdE1A at the later stages of 
infection (Look et al., 1998). These multiple strategies employed by AdE1A to inhibit 
STAT1 function may be due to the fact that STAT1 is crucial as a trigger of immune 
responses in mucosal epithelial cells, which are the natural hosts of adenovirus (Look et 
al., 1998). It is notable however that adenoviruses often target particular pathways in more 
than point. 
~ 58 ~ 
 
The inhibiting effect of AdE1A on the IFNγ pathway, affects the expressions of MHC class 
II, immunoproteasomes, PA28 and other proteins involved in IFNγ mediated immune 
response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                              Look et al., 1998 
Figure 1.18: Suppression of STAT1 function by AdE1A 
A     Under normal (unstimulated) conditions, the transcription factor Sp1 binds to the GC 
box and recruits the basal transcription factors that bind to the TATA box, eventually 
leading to transcription initiation (TIS=transcription initiation site). 
B     Upon IFNγ stimulation, the STAT1 homodimer binds to inverted repeat (IR) 
interacting with Sp1 and CBP/p300, that in turn associates with the basal transcription 
complex (via p/CIP).  
C     The presence of AdE1A  disrupts these processes by directly binding to STAT1 and 
CBP/p300. 
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1.6 Aims 
It has been known for some time that AdE1A targets multiple components of the antigen 
processing machinery. Most of these studies have focused on rat cell models; only a few 
have been carried out in human cells.  
The aim of this project is to examine the interaction of AdE1A (from both the oncogenic  
Ad12 and non-oncogenic Ad5) with the immunoproteasome components and the 
biological significance of this on antigen presentation in human cells.  We will also 
examine the effect of adenovirus infection on MHC class I and class II cell surface 
expression as well the effect of AdE1A transfection. The specific aims are:  
1. To examine the binding of AdE1A to the immunoproteasome subunits LMP2, 
LMP7 and MECL-1; mapping sites of interaction on AdE1A and comparing these 
with 20S proteasome components. 
2. To examine the effect of AdE1A on the ability of immunoproteasomes to hydrolyse 
peptide substrates. 
3. To determine the effect of AdE1A and adenovirus infection on MHC class I and 
class II expression. 
4. To examine how the interaction of AdE1A with the immunoproteasome and other 
cellular targets affects antigen presentation to T-cells. 
5. To determine the effect of AdE1A on the ability of cells to respond to IFNγ. 
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2.1 Cell culture techniques 
 
2.1.1    Cell culture media and solutions 
All tissue culture reagents were presterilised and purchased from Sigma Aldrich unless 
otherwise stated. All reagents were stored at 4C and pre-warmed at 37C unless 
otherwise specified. Cell lines were maintained in Roswell Park Memorial Institute 1640 
medium (RPMI-1640) or Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 2 mM L-glutamine. Before use, all media were supplemented with 10% foetal calf 
serum (FCS) unless otherwise stated. 
 
2.1.2  Cell lines 
Table 2.1: Human cell lines used in this study. 
Name Description Notes 
Tumour cell lines 
A549 Small cell lung carcinoma cell line  
12S (8) & 
12S(10) 
A549 expressing Ad5 E1A 12S Rasti et al., 2005 
13S (G418) A549 expressing Ad5 E1A 13S Rasti et al., 2005 
293 Ad5 E1 transformed human embryo kidney cells 
(HEK) 
Graham et al., 1977 
911 Ad5 E1 transformed human embryo retinoblasts Fallaux et al., 1996 
H1299 Non small lung carcinoma cell line  
HCT116 Colon carcinoma cell line   
HER lines Human embryonic retinoblast expressing Ad12E1, 
Ad2E1A + mutant ras, Ad5E1A + mutant ras or 
Ad12E1A + mutant ras 
Gallimore et al., 
1986, Byrd et al., 
1982 
T47D Human ductal breast epithelial tumor cell line  
Primary cells 
ICS5491 Tonsil epithelial cells (keratinocytes)*  
B237 Skin Fibroblast cells (HLA-A02, HLA-B4)#  
*Kindly donated by Claire Shannon-Lowe, University of Birmingham 
           #Liquid nitrogen stock, adult lab donor 
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2.1.3 CD8+ T- Cells 
EBV-specific HLA class I restricted CD8+ cytotoxic T lymphocyte clones that were specific 
to the following peptides generated from the LMP2A protein: HLA A*0201-restricted 
epitopes, CLGGLLTMV (CLG), FLYALALLL (FLY); and HLA B*4001-restricted epitope, 
IEDPPFNSL (IED) (Lautscham et al., 2001, 2003). These were kindly donated by Dr Jill 
Brooks, University of Birmingham. The T cells were cultured in 24-well tissue culture 
plates in a medium that contains 10% B-cell serum, 1% human serum, 30% MLA144 in 
RPMI 1640 supplemented with L-glutamine and penicillin/streptomycin. Cells were fed 
once a week by replacing half the medium with the above containing instead 60% 
MLA144.  
 
 
 
2.1.4 Cryopreservation of cells 
Cells were usually frozen at a concentration of 10 – 30 x 106/ ml /cryovial. Cells were first 
harvested by trypsinisation and resuspended in appropriate media. The total number of 
cells was determined using a haemocytometer. After the number of cryovials required 
have been calculated, the cells were pelleted by centrifugation at 1600 rpm for 5 minutes 
then resuspended in warm FCS (pre-incubated at 37C) at twice the density required and 
the tube was placed at 4C. When the cell suspension has chilled, an equal volume of 
freezing medium – FCS with 25% v/v dimethyl-sulphoxide (DMSO) – was added to the 
cells dropwise and with gentle agitation (the cells now being at the correct density for 
freezing). One millilitre aliquots of the resulting solution was transferred to cryovials which 
in turn placed in a “Mr Frosty” freshly filled with isopropanol. The container was 
transferred to the -80C freezer, and finally after 24 hrs, the cryovials were transferred to a 
liquid nitrogen storage tank.  
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2.1.5    Recovery of cells from liquid nitrogen 
To recover cells from nitrogen, the cell suspension were thawed rapidly in a 37C 
waterbath.  The contents of the cryovials were transferred to a centrifuge tube, and this 
was followed by the dropwise addition of 10 mls of the appropriate culture medium 
containing 10% FCS. The cells were then pelleted by centrifugation at 1600rpm and 
resuspended in fresh culture medium and re-plated and incubated at 37C. 
 
2.1.6    Maintenance of cell culture 
Cells were grown in humidified incubators in a 95% air and 5% carbon dioxide 
environment at 37C. Adherent cells were maintained in DMEM containing 10% FCS on 
10cm dishes. To subculture adherent cells, when cells reached confluency, medium was 
removed and cells washed twice with PBS.  Two millilitres of trypsin solution was added 
and dishes left at room temperature for a minute. Trypsin solution was removed and 
dishes were incubated at 37C as necessary. Detachment of the adherent cells was 
confirmed by microscopy, after which 10 mls of media containing FCS was added to 
deactivate the trypsin. After an even suspension of cells was obtained, the cells were re-
plated at a required density by dividing it between the appropriate number of dishes. 
Suspension cells were grown in 75 cm2 tissue culture flasks and subcultured by removing 
50% of the cell culture volume then adding an equal volume of RPMI-1640. 
 
2.1.7    Viral infection  
Cells were infected when cultures were approximately 90% confluent. Aliquots of virus 
was diluted with 0.4 ml serum free DMEM. Culture medium was removed from the cells 
and 0.4 ml of the virus-containing medium was added to each 10cm dish or 0.2 ml virus to 
each 6 cm dish, at an infectivity of 20 plaque forming units (p.f.u) per cell. The dishes 
were incubated at 37C and rocked at 15 minute intervals to ensure the even dispersal of 
the virus. Two hrs after the initiation of the virus infection, excess virus was removed and 
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10 ml of fresh complete media was added to the cells which were subsequently incubated 
at 37C until the harvesting time point. All the cells were grown and maintained in DMEM 
containing 10% FCS.  
 
2.2     Cell biology techniques 
2.2.1   Transient transfection of mammalian cells using Lipofectamine 2000 
Twenty four hours prior to transfection, cells were plated onto 6 cm tissue culture dishes 
such that they would reach 80-90% confluency by the time of transfection. Transfection 
solution was prepared by incubating 5 μl of Lipofectamine 2000 transfection reagent 
(Invitrogen) with 200 μl of Optimem media (serum-free) for five minutes at room 
temperature (5 μl of Lipofectamine 2000 was used for every 1 μg of DNA). One 
microgram of plasmid DNA was diluted into 200 μl of Optimem media. The transfection 
reagent and DNA mixture were then combined, mixed gently and incubated at room 
temperature for 20 minutes to allow DNA-liposome complexes to form. Meanwhile, 
medium from each dish was removed and replaced by 4 mls of fresh DMEM containing 
10% FCS. The transfection mixture was slowly added to the medium, followed by gentle 
rocking of the dish to mix in the transfection medium. The cells were then incubated at 
37C. Transfected cells were harvested at appropriate time after transfection and assayed 
for protein expression or reporter gene activity. The DNA plasmids used for transfection in 
this study are listed in Table 2.3. 
 
2.2.2   Electroporation 
One million cells were used per electroporation with in vitro transcribed mRNA (section 
2.3.11). Cells were harvested by trypsinisation and the total number determined using a 
haemocytometer. The cells were then washed twice with Optimem media by 
centrifugation at 1600 rpm for 5 minutes. One million cells were resuspended in 300μl 
Optimem. One microgram of mRNA was added to the cell suspension and gently mixed 
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then transferred to 4 mm electroporation cuvettes (Cell Projects/Geneflow). Cells were 
pulsed at 300 V voltage, 500 μF capacitance and resistance of ∞. Electroporation 
equipment was Gene Pulser Xcell from Biorad. Three hundred microlitres of pre-warmed 
media containing 10% FCS was added to the electroporated cells and slowly transferred 
to a tube containing an appropriate volume of pre-warmed media that gives the required 
cell density for the assay to follow. Any remaining cells were cultured in a 6 cm tissue 
culture dish and harvested after 24 hrs to check for protein expression. 
 
2.2.3   Flow cytometry analysis 
Flow cytometry was used to stain for MHC class I and class II on the cell surface of cells 
that had been either infected or transformed with adenovirus or electroporated with in vitro 
transcribed mRNA encoding E1A. The effect of AdE1A on the level of MHC class I and II 
prior to and after, interferon gamma (IFNγ) treatment at 400 U/ml was examined.  
Cells were harvested by trypsinisation and washed twice with ice-cold PBS and 
resuspended in 5 mls of PBS. About 5 x 104 - 5 x 105 cells from each treated and 
untreated sample were retained for MHC class I/II staining and the remaining were 
pelleted and resuspended in 9 M urea, 50 mM Tris (pH 7.3) and 0.15 M β-
mercaptoethanol for protein analysis. Cells for staining were pelleted and resuspended in 
20 μl FACS buffer (1% BSA, 0.02% sodium azide in PBS). For blocking reaction, 5 μl of 
mouse polyclonal IgG (Serotec) was added, gently tapped to mix, followed by incubation 
on ice for 30 minutes.  A volume of 75 μl of FACS buffer was added to the cells and mixed 
well.  Fifty microlitres of untreated cells were dispensed into 2 wells of a 96 well v-
bottomed plate (for the IgG2a and untreated MHC I/II), and another 50μl of the IFNγ 
treated in a third well. Three microlitres of each of IgG2a isotype control and MHC class 
I/II antibodies was added to the appropriate wells, gently mixed and left to incubate at 
room temperature for 30 minutes. Subsequently, in case of conjugated antibodies, the 
cells were washed twice with FACS buffer, and finally resuspended in 400 μl of PBS to be 
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analysed by flow cytometry. Unconjugated antibodies require an additional step involving 
an appropriate conjugated secondary antibody and further 30 minutes incubation at room 
temperature. 
 
 
 
2.2.4   20S Proteasome/Immunoproteasome assay 
The caspase-like, chymotrypsin-like and trypsin-like activity of the 
proteasome/immunoproteasome was examined in the presence or absence of AdE1A in 
vitro, using the fluorogenic substrates (Biomol) Z-LLE-AMC, Suc-LLVY-AMC and Bz-
VGR-AMC. The substrates were kept at a stock concentration of 10 mM in DMSO. This 
was diluted to 200 μM using the assay buffer 50 mM Tris pH 7.5, 25 mM KCl, 10 mM 
NaCl, 1 mM MgCl2, prior to being used in an assay. Purified human immunoproteasomes 
(Biomol) were diluted to a working dilution of 6.25 μg/ml. To set up the assays, 50 μl of 
each of the diluted proteasome and appropriate substrate were mixed in an microfuge 
tube, and to observe the effect of AdE1A, 5 μg of the protein was added to the reaction. 
Negative controls consisted of 50 μl of the substrate solution and 50 μl of assay buffer. 
The tubes were incubated at 37°C for 30 minutes. Forty microlitre duplicates of each 
reaction were transferred into individual wells in a 96-well fluorescence plate on ice then 
the reaction was stopped by adding 200 μl per well of stopping buffer, 100 mM sodium 
chloroacetate in 30 mM sodium acetate, 70 mM acetic acid, pH 4.3. The fluorescence of 
each sample was measured on “umbelliferone 360 nm/460 nm” on the Victor2 plate reader 
(Wallac). 
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2.3     Molecular biology techniques 
2.3.1     Bacterial strains 
Table 2.2:  Bacterial strains used in the study 
Strain Genotype 
BL21-codon Plus (DE3)-RIL 
(Stratagene) 
E.coli B F- ompT hsdS (ra-m-a-) dcm+ Tetr gal λ (DE3) 
endA Hte [argU ileY leuW Camr] DH5α 
DH5α (Invitrogen) supE44, ΔlacU169 (Φ80 lacZΔM15) hsdR17 
recA1end A1 gyrA96 thi-1 rellA1 
 
 
2.3.2     Media and buffers 
Luria Broth (LB): 10 g/L bactotryptone (Difco), 5 g/L bacto-yeast extract (Difco) and 10 
g/L NaCl, and was sterilised prior to use. 
 
LB-agar plates: LB was supplemented with 1.5% agar and sterilised. Prior to pouring 
ampicillin was added to a concentration of 100 μg/ml. 
 
2.3.3     Antibiotics 
Ampicillin was made up as a stock solution of 100 mg/ml in sterile water; filter sterilised 
through a 0.2 μm filter and stored at 4C. 
 
2.3.4    Long term storage of bacterial cultures 
A volume of 0.5ml of the 500ml overnight bacterial culture was added to 0.5 ml of 80% 
glycerol in sterile distilled water, gently mixed and frozen at -80°C in cryovials. 
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2.3.5     Plasmid DNA 
Table 2.3: DNA constructs used in the study 
Gene Vector Application Source 
12S Ad5 E1A pcDNA3.1+ Transfection 
In vitro transcription of RNA 
Prof. Joe Mymryk, 
University of 
Western Ontario 
13S Ad5 E1A pcDNA3.1+ Transfection 
In vitro transcription of RNA 
Prof. Joe Mymryk, 
University of 
Western Ontario 
12S Ad12 E1A pcDNA3.1+ Transfection  
In vitro transcription of RNA 
Jailal Ablack, 
University of 
Western Ontario 
13S Ad12 E1A pcDNA3.1+ Transfection 
In vitro transcription of RNA 
Jailal Ablack, 
University of 
Western Ontario 
12S Ad5 E1A 
L19/20A 
pcDNA3.1+ Transfection 
In vitro transcription of RNA 
Rasti et al., 2005, 
2006 
12A Ad5 E1A 
L19/20A 
pcDNA3.1+ Transfection 
In vitro transcription of RNA 
Rasti et al., 2005, 
2006 
LMP2A-HA pCMV.TnT In vitro transcription of RNA Dr Steve Lee, 
University of 
Birmingham 
pGAS-luc Reporter plasmid Luciferase assay Dr Cristina Areste, 
University of 
Birmingham 
pGL3-Basic Reporter plasmid Luciferase assay Dr Cristina Areste, 
University of 
Birmingham 
pGL3-Control Reporter plasmid Luciferase assay Dr Cristina Areste, 
University of 
Birmingham 
pGL3-Renilla Reporter plasmid Luciferase assay Dr Cristina Areste, 
University of 
Birmingham 
 
2.3.6    Measuring DNA concentration 
DNA concentration was measured using a NanoDrop® spectrophotometer.  
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2.3.7     Transformation of bacteria 
Transformation of DNA constructs into BL21 and DH5α competent cells was performed as 
follows (DNA constructs are displayed in Table 2.3). The cells were initially thawed on ice 
and 25 μl aliquots were combined with approximately 50 ng of DNA, and mixed with 
gentle pipetting. Following incubation on ice for 30 minutes, samples were heat shocked 
at 42C for 1 minute and cooled on ice for 5 minutes. After the addition of 250 μl of LB, the 
transformation mixture was incubated at 37C for 1 hr at 220 rpm in a shaking incubator. 
Cells were then pelleted at 13000 rpm for 1 minute, 175 μl of the supernatant removed 
and pellet resuspended in the remaining 100 μl of LB broth which was in turn spread onto 
L-agar plates containing ampicillin. After drying, the plates were incubated overnight at 
37C and analysed the next morning. 
 
2.3.8     Large scale preparation of DNA 
DNA was purified using the Qiagen plasmid maxi kit following the protocol supplied.  
Five millilitres of LB containing 100 μg/ml of ampicillin was inoculated with a single colony 
of bacteria containing the desired plasmid, and left at 37C for 9 hrs at 220 rpm in a 
shaking incubator. The culture was then used to inoculate 250 ml of LB containing 100 
μg/ml of ampicillin, and grown overnight. The following morning the bacterial cells were 
pelleted by centrifugation at 6000 g for 15 minutes at 4C, then resuspended in 10 ml of 
Buffer P1 (resuspension buffer) that had RNase A pre-added to it. Ten millilitres of Buffer 
P2 (lysis buffer) was then added and mixed thoroughly by vigorously inverting the sealed 
tube 4-6 times, and incubated at room temperature for 5 min. Ten millilitres of pre-chilled 
Buffer P3 (neutralisation buffer) was subsequently added and mixed immediately and 
thoroughly by vigorously inverting again 4-6 times, followed by incubation on ice for 20 
minutes. The lysate was centrifuged at 20,000g for 30 minutes to pellet the cell debris. 
The supernatant, which contains the plasmid DNA, was centrifuged again at 20,000 x g 
for 15 minutes to remove any remaining debris. Meanwhile, the QIAGEN-tip 500 (binding 
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column) was equilibrated by the addition of 10 ml of Buffer QBT and the column allowed 
to empty by gravity flow. After centrifugation, the supernatant was loaded onto the 
QIAGEN-tip 500 and allowed to pass through the resin by gravity flow. Once the column 
has emptied, it was washed twice with 30 ml Buffer QC (washing buffer), allowing the 
column to empty by gravity flow each time. The plasmid DNA was eluted by adding 15 ml 
of Buffer QF (pre-warmed to 65C). The DNA in the elutant was precipitated by adding 
10.5 ml of isopropanol, then mixed and centrifuged immediately at 5000 x g for 60 minutes 
at 4C. The supernatant was removed and the resulting DNA pellet was washed with 5 ml 
of 70% ethanol, then again centrifuged at  5000 x g for 60 minutes at 4C. The ethanol 
supernatant was carefully removed and the DNA pellet allowed to air-dry for 5-10 minutes. 
Finally, the pellet was redissolved in the appropriate volume of sterile nuclease-free 
distilled water. 
 
2.3.9     Restriction enzyme digestion 
The digest was carried out for 1.5 hrs at 37°C with restriction enzymes as in the 
manufacturer’s protocol. DNA plasmid constructs were digested so they were linear prior 
to the process of in-vitro translation of mRNA. 
 
XbaI and ClaI (Roche) 
For 1 μg digestion of DNA in a 20 μl mix: 2 μl 10 x restriction enzyme buffer, 0.2 μl of 
acetylated BSA (10 μg/μl), 1 μg of DNA, 0.5 μl restriction enzyme (10 u/μl), were made up 
to a total volume of 20 μl with sterile, nuclease-free water. The reaction was scaled up as 
required. 
 
XhoI (Roche) 
Digests carried out in a volume of 50 μl that contained 2 μg of DNA, 5 μl of 10 x buffer, 
and 25 units of the restriction enzyme. 
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The digests were analysed by agarose gel electrophoresis as described below. 
 
2.3.10   Agarose gel electrophoresis 
Analysis of DNA and RNA was performed using agarose gels prepared with 50 ml of TBE 
(0.89 M Tris Borate pH 8.3, 20 mM Na2EDTA) (Geneflow), 0.8% w.v agarose, and 1 μl of 
SYBR® Safe DNA gel stain (Invitrogen). DNA samples were diluted 1/6 with 6X gel buffer 
[30% v/v of glycerol, 0.25% w/v of bromophenol blue and 0.25% w/v of xylene cyanol FF 
in SDW] and then loaded. Gel electrophoresis was performed in 1X TBE at 60 V for 
approximately 40 minutes, depending on the size of the DNA/RNA to be analysed. 
DNA/RNA was visualised by exposure to UV light. 
 
2.3.11    In vitro transcription of RNA 
RNA for electroporation was in vitro transcribed from 4 μg of DNA construct plasmids 
listed in Table 2.3. It comprises of several steps: 
 
(a) Plasmid DNA linearisation: The first step involved linearising the plasmid using the 
appropriate restriction enzyme that cuts further downstream in the insert (see section 
2.3.8). The linearised plasmid was visualised by 0.8% agarose gel electrophoresis to 
confirm digestion. The DNA was then purified using the High Pure PCR Product 
Purification Kit (Roche), following the manufaturer’s instructions: The total volume of DNA 
was adjusted to 100 μl using nuclease free water, followed by the addition of 500 μl of 
Binding Buffer. The whole mixture was then loaded onto a High Pure filter tube which was 
centrifuged at maximum speed for 60 seconds at room temperature. The flowthrough was 
discarded. This was followed by two washes with 500 μl and 200 μl of Wash Buffer, 
centrifuging at 13000 g for 1 minute at room temperature each time and discarding the 
flowthrough. Finally the purified, digested DNA was eluted in 100 μl of Elution Buffer. The 
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next step was then to precipitate the DNA and resuspend in sterile nuclease-free water to 
obtain the appropriate concentration (see below). 
 
(b) DNA precipitation: To the 100 μl of DNA solution, 10% (10 μl) of 3 M sodium acetate 
(pH 5.5) (Ambion) followed by 250% (250 μl) of ethanol was added and tube incubated at 
-20°C for 30 minutes. To pellet the DNA, the tube was centrifuged at 13000 rpm for 15 
minutes at 4°C, and the supernatant was carefully removed and discarded. A volume of 
500 μl of 70% ethanol was slowly added and the tube centrifuged again at 13000 rpm for 
3 minutes at 4°C. The supernatant was discarded. The pellet was left to air-dry in the 
hood for 5-10 minutes, after which the DNA was resuspended in 18 μl of sterile nuclease-
free water. The DNA is now ready for the in vitro transcription reaction. 
 
(c) RNA in vitro transcription reaction: This reaction enables the synthesis of mRNA from 
the linearised DNA plasmid template. The pcDNA3 plasmids used contain T7 promoter, 
hence enabling in vitro transcription using the T7 RNA polymerase. The in vitro 
transcription reaction was assembled at room temperature using the components of the 
mMESSAGE mMACHINE® T7 kit (Ambion): 18 μl of cleaved DNA, 10 μl of 2 x NTP/CAP, 
6 μl of 10 x reaction buffer, 6 μl enzyme mix in a total volume of 60 μl. The NTP/CAP 
buffer contains ATP, CTP, UTP, GTP and cap analog. This allows 5’ capping of the newly 
formed mRNA. This step is crucial for creating mature and stable mRNA for translation.  
The reaction buffer contains mainly salt, buffer and dithiothreitol creating conditions for 
optimal enzymatic activity. The main constituents of the enzyme mix are buffered 50% 
glycerol containing T7 RNA polymerase and RNase inhibitor. All the components were 
mixed by flicking the tube and micro-centrifuging briefly. The reaction mix was incubated 
in a 37°C water bath for 2 hrs. In order to remove the DNA template, 3 μl of TURBO 
DNase was added and the reaction incubated again for a further 15 minutes.    
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(d) RNA clean up:  RNA was recovered using the RNeasy® mini kit (Qiagen) following the 
manufacturer’s protocol. The sample volume was adjusted to 100 μl with RNase-free 
water then 350 μl of lysis buffer RLT (pre-mixed with β-mercaptoethanol) was added, and 
mixed thoroughly. A volume of 250 μl of 100% ethanol was also added to the diluted RNA 
and mixed thoroughly by pipetting. The whole mixture was loaded onto an RNeasy mini 
column (that was placed in a 2 ml collection tube). Buffer RLT is a guanidine 
isothiocyanate-containing lysis buffer. Both RLT and ethanol create conditions that 
promote selective binding of RNA to the RNeasy mini column membrane. The column 
was centrifuged for 15 seconds at 10000 rpm. The collection tube with the flowthrough 
was discarded and replaced. This was followed by two washes with 500 μl of wash buffer 
RPE (pre-added with ethanol) at 10000 rpm for 15 seconds and 2 minutes, discarding the 
flow through each time. The empty column was placed in a new collection tube and spun 
again for 1 minute at maximum speed to remove any traces of wash buffer RPE. Finally 
the RNA was eluted twice with the same 30 μl of RNase free water by centrifuging for 1 
minute at 10000 rpm each time. RNA yield was determined by spectrophotometry 
(NanoDrop). 
 
(e) Polyadenylation of RNA: A reaction mix was assembled as follows: 5 μl reaction buffer 
(USB), 20 μg of RNA, 1.25 μl of 10 mM ATP (USB), 1 μl of 600 U poly (A) polymerase 
(USB), and RNase-free water to make up the volume to 25 μl. The reaction was mixed 
well and incubated at 37°C in a water bath for 20 minutes. The polyadenylation reaction 
enables the addition of the poly (A) tail (consisting of multiple adenosine 
monophosphates) to the mRNA molecule. The tail protects mRNA from degradation by 
enzymes in the cytoplasm as well as aiding export from the nucleus, and translation 
(Guhaniyogi and Brewer 2001).  
 
(f) Polyadenylated mRNA purification: The above reaction mix was made up to 300 μl with 
RNase-free water, and an equal volume of phenol chloroform was added and mixed by 
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gentle vortexing. The tube was centrifuged at 13000 rpm for 10 minutes at 4°C to 
separate the layers. The top aqueous layer that contained the purified RNA was carefully 
aspirated and transferred to a fresh tube. This RNA was then ethanol-precipitated by 
adding 10% (v/v) 3M sodium acetate (pH 5.5) (Ambion) and mixed. This was followed by 
the addition of 250% (v/v) ethanol and incubated at -80°C for 30 minutes. The tube was 
centrifuged at 13000 rpm for 20 minutes at 4°C, and the supernatant carefully removed 
and discarded. The RNA pellet was washed with 500 μl of 70% ethanol and centrifuged 
again at 13000 rpm for 5 minutes, and the supernatant carefully discarded. The pellet was 
left to air dry in the hood and finally the purified polyadenylated mRNA was resuspended 
in 20 μl of RNase free water. RNA yield was determined again and RNA aliquoted and 
stored at -80°C. 
 
2.3.12    Luciferase assays 
Typically, 0.5-2 μg of the relevant DNA constructs was transfected into H1299 cells in 6-
well tissue culture plates using Lipofectamine 2000 according to the manufacturer’s 
instructions (see Table 2.3). “Empty” pcDNA3.1 vector was used as a negative control for 
the transfections. All luciferase assays were carried out using the Dual-Luciferase® 
Reporter assay system (Promega) using white opaque 96-well optiplates (PerkinElmer), 
following the manufacturer’s instructions. After 48 hrs (including the 24 hrs IFNγ 
treatment), the cells were washed once with PBS, removing all traces of the rinse solution. 
500 μl of Passive Lysis Buffer (PLB) was dispensed into each well, and the plates left to 
rock gently for 15 minutes at room temperature. Each of the lysates was subsequently 
transferred to a tube. Twenty microlitres of each sample was pipetted into the white 
optiplate wells in triplicates, followed by the addition of 100 μl of LARII substrate. The 
firefly luciferase activity was measured using the luminometer (Victor2, Wallac). To 
measure the Renilla luciferase activity, a further 100 μl Stop & Glo® Reagent was added 
into each well then activity determined again by the luminometer. Luciferase readings are 
normalized by Renilla. The Renilla is a control reporter that is co-transfected into cells in 
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addition to the luciferase reporter. It has a different substrate to Luciferase thus allowing 
the evaluation of transfection efficiency. The data are normalised by dividing each 
luciferase reading by the Renilla values; in that way the variation in transfection efficiency 
is incorporated in the observed readings. 
 
2.3.13    In vitro translation of radio-labelled protein 
Eukaryotic in vitro translation was carried out using the Promega TNT T7/SP6 coupled 
rabbit reticulocyte system following the manufacturer’s instructions. Briefly, the reaction 
consisted of 25 μl reticulocyte lysate, 2 μl reaction buffer, 1 μl T7 RNA polymerase, 1 μl of 
1 mM amino acid mixture minus methionine, 2 μl of [35S]-methionine (1000 Ci/mmol at 
10mCi/ml; Amersham Biosciences), 0.5 μl RNasin ribonuclease inhibitor (40 U/μl), 1μg of 
DNA template and nuclease free water to a final volume of 50 μl. The reaction was 
incubated at 30C for 90 minutes, quickly centrifuged and then stored at -80C. 
 
2.3.14    GST fusion protein production and purification 
pGEX 4T-1 expression constructs containing the coding sequence of interest downstream 
of a region that encodes glutathione S-transferase (as displayed in Table 2.3) were 
transformed into BL21 cells and plated out as previously described. The following day, two 
colonies were used to inoculate 15 mls of LB containing 100 μg/ml ampicillin. This starter 
culture was incubated overnight at 37°C with shaking at 200 rpm. This was then used to 
inoculate 500 mls of LB in the presence of 100 μg/ml ampicillin; the cultures were placed 
in a 200 rpm shaker at 37°C for approximately 1.5 hrs, and the optical density 
subsequently monitored. Once the bacteria had reached an appropriate absorbance of 
0.6-0.8 (indicating that they were in the log phase of growth), the culture was cooled to 
30°C and incubated for 3 hrs in the presence of 0.02% w/v isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Sigma). The bacterial cells were then pelleted at 5000 rpm 
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for 15 minutes at 4°C, and stored at -80°C until ready to be used in lysis and protein 
purification. 
In order the purify the GST-fusion proteins, the bacterial cell pellet was lysed in 20 mls of 
lysis buffer containing PBS, 1 mM EDTA (pH 8) and 1% v/v Triton X-100. The lysate was 
sonicated 3 times on ice for 45 seconds, at two minute intervals. The lysate was then 
centrifuged at 15000 rpm for 10 minutes at 4°C to remove the cell debris, and the 
supernatant transferred to a fresh tube and then centrifuged again at 18000 rpm for 30 
minutes at 4°C. The supernatant was mixed with 2 mls of a suspension of 1:1 lysis buffer 
and glutathione-agarose beads (Sigma), and rotated for 2 hrs at 4°C. The beads were 
centrifuged at 3000 rpm and the supernatant transferred to a fresh tube (to which fresh 
beads were added and the whole process repeated), while the original beads were 
washed three times in lysis buffer and twice with wash buffer (PBS, 2 mM EDTA, pH 8). In 
order to elute the GST-fusion proteins, the glutathione agarose beads were incubated 
twice with 2 ml of 20 mM glutathione and 50 mM Tris solution pH 8 at 4°C for 1 hr with 
rotation each time.  Each of the eluants containing the GST-fusion protein was transferred 
to dialysis tubing, which was previously hydrated in distilled water. Overnight dialysis was 
carried out  at 4°C in 5 litres of 0.1 M NaCl, 50 mM Tris, 0.1 mM dithiothreitol (DTT) 
(Sigma), adjusted to pH 7.3. The dialysed GST-fusion protein was transferred to a new 
tube and its protein concentration determined by Bradford assay and quantified against a 
standard curve. The purity of the proteins was assessed by SDS-PAGE electrophoresis 
and Coomasie blue staining. The protein was stored in aliquots at -80°C. 
 
2.4     Protein chemistry techniques 
2.4.1    Preparation of cultured adherent cell samples for protein analysis by 
Western blotting 
Tissue culture medium was removed and cells were washed twice in 5ml of cold saline. 
Cells were lysed in buffer containing 9 M urea, 50 mM Tris (pH 7.3) and 0.15 M β-
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mercaptoethanol, and then detached from the tissue culture dish with a plastic cell scraper 
and transferred to a microfuge tube. Harvested cells were sonicated for 10 seconds. 
Protein concentration was determined and samples stored at -20C. 
 
2.4.2    Protein determination by Bradford assay 
A small volume (2-10 μl) of the protein sample was carefully diluted and mixed with 1ml of 
Bradford reagent (BioRad) which was pre-diluted 1:5 with distilled water. The resultant 
mixture was vortexed to mix. The absorbance was measured in a spectrophotometer at λ 
595 nm against the distilled water blank. Protein concentrations were determined by 
comparison with a standard calibration curve prepared from known quantities of bovine 
serum albumin (0-10 μg). 
 
2.4.3    Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Immunoprecipitates, GST pull-down samples, or 50 μg of whole cell lysates were 
electrophoresed on 11% polyacrylamide gels made from 30% bisacrylamide stock 
solution (Severn Biotech), 0.1 M Tris, 0.1 M Bicine (N,N-bis [2-hydroxy-ethyl-glycine]) pH 
8.3, 0.1% SDS and 0.3% v/v TEMED (N,N,N’,N’-tetramethyl-ethylenediamine) in a total 
volume of 50 ml. After the addition of 300 μl of 10% ammonium persulphate solution 
(APS), the gel was poured into the apparatus (Hoefer) and left to polymerise. A well-
forming comb was inserted into the gel before polymerisation occurred. Once the gel has 
set the comb was removed, the wells were rinsed with distilled water and immersed in 
running buffer (0.1 M bicine, 0.1 M Tris pH 8.3, 0.1% w/v SDS). Samples were diluted with 
an equal volume of Laemmli sample buffer (25% v/v glycerol, 62.5 mM Tris pH 6.8, 5% β-
mercaptoethanol, 2% w/v SDS and 0.01% w/v bromophenol blue), boiled for 5 minutes 
and applied to the gel. Pre-stained molecular weight markers were also applied to the gel. 
The samples were typically electrophoresed overnight, at 10 mA in running buffer. 
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2.4.4    Alkaline urea gel electrophoresis (urea-PAGE) 
Immunoprecipitated samples for immunodetection of AdE1A were fractionated in the 
absence of SDS on 15% polyacrylamide gels, containing 7 M urea, 15.2 mM Tris, 96 mM 
glycine, pH 8.5, 0.1 ml TEMED and 0.25 ml 10% APS in a total volume of 50 ml. The gel 
was poured into the apparatus and overlaid with a thin layer of water-saturated butan-2-ol 
(1:3). When the gel had fully polymerised, the butan-2-ol was washed off with water. 
Before loading the samples, the gel was pre-run for 1 hr at 25 mA in a running buffer of 
15.2 mM Tris, 96 mM glycine, pH 8.5. 50 μl of the immunoprecipitate or 25 μg of the 
protein lysate was diluted in an equal volume of urea buffer (9 M urea, 50 mM Tris-HCl pH 
7.4, 150 mM β-mercaptoethanol and 0.03% bromophenol blue). Samples were loaded 
onto the gel and electrophoresed at 15 mA for 4 hrs, followed by Western blotting. AdE1A 
migrates into the urea gel based on its negative charge (a preponderance of acidic amino 
acids) and relatively low molecular weight. Before, the urea gel is used for separation of 
low-molecular-weight acidic proteins, which have marked differences in charge (pI) or 
conformation (Grand and Gallimore 1984). As high molecular weight proteins such as 
antibodies (Ab) are not able to migrate into the gel, urea gels are a good way for analysing 
some proteins when the heavy chain of the Ab against the target protein is of similar 
molecular weight to the protein of interest. 
 
 
2.4.5    Staining of polyacrylamide gels 
After electrophoresis, gels were stained in 0.1% w/v Coomasie brilliant blue R-250 
(Sigma) in methanol/glacial acetic acid/water (3:1:6 v/v) on a shaker for 20 minutes at 
room temperature, and subsequently destained in methanol/glacial acetic acid/ water 
(3:1:6 v/v) as required. 
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2.4.6    Staining of proteins on nitrocellulose membranes 
To evaluate even loading and efficient transfer of proteins after electroblotting, 
nitrocellulose membranes were stained with Ponceau S stain (0.1% w/v Ponceau S 
(Sigma) and 3% w/v trichloroacetic acid (TCA)) for 1 minute. Excess stain was washed off 
with distilled water. After visualisation of protein bands, the dye on the membrane was 
removed with Tris-buffered saline with Tween 80 (TBS-T) (0.1% v/v TweenTM 80, 8 g/L 
sodium chloride and 0.02 M Tris-HCl pH 7.6) and the proteins on it were subjected to 
immunoblot analysis. 
 
2.4.7    Detection of radioactive proteins on gels 
Following electrophoresis, gels were stained with Coomasie Blue as previously described. 
The gel was then soaked in the AmplifyTM reagent (Amersham Bioscience) for 30 minutes 
with agitation. AmplifyTM reduces exposure times for gels containing [35S]-labelled 
samples. The gel was dried under vacuum at 80C for 1 hr and exposed for 
autoradiography at   -20C. 
 
2.4.8    In vitro GST pulldown assays 
The binding capacity of [35S]-labelled LMP2, LMP7 and MECL-1 for GST-12SAd5E1A, 
13SAd5E1A and 13SAd12E1A, and their corresponding GST-tagged mutant fragments 
were assayed by GST-pulldown assay. Typically, 20 μg of GST-fusion protein was 
incubated with 10-20 μl of [35S]-labelled protein on ice for 2 hrs in PBS, 1 mM EDTA, 1% 
Triton x100. The volumes were then equalised by adding 1 ml of lysis buffer and protein 
complexes were isolated by incubation with 20μl glutathione-agarose beads for 1 hr with 
rotation at 4°C. Beads were then washed with 1 ml of lysis buffer 3 times followed by a 
further two washes in PBS, 2 mM EDTA, pH 8. GST-protein complexes were then eluted 
with 60 μl of buffer containing 20 mM glutathione and 50 mM Tris pH 8, on ice for 1 hr with 
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occasional mixing. The beads were pelleted and supernatant containing the protein 
complexes transferred to a fresh tube. A further 40 μl of the elution reagent was added 
and tube left on ice for a further 30 minutes. The beads were pelleted again and 
supernatant pooled together with the previous 60 μl elution. Lastly, the eluate was mixed 
with Laemmli sample buffer and boiled for 2 minutes in preparation for SDS-PAGE. 
 
2.5     Immunological techniques 
2.5.1    Antibodies 
Table 2.4: Antibodies used in the study. 
Name Species 
M.W. 
(K) 
Application Dilution Source 
Anti-LMP2 Rabbit polyclonal 23 WB 1:2000 AbCam 
Anti-LMP7 Rabbit polyclonal 20 WB 1:2000 AbCam 
Anti-MECL-1 Rabbit polyclonal 29 WB 1:10000 
Dr Marcus Groettrup, 
University of Constance 
Anti-20S 
(α1,2,3,5,6 and 7 
subunits) 
Mouse 
monoclonal 
29,32 WB, IP 1:2000 Biomol 
Anti-Ad5 E1A 
(M73/M58) 
Mouse 
monoclonal 
45 WB 1:2000 E. Harlow et al., 1985 
Anti-Ad12 E1A 
Mouse 
monoclonal 
45 WB 1:10 In-house 
Anti-Ad5 E1B 
(2A6) 
Mouse 
monoclonal 
58 WB 1:10 
A. Levine (Sarnow et al., 
1982) 
Anti-Ad12 E1B 
(XPH9) 
Mouse 
monoclonal 
58 WB 1:10 Merrick et al., 1991 
Anti-β actin Mouse 45 WB 1:20000 Sigma 
Anti-mouse HRP Goat IgG - WB 1:2000 Dako 
Anti-rabbit HRP Swine IgG - WB 1:3000 Dako 
Anti-human HLA 
ABC (class I) 
Mouse 
monoclonal 
- 
Flow 
cytometry 
 Serotec 
Anti human HLA 
II DP DQ DR 
RPE (class II) 
Mouse 
monoclonal 
- 
Flow 
cytometry 
 Serotec 
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IgG2a Isotype 
control PE 
Mouse 
monoclonal 
- 
Flow 
cytometry 
 R & D systems 
of CD107a-FITC 
antibody 
Mouse 
monoclonal 
- 
Flow 
cytometry 
 BD Pharmingen 
 
 
2.5.2    Western blotting 
Following electrophoresis, cell lysates were electrophoretically transferred to a 
nitrocellulose membrane. A blotting cassette was set up containing a piece of 
nitrocellulose membrane pre-soaked in blotting buffer (0.05 M Tris, 0.19 M glycine and 
20% v/v methanol). The membrane was placed onto a sheet of 3 MM Whatman filter 
paper on a blotting pad and then the gel was placed onto the nitrocellulose membrane. 
The gel was then overlaid with another sheet of pre-soaked 3 MM Whatman filter paper 
and a second blotting pad. The blotting cassette was placed in a Hoefer transblot 
electrophoresis apparatus that was filled with blotting buffer with the nitrocellulose towards 
the anode. Blotting was carried out for 6-7 hrs at 20-30 volts. After transfer, the membrane 
was stained with Ponceau S stain as previously described, in order to visualise the 
transferred proteins. The membrane was then washed for 10 minutes in Tris-buffered 
saline with Tween 80 (TBS-T) (0.1% v/v TweenTM 80, 8g/L sodium chloride and 0.02 M 
Tris HCl pH 7.6) to remove the Ponceau S stain. The nitrocellulose membrane was 
incubated on an orbital shaker for 1 hr at room temperature in blocking agent (5% w/v 
skimmed dried milk, in PBS) to block non-specific binding sites. Primary antibodies were 
diluted in TBS-T with 5% w/v skimmed milk, and added to the blots in polythene bags, 
which were heat sealed and incubated for 5 hrs at room temperature or overnight at 4°C 
on a rocking platform. The membrane was rinsed and washed with 6 x 5 minute washes in 
TBS-T. Blots were then incubated with the appropriate secondary antibody conjugated to 
horseradish peroxidase, which was diluted in TBS-T with 5% w/v skimmed milk and 
incubated for 1-2 hrs at room temperature on a rocking platform. After a further 6 x 5 
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minute washes in TBS-T, the antigen-antibody complex was visualised using the 
enhanced chemiluminescence (ECL) detection reagent (ImmobilonTM Western, Millipore). 
The membranes were soaked in 1:1 mixture of ECL detection solution for one minute. The 
membranes were wrapped, protein side up, in a Saran wrap and exposed to X-ray film for 
an appropriate period of time. Exposure times, ranging from a few seconds to 5 minutes 
were used, depending on the protein being detected or the primary antibody. 
 
2.5.3    Immunoprecipitation of proteins 
Cells were lysed in 0.5 ml of immunoprecipitation (IP) buffer containing 50 mM Tris pH 
7.4, 0.825 M NaCl and 1% v/v NP-40. Cell lysates were centrifuged at 35000 rpm for 20 
minutes at 4°C. Protein complexes were then immunoprecipitated by adding an 
appropriate antibody, typically 10 μl, and mixed by rotation overnight at 4°C. The resulting 
protein-antibody complexes were then mixed for a further hour with 20 μl of packed 
protein G agarose beads (Sigma). Immunocomplexes bound to the beads were then 
centrifuged and washed three times with 1 ml of IP buffer, prior to resuspending in 
Laemmli sample buffer and boiling for 5 minutes in preparation for alkaline urea gel 
electrophoresis. 
 
2.5.4    Enzyme linked immunosorbent assay (ELISA) 
ELISA was used to measure IFNγ release from T cells incubated with target cells 
expressing the appropriate epitope in the absence or presence of AdE1A.  The assay was 
first set up by incubating the appropriate T-cells with target cells (fibroblasts) that were 
electroporated with mRNA encoding the LMP2A epitope (from Epstein Barr Virus) in the 
presence or absence of mRNA encoding AdE1A. In one well, 1x103 CD8+ T-cells to 5x104 
electroporated fibroblasts were used in the assay and 1 μg of RNA was used to 
electroporate 106 fibroblasts. Background levels were monitored by incubating each of the 
targets and T cells alone with only media. The cells were incubated in 96-well round-
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bottomed plates overnight at 37°C. On the same day as this was being set up, Maxisorp 
plates (Nunc) were coated with 50 μl anti-human IFNγ antibody (Thermo-Scientific) that 
was diluted 1/1360 to 0.75 μg/ml in coating buffer (0.1 M Na2HPO4 adjusted to pH 9 with 
0.1 M NaH2PO4), and left overnight (covered in foil) at 4°C. The next day, the coating 
antibody was flicked off and 200 μl of blocking buffer (1%BSA in PBS, filtered, 0.05% 
Tween 20) was added to each well and left to incubate at room temperature for 1 hr 
(covered in foil). In the meantime, standards using two-fold dilutions of IFNγ from 2000 
pg/ml to 31.25 pg/ml in ELISA medium (RPMI1640, 10% FCS) plus ELISA medium alone 
were prepared for the purpose of generating a standard curve.  The Maxisorp plates were 
washed six times with PBS-T (PBS/0.05% v/v Tween 20) using a water bottle to squirt 
each well thoroughly. Subsequently, 50 μl of standard and test supernatants from the 
cultures in the round-bottomed plates were carefully dispensed into each well of the 
Maxisorp plates and then left to incubate at room temperature for 2-4 hrs. After this, the 
plates were washed again 6 times with PBS-T followed by the addition of 50 μl of biotin-
labelled anti-human IFNγ antibody that has been diluted with blocking buffer to 0.36 μg/ml. 
The plates were left to incubate at room temperature for 1 hr, and then washed 6 times 
with PBS-T followed by the careful addition of 50 μl of Extravidin Peroxidase (Sigma) 
diluted 1/1000 with blocking buffer and plates were left incubating at room temperature for 
30 minutes. The plates were washed 8 times with PBS-T for the last time and 100 μl of 
TMB substrate (tebu-bio laboratories) was dispensed in each well. The plates are left at 
room temperature for 20 minutes. The reaction was stopped by the addition of 100 μl of 
0.1 M hydrochloric acid. The absorbance was finally read at 450 nm on a plate reader 
(Victor2, Wallac). 
 
2.5.5    Chromium release assay 
On designated work stations for radioactive use, chromium release assays were carried 
out in conjunction with ELISA as confirmation of T-cell killing. 24 hrs after fibroblasts had 
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been electroporated, they were labelled with 51Cr Chromium (sodium chromate in PBS). 
Approximately 5x105 fibroblasts were first washed once with 10 ml RPMI-1640 with 
centrifugation at 1600 rpm for 5 minutes. To the pellet of cells, 20 μl of 51Cr was added 
and then placed in an incubator for 90 minutes at 37°C with gentle shaking to mix every 
15 minutes. Meanwhile, during this incubation time, the appropriate T-cells were prepared 
by resuspending them at two concentrations of 2.5 x 105/ml and 1.25 x 105/ml. The 
labelled fibroblasts were washed twice with RPMI-1640 containing 10% FCS and then 
resuspended at 2.5 x 104/ml. One hundred microlitres of this cell suspension was pipetted 
into each well (5000 cells/well) in triplicate in a V-bottomed 96-well assay plate. One 
hundred microlitre of the previously prepared T-cells were dispensed into the plated 
fibroblasts (2.5 x 104/well and 1.25 x 104/well). For spontaneous (background) and 
maximum release, targets were plated alone with 100 μl media and with 100 μl of 1% 
SDS respectively (in place of T-cells). Additional controls also include, using peptide-
loaded chromium-labelled LCLs. Here chromium labelling also includes addition of the 
appropriate peptide while the remaining method stayed the same. The plate was 
centrifuged for 3 minutes at 1000 rpm and then incubated for 6 hrs at 37°C. A volume of 
100 μl of the supernatant was harvested from each well and transferred into LP2 tubes, 
racked in an empty 96-well plate. The 51Cr Chromium release was counted using a 
gamma counter.  
 
2.5.6    CD107a staining 
CD107a staining was conducted simultaneously with the ELISA  (section 2.5.4). Some 
electroporated fibroblasts from the ELISA assay were retained for this experiment. This 
assay was used to measure the level of CD107a on the surface of T-cells. CD107a is a 
functional marker of CTL degranulation following stimulation (Betts and Koup 2004). CTLs 
degranulate after recognition of a peptide-MHC class I complex on a target cell. It 
comprises several steps: 
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(a) Peptide loading of LCL control:  Approximately 2 x 106 of the appropriate HLA-
matching LCLs were washed twice with serum-free RPMI-1640 and resuspended in 200 
µl of the same media. The cell suspension was split into two 15 ml tubes, and 100 µg/ml 
of the appropriate peptide was added to one tube and an equivalent volume of DMSO to 
the other. Both were incubated at 37°C for 90 minutes with occasional shaking (every 15 
minutes). During the 90 minute incubation time, T-cells and fibroblasts (targets)  
electroporated with the appropriate mRNA were prepared (see below). At the end of the 
incubation, LCLs were washed with 10% FCS RPMI-1640 and resuspended at 5 x 105 – 1 
x 106/ml (1:1 ratio with T-cells).   
 
(b) Preparation of T-cells:  T-cells were harvested and washed twice with 10% FCS RPMI-
1640, then resuspended at 5 x 105 – 1 x 106/ml. Fifty microlitres of this was aliquoted to 
the required number of wells (in triplicates) to a 96-well V-bottomed plate (2.5 x 104 – 5 x 
104 T-cells per well). Unused wells were filled with 200 µl of media. 
 
(c) Electroporation of fibroblasts: About 1 x 106 fibroblasts were electroporated as 
described in section 2.2.2. The cells were finally suspended at 5 x 105 – 1 x 106/ml (1:1 
ratio with the T-cells). Fifty microlitres were aliquoted from this to each well.  
 
(d) Setting up the plates:  Fifty microlitres of T-cells were aliquoted to the required number 
of wells (in triplicates).  Five microlitres of CD107a-FITC antibody (BD Pharmingen) was 
added to each well containing the T-cells (with the exception of the compensation wells). 
This was followed by the addition of 50 µl LCLs, and fibroblasts to each of the appropriate 
wells. Five microlitres of monensin was added to each well and mixed. A summary of the 
plate plan is illustrated in Table 2.5 below. Finally, the plate was centrifuged for 3 minutes 
at 1000 rpm and incubated at 37°C for 12 hrs. 
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(e) Flow cytometry: After the 12 hr incubation, the cells were washed twice with 150 µl of 
FACS buffer (1% BSA, 0.02% sodium azide in PBS) and then finally resuspended in 50 µl 
of the same solution. Five microlitres of CD3 FITC (for the compensation control) or CD3 
PE (for the experimental samples) was added and plate left to incubate at room 
temperature for 30 minutes. The cells were washed twice again with FACS buffer, then 
finally resuspended in 600 µl PBS. The samples were analysed via flow cytometry. 
 
The plate plan illustrating the different additions is summarized in Table 2.5 below. 
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 T cells only T cells + Targets 
 Controls and compensation Experimental 
Well 1 2 3 4 5 6 7 8 9 
Purpose Background PE (FL2) 
FITC 
(FL1) 
CD107a 
Background Mock LMP2a 
LMP2a + 
E1A LCL 
LCL 
+PEPTIDE 
Surface Stain 
CD107a-
FITC (μl) 
0 0 0 5 5 5 5 5 5 
Monensin 
(μl) 5 5 5 5 5 5 5 5 5 
12 hrs Incubation at 37°C 
CD3-PE 
(μl) 0 5 0 5 5 5 5 5 5 
CD3-FITC 
(μl) 
0 0 5 0 0 0 0 0 0 
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INTERACTION OF AdE1A WITH THE 
IMMUNOPROTEASOME 
COMPONENT MECL-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 89 ~ 
 
3.1     Introduction 
Adenovirus early region 1A (AdE1A) functions primarily through a complex series of 
protein-protein interactions targeting various cellular regulatory proteins involved in cell 
cycle, DNA synthesis, differentiation, apoptosis, transcription and antigen processing 
(Berk 2005; Gallimore and Turnell 2001, Mymryk 1996).  AdE1A exists in various isoforms 
with mRNAs 12S and 13S being the most abundant. These encode  243 and 289 amino 
acid 12S and 13S AdE1A proteins respectively in Ad2/Ad5.  Both proteins are identical 
with the exception of a 46 amino acid conserved region 3 (CR3) region that is present in 
13SAdE1A. Comparison of AdE1A amino acid sequences from the different adenovirus 
serotypes of human and simian origin have revealed the presence of 4 highly conserved 
regions known as CR1, CR2, CR3 and CR4 (Kimelman et al., 1985; Avvakumov et al., 
2002, 2004). These encompass amino acid 42-72, 113-137, 144-191 and 240-288 
respectively in the Ad513SE1A; and there is also an N-terminal region, amino acids 1-39, 
which is less conserved but equally important in mediating interactions. The conserved 
regions and the N-terminal region mediate nearly all of the interactions of AdE1A with 
cellular binding partners. Cellular protein targets bind to one or more of these regions, 
hindering their normal activity and creating a suitable environment for viral replication.  
Immunoproteasomes are a subtype of 20S proteasomes whose expression can be 
induced following IFNγ exposure of cells. They are more efficient than 20S proteasomes 
at presenting to CD8+ T-cells peptides of viral origin. Past studies of the relationship of 
AdE1A and immunoproteasomes have shown that there is a down-regulation of 
immunosubunit expression in Ad12 transformed rat cells compared to those transformed 
by Ad5. (Vertegaal et al., 2003; Rotem-Yedudar et al., 1996). A further study revealed 
down-regulation of LMP2 transcription by adenovirus AdE1A (Chatterjee-Kishore et al., 
2000). Research into AdE1A inhibition of immunosubunits hinted at disruption of the 
JAK/STAT pathway, specifically the repression of STAT1 activity, however these studies 
did not examine whether if AdE1A also targets immunosubunits through direct binding 
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(Look et al., 1998).  In this chapter, we consider the relationship of AdE1A and 
immunosubunit interaction in detail, to investigate if AdE1A directly binds to the 
immunoproteasome subunits LMP2, LMP7 and MECL1, and if that is the case, what 
regions on AdE1A are involved in this interaction. We also examine AdE1A binding to the 
catalytic β1, β2 and β5 subunits of the 20S proteasome.  
 
 
3.2    Results  
3.2.1   Co-immunoprecipitation of AdE1A with the immunoproteasome 
To examine AdE1A binding to the immunoproteasome, a co-immunoprecipitation (IP) 
experiment (as in section 2.5.3) was carried out using H1299 cells that had been treated 
with IFNγ for 48 hrs prior to Ad5 infection for a further 24 hrs. Protein complexes were 
immunoprecipitated with LMP7 antibody. Immunoprecipitates were run on urea gels in the 
absence of SDS then blotted for AdE1A. The results show that AdE1A co-
immunoprecipitated with the immunoproteasome and the proteasome (Figure 3.1) as has 
been shown previously (Grand et al., 1999; Turnell et al., 2000). 
 
 
3.2.2 In vitro binding of AdE1A to MECL-1 
In vitro binding of AdE1A to the individual immunoproteasome subunits was also tested. 
The binding capacity of in vitro translated [35S]-labelled LMP2, LMP7 and MECL-1 for GST 
tagged 12SAd5E1A, 13SAd5E1A, and 13SAd12E1A was analysed by GST pull-down 
assay (as in section 2.4.8). Twenty microgram of GST-fusion protein was incubated with 
10-20 µl of the in vitro translated [35S]-labelled immunosubunits. GST- pulldown was 
carried out using glutathione-sepharose beads; and the bound proteins were eluted with 
25 mM glutathione solution; the resulting eluate was resolved by SDS-PAGE. The relative 
binding capacity of each immunosubunit was visualised by autoradiography (section 
2.4.7). The results show that [35S]-labelled MECL-1 but not [35S]-labelled LMP2 or [35S]-
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labelled LMP7 bound to GST -12SAd5E1A, GST-13SAd5E1A and GST-13SAd12E1A 
(Figure 3.2). 
 
3.2.2.1 Sites of interaction on Ad5E1A for MECL-1 
In light of the above observation that showed AdE1A binding specifically to MECL-1, we 
next investigated what regions of Ad5E1A are involved in this interaction. The binding of in 
vitro translated [35S]-labelled MECL-1 to GST-tagged fragments from across the length of 
Ad5E1A was analysed by GST-pulldown assay. The GST fragments were amino acids 1-
40, 41-80, 81-140, 141-185, 186-289 (which encompass the N-terminal region, CR1, CR2, 
CR3 and CR4 respectively) as well as GST alone and GST-13SAd5E1A as negative and 
positive controls respectively. The results (Figure 3.3) indicated that [35S]-labelled MECL-1 
binds strongly to the N-terminal region (amino acid 1-40) and CR3 region (amino acids 
141-185) of Ad5E1A. The amino acids within these two regions that have an important 
role in this binding were further mapped (see 3.2.2.2 and 3.2.2.3 below). 
 
 
3.2.2.2   Mapping the binding sites within the Ad5E1A N-terminal region 
The sites of interaction for MECL-1 in the N-terminal region of AdE1A were further 
defined, by assessing the role of each residue in the N-terminal region in this interaction. 
Twenty-two GST-12SAd5E1A proteins with a series of point mutations (Figure 3.4) across 
the N-terminal region (Rasti et al., 2005) were incubated with in vitro translated [35S]-
labelled MECL-1 in a pulldown assay. The raw autoradiography results are shown in 
Figure 3.5A. These were analysed by densitometry (Figure 3.5C). The results show that 
mutations at mainly hydrophobic residues: L20A, L19/20A, D21A, L23A, I24A and L28A 
have severely disrupted binding of the N-terminal region to MECL-1 (Figure 3.5C).  
Whereas R2G, I5G, C6A, H7A, G8A, V10A, I11A, T12A, E14A, A16G, S18G, E25A, 
E26A, V27A, A29G and D30A bound to [35S]-labelled MECL-1 as well as wild type 
12SAd5E1A (Figure 3.5A).  
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Figure 3.1 Ad5E1A binds to the immunoproteasome  
H1299 cells were treated with IFNγ for 24 hrs followed by infection by Ad5 virus for a 
further 24 hrs. Immunoprecipitation was carried out with the antibodies shown in the 
figure, 20S proteasome antibody: anti-α1, 2, 3, 5, 6 and 7 (mouse), anti-S8 antibody 
(rabbit) and anti-LMP7 (rabbit). Immunoprecipitated proteins were run on urea gels in the 
absence of SDS, then blotted for Ad5E1A. 
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Figure 3.2  AdE1A binds to MECL-1 but not LMP2 or LMP7  
Ten microlitres of [35S]-labelled LMP2, LMP7 and MECL-1 were incubated with 20 µg of 
GST tagged 12SAd5E1A, 13SAd5E1A, and 13SAd12E1A on ice for 2 hrs in PBS, 1 mM 
EDTA, 1% Triton X100. GST pull down assay was conducted as described in section 
2.4.8. The eluate along with 5% of each input was run on an SDS-PAGE gel. The gel was 
stained with Coomassie Blue (B), soaked in AmplifyTM Reagent (Amersham bioscience) 
for 30 minutes with agitation and dried under vacuum at 80°C for 1 hr and exposed for 
autoradiography at -20°C (A). M.W. of LMP2 = 24kDa, LMP7 = 23kDa, MECL-1 = 29kDa. 
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Figure 3.3 MECL-1 binds to the N-terminal and CR3 regions of Ad5E1A 
Ten microlitres [35S]-labelled MECL-1 was incubated with 20 µg of GST-tagged fragments 
from across the different regions of Ad5E1A in a pulldown assay as described in section 
2.4.8. 5% of the input was run on the SDS-PAGE gel (A) Autoradiography results from the 
(B) Coomassie Blue stained gel.     
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Figure 3.4 Diagram showing the positions of the point mutations at the N-
terminal of Ad5 E1A used in the study. 
Generated by Rasti et al., (2005). 
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Figure 3.5 Mapping the binding site for MECL-1 in the Ad5E1A N-terminal 
region 
Ten microlitres of [35S]-labelled MECL-1 was incubated with 20 µg of GST-12SAd5E1A 
with a series of point mutations in the N-terminal region in a pulldown assay as briefly 
described in section 2.4.8. 5% of the input was also run on the SDS-PAGE gel (A) 
Autoradiography results from the (B) Coomassie Blue stained gel.   The lower panel is a 
continuation of the upper panel list of mutants. (C) Densitometric scan of the 
autoradiograph results shown in (A). 
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3.2.2.3 Mapping the binding sites within the Ad5E1A CR3 region.  
A series of deletion mutants of GST-Ad5E1A CR3 (Figure 3.6A, Rasti et al., 2006) were 
incubated with in vitro translated [35S]-labelled MECL-1 in pulldown assays carried out as 
section 2.4.8. All mutations have to varying degree affected the binding to MECL-1. 
Deletion mutants GST-CR3 Δ180-184 and GST-CR3 Δ188-204 had about two-fold less 
binding to MECL-1 than mutants GST-CR3 Δ 139-160, GST-CR3 Δ 161-168 and GST-
CR3 Δ169-177 (Figure 3.7A). An additional CR3 fragment that is mutated at one of the 
Zn2+ binding residues (in order to disrupt the zinc finger structure of CR3 - see section 
1.3.5.1.1) was used to determine if this motif plays any role in the interaction with MECL-
1.  The results reveal that this mutation slightly affected binding in comparison to w.t. CR3 
(GST-CR3). However, this was not as evident as GST-CR3 Δ 139-160 (Figure 3.7B). In a 
further experiment, w.t. GST-AdE1A CR3 regions derived from different adenovirus 
serotypes (Figure 3.6B) were also used with [35S]-labelled MECL-1 in a pulldown assay. 
The results show that CR3 regions from Ad9 and Ad12 bind about 3-fold and 2-fold more 
strongly (respectively) to MECL-1 in comparison to CR3s from Ad4, Ad3 and Ad40 (Figure 
3.8). 
 
3.2.3   In vitro binding of AdE1A to the constitutive homologues β1, β2 and 
β5 
AdE1A binding to the 20S proteasome was examined. HCT116 lysates (in the absence of 
IFNγ) were incubated with GST-13SAd5E1A and GST-13SAd12E1A proteins and 
pulldown assays carried out were using glutathione-sepharose beads followed by elution 
of binding proteins with glutathione. The eluates were run on an SDS-PAGE gel and 
blotted with anti-20S antibody (which recognises α1, 2, 3, 5, 6 and 7 subunits). The results 
showed that both AdE1A proteins bound to the 20S proteasome, with GST-13SAd12E1A 
binding considerably more strongly than GST-13SAd5E1A (Figure 3.9). In a further 
experiment, the binding capacity of in vitro translated [35S]-labelled β1, β5, and β2 
(homologues of LMP2, LMP7 and MECL-1 respectively) for GST tagged 12SAd5E1A, 
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13SAd5E1A, and 13SAd12E1A were also assessed in a pulldown assay. In contrast to 
the immunoproteasome, where AdE1A showed preferential binding to MECL-1, but not 
LMP2 or LMP7; the pulldown assay on the homologues shows that 12SAd5E1A, 
13SAd5E1A, and 13SAd12E1A bind preferentially to β1 and β5 but very weakly to the 
MECL-1 homologue β2 (figure 3.10A and B).  The binding to MECL-1 was much weaker 
compared to the other β subunits. 
Results from the above pulldown assays were analysed by densitometry in order to 
compare the AdE1A binding affinities between the homologues. Perhaps, a more accurate 
comparison can be deduced from the densitometric data as the capacity of the binding is 
quantitated. As we observe from Figure 3.10C, 12SAd5E1A, 13SAd5E1A, and 
13SAd12E1A all bound to MECL-1 but not LMP2 and LMP7. The trend observed from 
comparing the binding of AdE1A to the three 20S β subunits was rather different.  All 
AdE1A proteins bound preferentially to β1 and β5, but weakly to β2, with the exception of 
13SAd12E1A where it bound most strongly to β5, while binding to β1 and β2 equally but 
at a lower capacity than that of β5. 12SAd5E1A and 13SAd5E1A interacted more strongly 
to MECL-1 than to the three β subunits. However 13SAd12E1A binds equally to MECL-1 
and β5. Similarly, comparing binding to MECL-1 and its homologue β2, there is 
approximately a 3 fold reduction in binding of the 13SAd12E1A and 6 fold reduction of 
12SAd5E1A with β2 compared to MECL1. The reduction for 13SAd5E1A is very marked, 
with approximately 8 fold more protein bound to MECL1 than to β2. 
 
3.2.3.1   Sites of interaction on Ad5E1A for β1 and β5 
In the light of the above findings that revealed AdE1A binding to β1 and β5, the sites of 
interaction on Ad5E1A were investigated to compare binding to the immunosubunit 
MECL-1.  In vitro translated [35S]-labelled β1 and β5 were incubated with GST-tagged 
fragments from across the length of Ad5E1A in a pulldown assay (as above). As with 
MECL-1, the GST fragments were 1-40, 41-80, 81-140, 141-185, 186-289 as well as GST 
alone and GST-13SAd5E1A as negative and positive controls, respectively. Consistent  
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Figure 3.6 Schematic representation of the Ad5E1A CR3 deletion mutants 
and AdE1A CR3 from different serotypes used in the study 
(A) Ad5 CR3 region as defined by Avvakumov et al., 2002. Mutants as described by Rasti 
et al., (2005). The cysteine residues constitute the Zn2+ binding site. (B) GST-AdE1A CR3 
fragments from different adenovirus serotypes used in this study, and their sequence 
alignments. Numbers represent amino acid positions in Ad5E1A (HAdV-5). Adenovirus 
serotype is stated on the left. Darker shading indicate greater conservation. Asterisks 
denote cysteine residues that co-ordinate with zinc. 
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Figure 3.7 Mapping the binding site for MECL-1 in the Ad5E1A CR3 region. 
Ten microlitres of [35S]-labelled MECL-1 was incubated with (A) Twenty microgram of 
GST-Ad5E1A with a series of deletion mutations in the CR3 region or (B) a mutant in the 
zinc finger region within CR3,  in a GST-pulldown assay as described in section 2.4.8. 5% 
of the input was also run on the SDS-PAGE gel. The upper panel of each figure 
represents the autoradiography results, and the lower panel shows the Coomassie 
stained gel prior to being dried under vacuum.  
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Figure 3.8 MECL-1 interaction with CR3 regions from different adenovirus 
serotypes. 
Ten microlitres of [35S]-labelled MECL-1 was incubated with 20 µg of GST-AdE1A CR3 
from different adenovirus serotypes in a pulldown assay as described in section 2.4.8. 5% 
of the MECL-1 input was also run on the SDS-PAGE gel. (A) represents the 
autoradiography results, and (B) shows the Coomassie stained gel prior to being dried 
under vacuum.  
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Figure 3.9 Binding of AdE1A to the 20S proteasome. 
Twenty microgram of GST tagged 13S Ad5E1A and13S Ad12E1A were added to HCT116 
lysates and a GST pull down carried out as described in section 2.4.8. The final eluate 
was analysed by Western Blotting for the presence of 20S proteasome α subunits. M.W. 
of 20S alpha units = 25-30kDa. 
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Figure 3.10 AdE1A binds to β1 and β5, but not β2 components of the 20S 
proteasome. 
Ten microlitres of [35S]-labelled β1, β2 and β5 were incubated with 20 µg of GST tagged 
12SAd5E1A, 13SAd5E1A, and 13SAd12E1A in a pulldown assay as described in section 
2.4.8. 5% of each input was also run on the SDS-PAGE gel. (A) represents the 
autoradiography results, and (B) shows the Coomassie stained gel prior to being dried 
under vacuum. (C) Densitometry results comparing the different binding capacities of 
AdE1A to immunosubunit and the constitutive 20S proteasome catalytic subunits. Data 
are means +/- SEM from three repeats. ‡ = † = * = P > 0.05, # = P <0.05 
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Figure 3.11  20S proteasome components β1 and β5 bind to the N-terminal 
and CR3 regions of Ad5E1A 
Ten microlitres [35S]-labelled β1 and β5 was incubated with 20 µg of GST-tagged 
fragments from across the different regions of AdE1A in a pulldown assay as described in 
section 2.4.8. 5% of the input was also run on the SDS-PAGE gel.  A) represents the 
autoradiography results, and (B) shows the Coomassie stained gel prior to being dried 
under vacuum. (C) Densitometry results comparing the different binding capacities of 
AdE1A N-terminal and CR3 fragments to constitutive 20S proteasome catalytic subunits. 
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Figure 3.12  Mapping the binding site for β2 and β5 in the Ad5E1A CR3 
region. 
(A) Ten microlitres of [35S]-labelled β2 and β5 was incubated with 20 µg of GST-Ad5CR3 
carrying a series of deletions in a pulldown assay as briefly described in section 2.4.8. 5% 
of the input was also run on the SDS-PAGE gel. (B) pulldown assay using the same 
mutants with [35S]-MECL-1. 
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with MECL-1, both β1 and β5 bound strongly to the N-terminal and CR3 regions of 
Ad5E1A (Figure 3.11). 
 
 
3.2.3.2   Mapping the binding sites for β1 and β5 within the Ad5E1A CR3 
region 
Amino acid residues critical for the interaction of AdE1A CR3 with β2 and β5 were also 
mapped.  β2 was included in order to compare its binding sites to those of its IFNγ 
inducible homologue MECL-1. A series of deletion mutants of GST-Ad5E1A CR3 (Figure 
3.6) were used with [35S]-labelled β1 and β5 in a pulldown assay. In comparison to w.t. 
Ad5E1A CR3, there was a varying degree of reduced binding to β2 and β5 in all of the 
mutants; with GST-Δ169-177 and GST-Δ180-184 mutants binding the weakest to β2, and 
GST-Δ 169-177, GST-Δ 180-184 and GST-Δ188-204 mutants being least binding to β5 
(Figure 3.12).  
 
3.3      Discussion 
Studies to date onto the relationship of AdE1A with immunoproteasomes mainly focused 
on immunosubunit expression in adenovirus transformed cells (Vertegaal et al., 2003; 
Rotem-Yedudar et al., 1996) and to a limited level, in AdE1A transfected cells (Chatterjee-
Kishore et al., 2000). Direct interaction of AdE1A to components of the 26S proteasome 
was rather discovered, for instance, binding to the ATPase (S4 and S8) and non-ATPase 
(S2) components of the 19S complex (Turnell et al., 2000; Zhang et al., 2004) or binding 
to several α subunits of the 20S proteasome (Rasti et al., 2006). However, there have 
been no studies to date exploring the binding of AdE1A to the immunoproteasome, hence 
for the first time, this topic was addressed in this chapter. 
Firstly, the binding of AdE1A to the immunoproteasome was examined. In a co-
precipitation assay using antibodies directed at the immunosubunit LMP7, direct binding 
of AdE1A to the immunoproteasome was suggested (Figure 3.1).  Immunoproteasomes 
are known to be efficient at generating peptides of viral origins and hence previous 
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research has shown that they are also a target for other viral proteins such as HIV-1 Gag 
p24 (Steers et al., 2009), HIV Tat (Areste and Blackbourn 2006), Hepatitis C virus non-
structural protein (NS3) (Khu et al., 2004), EBV lytic cycle (De Leo et al., 2010), human T-
cell leukemia virus type 1 (HTLV-1) Tax protein  (Hemelaar et al., 2001) and now also 
adenovirus AdE1A. 
Given that AdE1A binds to the immunoproteasome, whether this interaction was specific 
to one or more of the immunosubunits was further investigated. In a GST pulldown assay 
utilizing [35S]-labelled LMP2, LMP7 and MECL-1 and GST tagged 12SAd5E1A, 
13SAd5E1A, and 13SAd12E1A, it was observed that AdE1A in all cases bound 
preferentially to MECL-1 rather than to LMP2 and LMP7 (Figure 3.2). The MECL-1 gene is 
found separately from LMP2 and LMP7 in a locus on human chromosome 16q22.1 
(Larsen et al., 1993). The reason for AdE1A specifically targeting MECL-1 is not clear, 
although, one study has shown that it is also targeted by HIV-1 tat protein that binds 
directly to MECL-1 and LMP7 leading to the inhibition of immunoproteasomal activity 
(Apcher et al., 2003). Other studies, however, have shown that other viral proteins target 
MECL-1 expression rather than directly binding to it, for instance, HIV-1 p24 which inhibits 
MECL-1 (as well as LMP7) expression in dendritic cell (Steers et al., 2009). Additionally, it 
was also targeted by Epstein-Barr virus where its expression was also repressed during 
the lytic cycle (De Leo et al., 2010).  
In MECL-1-deficient mice, there was a slight reduction in the incorporation of LMP2 into 
immunoproteasomes, (Basler et al., 2006), as well as abrogating trypsin-like activity 
(Salzmann et al., 1999). During immunoproteasome assembly, LMP2 and MECL-1 were 
incorporated first, and this incorporation was mutually dependent (Groettrup et al., 1997). 
Together LMP2 and MECL-1 form a pre-proteasome that favours incorporation of LMP7, 
which, in turn, is required for efficient maturation to immunoproteasomes (Griffin et al., 
1998). This cooperative model (proposed by Griffin et al., 1998) is thought to ensure the 
generation of homogeneous immunoproteasomes containing all the inducible subunits. In 
view of these observations, it can be hypothesized that AdE1A targeting MECL-1 might 
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interfere with immunoproteasome composition and hence affect the overall proteasomal 
activity leading to a modulated array of peptides presented in a manner that avoids 
adenovirus detection. Since incorporation of MECL-1 is inter-dependent with LMP2, the 
binding of AdE1A to MECL-1 may hinder the incorporation of not only MECL-1, but LMP2 
as well. As a result, no pre-proteasomes favourable to LMP7 incorporation are generated. 
Hence, a hypothesis can be drawn that suggests AdE1A binding to MECL-1, may be 
sufficient to create a domino effect that eventually inhibits immunoproteasome formation. 
This, in addition to the repression of immunosubunit expression at transcriptional level 
(see section 4.2.1), might have a devastating effect in the functioning of the 
immunoproteasome. However, in order to test this hypothesis, further experiments need 
to be conducted into the effect of AdE1A on the proposed assembly of 
immunoproteasomes. This can be done via metabolic pulse-chase labelling of 
proteasomes and immunoproteasomes. These can then by analysed by two dimensional 
gels after immunoprecipitation (Griffin et al., 1998). 
The regions within AdE1A that are involved in MECl-1 binding were investigated. The 
results of a pulldown assay using [35S]-labelled MECL-1 and GST-tagged fragments from 
across the different regions of AdE1A have shown that MECL-1 binds to the N-terminal 
and CR3 regions of AdE1A (Figure 3.3). These regions play a very important role in 
mediating the interaction of AdE1A with many host proteins (Gallimore and Turnell 2001). 
The N-terminal region also interacts with other proteins involved in the antigen processing 
machinery such as STAT1 (Look et al., 1998), S4 and S8 (Grand et al., 1999; Turnell et 
al., 2000; Zhang et al., 2004) as well as other crucial proteins involved in transcription, 
such as CBP/p300 and TBP (Berk 2005). The CR3 region is involved in binding several α 
subunits of the 20S proteasome (Rasti et al., 2006) among others. These two regions are 
already involved in the targeting of proteasomes and other components of the antigen 
processing machinery, in addition to the immunoproteasome that is now shown in the 
present study. These binding sites were mapped more closely to determine the role of 
particular residues within those two regions in the interaction with MECL-1. At the N-
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terminal region, the data have shown that the mutations L20A, D21A, L23A, I24A, L28A 
and L19/20A have reduced binding capacities, with the double mutant L19/20A most 
impaired (Figure 3.5). A study by Rasti et al., (2005) used the same set of N-terminal 
region mutants in order to assess their binding to a number of cellular proteins namely 
CBP/p300, P/CAF, hGCN5, S4, S8, TBP and Ran. They found different binding patterns 
across the different proteins, with the double-mutant L19/20A completely eliminating the 
interaction with all of the seven proteins (Rasti et al., 2005).  Consistent with data from 
Rasti et al., study, the same mutations that affected the binding of MECL-1 to the N-
terminal region, have also significantly disrupted the binding to all of cellular proteins. All 
five mutations (L20A, L23A, I24A, L28A and L19/20A) have either eliminated or showed a 
maximum of 25% binding to each of CBP/p300, P/CAF, hGCN5, S4 and S8, with the 
exception of TBP and Ran where the L28A mutation showed a binding of 75-100% and 
50-75% respectively (Rasti et al., 2005). Other mutations had different binding patterns, 
with TBP and Ran showing closest similarity to MECL-1. Past mutagenesis studies have 
shown that R2, L20 (Ad5) and L19 (Ad12) are absolutely conserved between the different 
serotypes (Lipinski et al., 1999; Wang et al., 1993; Avvakumov et al., 2004), highlighting 
their functional importance. Other mutations that affected binding with the seven proteins 
were C6A and I11A (Rasti et al., 2005), however these did not show any significant 
decrease in binding capacity with MECL-1. Hence, we can deduce from the above data 
that MECL-1 may share the same binding sites at the N-terminal region as the seven 
proteins examined by Rasti et al., 2005. However, in vitro GST pulldown assays may not 
necessarily reflect the situation in an in vivo setting, so it would be ideal to undertake the 
experiment in cells that express the mutant AdE1As and MECL-1. 
The binding sites within the CR3 region were also mapped. GST pulldown using [35S]-
labelled MECL-1 and GST-Ad5E1A CR3 with a series of deletion mutations (Figure 3.6), 
namely GST-CR3 Δ139-160, GST-CR3 Δ161-168, GST-CR3 Δ169-177, GST-CR3 Δ180-
184 and GST-CR3 Δ188-204 was undertaken (Figure 3.7A). It was found that all of the 
deletions have, to various extents, impacted on the binding capacity of CR3, with the 
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weakest binding seen with deletions Δ180-184 and Δ188-204, which may suggest an 
MECL-1 binding site around residues 180-204. The other deleted residues (Δ139-160, 
Δ161-168 and Δ169-177) may play a role in stabilising the interaction of MECL-1 with the 
region 180-204, or may be (more likely) required for the stabilisation of the conformation 
of the whole region. Further studies with a series of point mutations across the CR3 region 
might clarify or narrow down the binding regions of the AdE1A CR3 region. Research by 
Rasti et al., (2006) used the same deletion mutants to study binding to the ATPase 
component S8 and the 20S α proteasome subunits. Their results have shown that the S8 
binding site extends from residues 169-188 and the 20S proteasome binding site extends 
from residues 161-177. This suggests that MECL-1 binds to a different region of CR3 from 
S8 and 20S proteasome. The same group have also found that mutations of the zinc 
finger motif within the CR3 had no effect on S8 binding, whereas it disrupted binding to 
the 20S proteasome. In this study, we observed that mutation of the zinc finger region did 
slightly affect (but did not eliminate) binding to MECL-1, indicating that it may play a role in 
this interaction (Figure 3.7B). Similarly, MECL-1 bound, with different affinities, to CR3 
from different serotypes of adenovirus, signifying a conserved function of AdE1A (Figure 
3.8). This was also consistent with data on S8 and 20S proteasomes (Rasti et al., 2006). 
Sequence comparison of AdE1A CR3 from the different serotypes is illustrated in Figure 
3.6B. Residues 180-204 that was shown to affect binding of Ad5E1A CR3 to MECL-1 
covers the region VYSPVSE (Ad5) which is conserved in all of the different serotypes. 
The immunosubunits LMP2, LMP7 and MECL-1 replace the constitutive subunits β1, β5 
and β2 respectively after exposure of cells to IFNγ (Hisamatsu et al., 1996). So it would be 
of interest to investigate if AdE1A also binds to catalytic components of the 20S 
proteasome in addition to the immunoproteasome, which has not been addressed so far 
by previous research. Past studies have shown binding of AdE1A to components of the 
20S and 26S proteasome (Rasti et al., 2005, 2006, Turnell et al., 2000, Zhang et al., 
2004). Preliminary data using GST tagged 12SAd5E1A, 13SAd5E1A, and 13SAd12E1A 
with IFNγ untreated HCT116 lysates in a GST pulldown assay, and Western blotting the 
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eluates for 20S proteasome alpha subunits, has shown binding of AdE1A to the 20S 
proteasome (Figure 3.9). Nevertheless, from this experiment, it cannot be determined if 
this interaction is through the 19S components or the α and β subunits of the 20S 
proteasome. To expand on this, experiments assessing the binding of AdE1A to the 
individual β1, β2 and β5 were conducted. In another GST pull down assay, [35S]-labelled 
β1, β2 and β5 were used with GST tagged 12SAd5E1A, 13SAd5E1A, and 13SAd12E1A. 
It was shown that, in contrast to the immunosubunits where AdE1A have shown 
preferential binding to MECL-1, here the AdE1A has bound strongly to β5 and β1, (LMP7 
and LMP2 homologues, respectively), whereas it bound only weakly to β2 (MECL-1 
homologue) (Figure 3.10). This may indicate a different strategy of AdE1A targeting the 
20S proteasome. β1, β2 and β5 possess caspase-like, trypsin-like and chymotrypsin-like 
activity respectively (Groettrup et al., 2001). When cells are exposed to IFNγ, this causes 
the catalytic β subunits to be substituted by LMP2, MECL-1 and LMP7 respectively 
forming the immunoproteasome (Hisamatsu et al., 1996). This substitution results in the 
enhancement of the chymotrypsin-like activity and the abrogation of the caspase-like 
activity (Groettrup et al., 2001). This may hint that the chymotrypsin activity has an 
important role in the generation of peptides for antigen processing. It is not yet known 
whether this interaction with β5 or any of the other β subunits leads to an increase or 
decrease in catalytic activity. On one hand, if it was to be presumed that the aim of AdE1A 
is to inhibit activity, then it can be hypothesized that since β5 possesses a chymotrypsin-
like activity, AdE1A may target this in order to reduce the presentation of viral epitopes. 
However, this does not explain why AdE1A targets MECL-1, the immunosubunit that 
exhibits trypsin-like activity but not the chymotrypsin activity of LMP7. So it could be 
suggested that this may just be a general targeting of the total cellular proteasomal activity 
by AdE1A, rather than specific catalytic activities, in order to adjust or modulate the array 
of peptides presented to CTLs, thus playing a role in disrupting antigen recognition. On 
the other hand, if AdE1A interaction causes an increase in catalytic activity, then it can be 
hypothesized that AdE1A may recruit this to aid either the expression of viral proteins or 
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the degradation of DNA transcription regulators. For instance, the human T-cell leukemia 
virus type 1 (HTLV-1) Tax protein was found to interact with and enhance the activity of 
immunoproteasomes (Hemelaar et al., 2001). The group proposes that this may be 
involved in the regulation of transcription control (Hemelaar et al., 2001), such as the 
degradation of the nuclear pool of IκBα, a regulatory protein that inhibits the activity of the 
transcription factor NF-κB (Arenzana-Seisdedos et al., 1995, 1997). Further experiments 
into the proteolytic activity of the 20S proteasomes and immunoproteasomes in the 
presence or absence of AdE1A are addressed in the chapter 5. 
The regions of AdE1A involved in the interaction with β1, β2 and β5 were examined. A 
GST pulldown assay using [35S]-labelled β1, β2 and β5 and GST-tagged fragments from 
across the different regions of AdE1A have shown that, just like MECL-1, all three β 
catalytic subunits bind to the N-terminal and CR3 regions of AdE1A (Figure 3.11). The 
amino acid residues in CR3 involved in the interaction were mapped by a further GST pull 
assay using [35S]-labelled β2 and β5 and the same GST-tagged CR3 deletion mutants 
used with MECL-1. In this case, the weak binding β2 was used in order to compare its 
interaction, with that of its homologue MECL-1. The data have revealed that both β2 and 
β5 interact with similar set of residues. AdE1A binding capacity to both subunits has been 
significantly reduced by the deletions Δ169-177, Δ180-184 and Δ188-204, with β2 
showing a more marked decrease in binding with deletions Δ169-177 and Δ180-184 
(Figure 3.12). Furthermore, comparing the binding site of β2 to MECL-1, it was seen that 
binding to MECL-1, has been more affected with the deletions at Δ180-184 and Δ188-204, 
whereas β2 displayed less binding to mutants with deletions Δ169-177 and Δ180-184. 
This may indicate that AdE1A has different binding sites for both the homologues β2 and 
MECL-1. These data are however, not sufficient to draw definitive conclusions about the 
nature of AdE1A binding to the β subunits and MECL-1. Further investigations need to be 
carried out into to specific residues involved, such as using CR3 mutants with a series of 
point mutations across the sequence, similar to those employed for the N-terminal region. 
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Also, it would be interesting to examine if AdE1A binds to each of the subunits 
independently or if more than one subunit can bind to AdE1A at the same time. 
Finally, results from the above GST-pulldown assays were analysed by densitometry in 
order to compare binding of the different subunits. The data in Figure 3.13 show that β5 
binds to AdE1A more strongly than the other constitutive subunits. All of the β subunits 
have shown strongest binding to 13S Ad12E1A followed by 13S Ad5E1A and 
12SAd5E1A, with the exception of β1 that displayed stronger binding to 13S Ad5E1A 
followed by 13S Ad12E1A and 12SAd5E1A.  MECL-1 binds more strongly to AdE1A than 
to the other three constitutive subunits. 13S Ad12E1A and 13S Ad5E1A had similar 
binding affinities for MECL-1, followed by 12SAd5E1A. 13S AdE1A binds more strongly 
than 12SAdE1A. This may be due to the presence of CR3 in 13S AdE1A, which in 
combination with the N-terminal region make up two binding sites for the subunits. 
Generally, there was a stronger binding to Ad12E1A than to Ad5E1A. 
In this chapter, it was demonstrated that AdE1A also binds preferentially to MECL-1, 
rather than LMP2 and LMP7. MECL-1 binds to the N-terminal region and CR3 regions of 
AdE1A. Through a series of GST pulldown assay, important residues involved in this 
interaction were mapped for both the N-terminal and CR3 regions. Additionally, the 
binding of AdE1A to the constitutive subunits β1, β2 and β5 was also addressed. It was 
found that AdE1A binds most strongly to β5 and β1 and the least binding to β2. These 
three catalytic subunits also bind, as MECL-1, to the N-terminal and CR3 regions of 
AdE1A. Further mapping of the binding sites within the CR3 region have shown different 
residues involved for the interactions with the β subunits and MECL-1.   
In the next chapter, the effect of AdE1A binding on the expression of the 
immunoproteasome subunits was examined. 
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4.1    Introduction 
AdE1A is essential for viral replication and induction of cell cycle progression as well as 
having an involvement in transformation and oncogenesis. Through a series of protein-
protein interactions, it targets multiple host regulatory proteins to activate or repress 
transcription, inhibit differentiation, promote progression into S phase as well as causing 
apoptosis (Berk 2005; Gallimore and Turnell 2001, Mymryk 1996).  AdE1A is expressed in 
various isoforms as a result of differential splicing of the primary transcript,  12S and 13S 
mRNA are the most abundant and are transcribed earlier during infection whereas 9S, 
10S and 11S are at low levels and accumulate later during infection (Stephens and 
Harlow 1987; Ulfendahl et al., 1987). Most of the biological functions of AdE1A can be 
attributable to the protein products of the 12S and 13S RNA that encode 243 and 289 
amino acid oncoproteins respectively in Ad2/Ad5. The proteins are identical apart from the 
presence of the additional 48 amino acid conserved region (CR3) in 13SAdE1A. The 
AdE1A conserved regions CR1, CR2, CR3, CR4 and the less conserved N-terminal 
region all contribute to the function of AdE1A in deviating cell cycle regulation and 
transcription. 
AdE1A is already known to target a number of cellular proteins monitoring the cell cycle 
and transcription such as retinoblastoma tumour supressor (Rb) (and its related proteins 
p107 and p130) as well as CBP/p300 (Frisch and Mymryk 2002; Gallimore and Turnell 
2001). It is thought that AdE1A can induce quiescent cells into S-phase by interacting with 
at least these two sets of proteins (Howe et al., 1990). While AdE1A exerts its effect on 
host transcription pathway, it can also target components of the antigen processing 
pathways such as the proteasomes and major histocompatibility complex (MHC) class I 
and II (Rasti et al., 2005, 2006; Grand et al., 1999; Turnell et al., 2000; Zhang et al., 
2004).  
Proteasomes are proteolytic complexes that degrade intracellular proteins, as well as 
processing peptides required for loading onto MHC molecules. The 20S proteasome 
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consists of 28 α and β subunits that are arranged in a barrel-like structure (refer to Figure 
1.11)(Lowe et al., 1995; Groll et al., 1997; Baumeister et al., 1998; Coux et al., 1996). It 
combines with the 19S regulatory complex to form the 26S proteasome (Marteijn et al., 
2006; Baumeister et al., 1998). Only three subunits are responsible for the proteolytic 
activity of the 20S proteasome namely β1, β2 and β5 (Rivett and Hearn 2004; Groetrrup 
et al., 2001).  Upon exposure to IFNγ, these three constitutively expressed subunits are 
substituted by their inducible homologues LMP2, LMP7 and MECL-1 respectively 
(Hisamatsu et al., 1996). Immunoproteasomes have different cleavage specificity and thus 
produce a different array of peptides in comparison to 20S proteasomes and it is thought 
to be more efficient at processing peptides of viral origin (Groettrup et al., 2001; Ehring et 
al., 1996; Gaczynska et al., 1996; Cascio et al., 2001; Cerundolo et al., 1995).    
MHCs are heterodimer glycoproteins that exist on the surface of cells where they display 
fragments of processed proteins (peptides) for cytotoxic T cells (CTLs) and natural killer 
cells (NK) recognition (Flutter and Gao 2004); resulting in initiation of an immune 
response. MHC class I is expressed on the surface of all cells (York and Rock 1996) 
whereas MHC class II is expressed on antigen presenting cells of the immune system, 
such as dendritic cells and macrophages (Benoist and Mathis 1990; Steimle et al., 1994); 
it can be induced in other cells by exposure to IFNγ (Steimle et al., 1994). Whilst MHC 
class I presents peptides of viral or cytosolic origin, MHC class II mainly displays peptides 
processed from endocytosed extracellular proteins such as bacterial pathogens and viral 
antigens (Hegde et al., 2003).  
AdE1A targets the ATPase (S4 and S8) as well as the non-ATPase components (S2) of 
the 19S complex (Grand et al., 1999; Turnell et al., 2000; Zhang et al., 2004) possibly 
affecting its ATPase activity. AdE1A also binds to multiple α subunits of the 20S 
proteasome (Rasti et al., 2006) potentially affecting its function. With regard to the 
immunoproteasome, research so far indicates that AdE1A down-regulates LMP2 
transcription partly by interference with components of the JAK/STAT1 pathway that is 
responsible for the induction of cellular response to IFNγ (Chatterjee-Kishore et al., 2000). 
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LMP2, LMP7 and MECL-1 expression was also found to be down-regulated in Ad12 
transformed but not Ad5 transformed rat cells (Vertegaal et al., 2003; Rotem-Yedudar et 
al., 1996). 
In rat cells that have been transformed with AdE1A, downregulation of MHC class I was 
observed in Ad12 transformed cells but not in Ad2/5 (Schrier et al., 1983; Ackrill and Blair 
1988), similar results were also observed in a small panel of human cells transformed with 
AdE1A (Bottley et al., 2005; Vasavada et al., 1986). Ad12 is oncogenic, inducing tumours 
in new-born rodents whereas Ad2/5 is not. A study by Ackrill et al., (1991) examined the 
effect of AdE1A on MHC class II expression; it was observed that transfected AdE1A 
represses MHC class II expression by inhibiting the cellular response to IFNγ. The effect 
of AdE1A on the immunoproteasome has not been studied extensively and as previously 
mentioned, research so far only indicates repression of LMP2 at a transcriptional level.  
In this chapter, this will be explored further to study the effect of AdE1A on the 
immunosubunit expression to include both LMP7 and MECL-1, as well as LMP2 and to 
observe this in the setting of adenovirus infection, AdE1A transfection and in established 
adenovirus transformed human cells. Additionally, as the effect of AdE1A on MHC class I 
surface expression has been heavily focused on transformed cells lines, mainly of rodent 
origin, this will be further examined to include a wider panel of adenovirus transformed 
human cells as well as during adenovirus infection and AdE1A transfection. The cellular 
response to IFNγ in the presence of transfected AdE1A and adenoviral infection will also 
be investigated. 
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4.2    Results  
4.2.1 AdE1A down-regulates expression of the proteasome immunosubunits 
 4.2.1.1   Adenovirus infection 
To assess the effect of adenovirus infection on cellular immunosubunit levels, H1299 cells 
were infected (for 24 hrs) with Ad5, Ad12 and Ad5 ΔE3 at 20 plaque forming units (p.f.u) 
per cell. In order to induce immunosubunit expression, some of the cells were treated with 
300 U/ml IFNγ for a further 24 hrs after which 30 μg of whole cell lysates were analysed 
for protein expression by western blotting using rabbit polyclonal LMP2 or LMP7 
antibodies (Abcam) and rabbit polyclonal MECL-1 antibody (Figure 4.1). Immunosubunit 
expression was clearly induced following IFNγ in the mock infected cells. However, in 
comparison to mock infected cells, all of Ad5, Ad12 and Ad5 ΔE3 inhibited IFNγ-mediated 
induction of LMP2, LMP7 and MECL-1. Additionally, basal expression of the 
immunosubunits (prior to IFNγ treatment) was also sharply reduced following infection, as 
clearly observed with LMP2. The deletion of the adenovirus E3 gene has little effect on 
this inhibition. The E3 gene, like E1A, encode for proteins with immunosubversive 
functions, such as the down-regulation of MHC class I (Burgert et al., 1987; Wold et al., 
1999) and inhibition of tapasin (Bennett et al., 1999); hence the inclusion of an adenovirus 
with deleted E3 gene in this study will allow the ruling out its involvement in the observed 
experimental data. 
These results show that infection prior to IFNγ treatment inhibited immunosubunit 
expression, so a further experiment was carried out to look at the effect of adenovirus 
infection in IFNγ pre-treated cells. In this case, it was found that the expression of LMP2, 
LMP7 and MECL-1 remain unaffected following infection with Ad5, Ad12 and Ad5 ΔE3 
(Figure 4.2). It was also noticed that Ad5E1A and Ad12E1A expression was reduced in 
IFNγ pre-treated cells compared to the ones that were infected first.  Furthermore, an 
additional time point was added so that Ad5 infection was extended to 48 hrs following 
IFNγ treatment and the same procedure repeated as above. It was found that at 24 hrs, 
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there was no effect on immunosubunit expression by infection; however, at 48 hrs a 
significant decrease in LMP2, LMP7 and MECL1 expression was observed in comparison 
to the mock infected cells (Figure 4.3). In order to examine whether this reduction of 
LMP2, LMP7 and MECL1 expression can also be seen after infection with other 
adenovirus serotypes, H1299 cells were infected with Ad3, Ad4, Ad5, Ad7, Ad9 and Ad12 
for 24 hrs followed by a further 24 hrs of IFNγ treatment. Cell lysates were analysed by 
western blotting for LMP2, LMP7 and MECL1 expression. A significant decrease in IFNγ-
mediated immunosubunit induction was observed in all the serotypes with the exception of 
Ad11 (Figure 4.4). Viral infection was confirmed by the presence of structural proteins in 
cell lysates as specific antibodies are not available for most of these viruses.  
In view of these results that have shown the inhibition of immunosubunit expression by 
AdE1A, the effect of infection with adenoviruses that had their AdE1A gene deleted was 
subsequently examined. Two ΔE1A Ad5 mutant viruses, dl312 and dl343 (Stanton et al., 
2008; Winberg and Shenk 1984; Hearing and Shenk 1985), were used to infect H1299 
cells for 24, 48 and 72 hrs followed by IFNγ treatment for a further 24 hrs. Infection by the 
mutant virus did not affect the induction of immunosubunit expression (Figure 4.5A) when 
compared to the mock infected cells (Figure 4.5B). There was an increasing expression of 
each of the subunits as infection progressed. The progression of infection with the 
adenoviruses that lack AdE1A was very slow compared to w.t. virus. Viral infection was 
confirmed by western blotting for Ad5E1B55K. AdE1A facilitates the expression of the 
other early genes including AdE1B. However, it is not an absolute requirement, because 
at a higher virus dose, or in this case, a prolonged incubation time at 24hrs, the early 
region genes will eventually be expressed although at a slower rate (Nevins 1981). 
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Figure 4.1 Adenovirus infection down-regulates LMP2, LMP7 and MECL1 
expression. 
H1299 cells were infected with 20 p.f.u. per cell for 24 hrs, followed by treatment with 
300U/ml IFNγ for another 24 hrs. The cells were lysed with 9 M urea, 50 mM Tris (pH 7.3) 
and 0.15 M β-mercaptoethanol. 30 µg of this lysate was analysed by Western blotting to 
determine immunosubunit and E1A levels.   
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Figure 4.2 Adenovirus infection has no effect on immunosubunit expression of IFNγ 
pre-treated cells at 24 hrs 
H1299 cells were treated with 300 U/ml IFNγ for 24 hrs then infected with 20 plaque 
forming units (p.f.u) per cell for another 24 hrs and vice versa. The cells were lysed with 9 
M urea, 50 mM Tris (pH 7.3) and 0.15 M β-mercaptoethanol. 30 µg of this lysate was 
analysed by Western blotting to determine immunosubunit and E1A expression.   
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Figure 4.3 Prolonged adenovirus infection (48hrs) reduces immunosubunit 
expression in IFNγ pre-treated cells  
H1299 cells were treated with 300 U/ml IFNγ for 24 hrs then infected with 20 plaque 
forming units (p.f.u) per cell for another 24 hrs or 48 hrs and vice versa (for 24 hr 
infection). The cells were lysed with 9 M urea, 50 mM Tris (pH 7.3) and 0.15 M β-
mercaptoethanol. 30 µg of this lysate was analysed by Western blotting to determine 
immunosubunit and E1A expression.   
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Figure 4.4 Infection with different adenovirus serotypes down-regulate 
immunosubunit expression  
H1299 cells were infected with 20 p.f.u. per cell of each virus for 24 hrs, followed by 
treatment with 300 U/ml IFNγ for a further 24 hrs. The cells were lysed with 9 M urea, 50 
mM Tris (pH 7.3) and 0.15 M β-mercaptoethanol. Thirty microgram of this lysate was 
either analysed by Western blotting to determine immunosubunit levels (upper panel) or 
analysed by PAGE and stained with 0.1% (w/v) Coomassie Brilliant Blue (lower panel) to 
illustrate hexon expression. 
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Figure 4.5 ΔE1A mutant viruses do not down-regulate immunosubunit expression 
H1299 cells were either mock infected (B) or infected with 20 p.f.u. of the mutant viruses 
per cell for 24 hrs (A), followed by treatment with 300 U/ml IFNγ for another 24 hrs. The 
cells were lysed with 9 M urea, 50 mM Tris (pH 7.3) and 0.15 M β-mercaptoethanol. Thirty 
microgram of this lysate was analysed by Western blotting to determine immunosubunit 
and E1A levels.   
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4.2.1.2   The effect of transfection of AdE1A on immunoproteasome 
expression 
In order to investigate whether AdE1A transfection alone can show similar results to those 
obtained by viral infection, H1299 cells were transfected with plasmids encoding 12S and 
13S Ad5E1A and Ad12E1A for 24 hrs. The cells were then treated with 300 U/ml of IFNγ 
for a further 24 hrs after which 30 μg of whole cell lysates were analysed for protein 
expression by western blotting using rabbit polyclonal LMP2 or LMP7 antibodies and 
rabbit polyclonal MECL-1 antibody. pcDNA3 was used for the transfection control 
transfection.  
In pcDNA3 transfected cells, there was a large induction of LMP2, LMP7 and MECL1 
expression following IFNγ treatment. However, in cells that have been transfected with 
12S and 13S Ad5 and Ad12 E1A, this IFNγ-mediated induction was considerably reduced 
(Figure 4.6 A and B). This was particularly marked in case of MECL1 where little to no 
expression was visible after the transfection of Ad5 or Ad12E1A, although its worth noting 
that the MECL-1 antibody is of low titre. Efficiency of transfection was in excess of 80% in 
most cases as shown in Table 4.1. 
In order to examine if this reduction varied in an AdE1A dependent manner, increasing 
amounts of pcDNA3 control and 13S Ad5 E1A (0.1 µg, 0.3 µg 1 µg and 2 µg) were 
transfected into cells and the expression of LMP2, LMP7 and MECL1 determined by 
western blotting. The results have shown that there was a direction correlation between in 
immunosubunit expression and increasing amount of Ad5 E1A (Figure 4.7) with 2 µg of 
13S Ad5 E1A causing the greatest inhibition. This repression was again most marked in 
MECL1 with very little expression at 1µg in comparison to the corresponding LMP2 and 
LMP7 western blots. 
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                           Table 4.1: Transfection efficiency of AdE1A constructs 
 
 
 
 
 
 
 
 
 
 
 
 
 
Construct Transfection efficiency (%) 
12SAd5E1A 96.1 
13SAd5E1A 90.2 
12SAd12E1A 84.8 
13SAd12E1A 72.9 
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Figure 4.6 Transfection with AdE1A reduces IFNγ-induced immunosubunit 
expression. 
H1299 cells were transfected with 1 µg each of 12S and 13S Ad5 and Ad12 E1A 
constructs for 24 hrs, followed by a further 24 hrs of IFNγ treatment. Cells were lysed in 9 
M urea, 50 mM Tris (pH 7.3) and 0.15 M β-mercaptoethanol. Thirty microgram of this 
lysate was analysed for protein expression by Western blotting. A. Transfection of 
Ad5E1A  B. Transfection of Ad12E1A. 
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Figure 4.7 Immunosubunit down-regulation by Ad5E1A varies with AdE1A 
expression 
H1299 cells were transfected with 0.1, 0.3, 1 and 2 µg of 13S Ad5E1A construct for 24 
hrs, followed by a further 24 hrs of IFNγ treatment. Cells were lysed in 9 M urea, 50 mM 
Tris (pH 7.3) and 0.15 M β-mercaptoethanol. Thirty microgram of this lysate was analysed 
for protein expression by Western blotting. 
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4.2.1.3   Immunoproteasome subunit expression in established adenovirus 
transformed human embyonic retinoblast (HER) cell lines 
The relative levels of immunosubunits in a large panel of established adenovirus 
transformed human cell lines was examined (Figure 4.8A). The cell lines express various 
combinations of Ad5 and Ad12 E1A, Ad5 and Ad12 E1B and mutant ras (Figure 4.8B – 
lower panel). Cells were treated with 600 U of IFNγ for 48 hrs then lysed with 9 M urea 
lysis buffer. Thirty microgram of the whole cell lysates were analysed for expression of 
LMP2, LMP7 and MECL1 by western blotting. Before IFNγ treatment, there was little to no 
expression of LMP2, LMP7 and MECL1 in any of the cell lines (Figure 4.8B – upper 
panel), however, upon exposure to IFNγ, there was an upregulation of the expression of 
immunosubunits LMP2 and LMP7 in cell lines that express generally (not exclusively) 
Ad5E1A but not Ad12E1A (Figure 4.8A). The presence of activated mutant H-ras, N-ras or 
Ad12E1B had no effect on this trend. There was no expression of MECL1 observed in 
either Ad5 and Ad12 E1A expressing cell lines (Figure 4.8B).  
A549 cells that constitutively express either 12SAd5E1A (12S10) or 13SAd5E1A (13S and 
13S G418) were also analysed for immunosubunit expression (Figure 4.9).  There was a 
strong induction of immunosubunit expression after IFNγ treatment of A549, whereas 
there was little or no expression in all of the Ad5E1A expressing A549 cells. 
 
 
4.2.2    Adenovirus E1A and MHC Class I and Class II expression 
In view of the observation that AdE1A negated the IFNγ-induced expression of 
immunoproteasome subunits and the well established role of Ad12E1A in the down-
regulation of MHC class I in Ad transformed rat cells, an examination of the effect of 
AdE1A on the expression of MHC class I and MHC class II in human cells, following viral 
infection, transient transfection and cell transformation was undertaken. 
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Figure 4.8 Immunosubunit expression is down-regulated in Ad12 transformed but 
not in Ad5 transformed cells 
Adenovirus transformed human embryonic retinoblast cell lines (HER) were treated with 
600 U/ml of IFNγ for 48 hrs. Cells were then lysed in 9 M urea, 50 mM Tris (pH 7.3) and 
0.15 M β-mercaptoethanol. The “positive control” is IFNγ-treated H1299 cells Thirty 
microgram of each lysate was analysed for immunosubunit expression by Western 
blotting. A. Relative level (to actin) of immunosubunit expression (by densitometric 
analysis of Western blots).   B. Western blot result (upper panel). Details of the numbered 
cell lines are listed in lower panel. 
 
Ad5 E1A   X X    X  X X 
Ad5 E1B        X  X  
Ad12 E1A X X   X X X  X   
Ad12 E1B X X   X  X     
Mutant Ras   X X  X     X 
 
Effect of AdE1A on immunosubunit expression in established 
adenovirus transformed human embryonic retinoblasts 
 
 
A 
B 
1 - Ad12E1HER12  
2 - Ad12E1HER3  
3 - Ad5E1A+NrasHER286.1  
4 - Ad5E1A+NrasHER313.B  
5 - Ad12E1HER11 
6 - Ad12E1A+NrasHER414.B  
 
7 - Ad12E1HER5 
8 - Ad5E1HER911  
9 - Ad12E1AHER 283  
10 - Ad5E1HER359A2  
11 - Ad2E1A+Nas HER 313A  
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Figure 4.9  Immunosubunit expression in A549 cells expressing Ad5E1A 
A549 cell lines expressing 12S and 13S Ad5E1A were treated with 300 U/ml of IFNγ for 
24 hrs. Cells were then lysed in 9 M urea, 50 mM Tris (pH 7.3) and 0.15 M β-
mercaptoethanol. Thirty miocrogram of this lysate was analysed for immunosubunit 
expression by Western blotting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 133 ~ 
 
4.2.2.1   The effect of adenovirus infection on MHC Class I and Class II 
expression 
To examine the effect of viral infection on surface expression of MHC class I and II, 
primary tonsil epithelial cells, as well as various human tumour cell lines, were infected 
with Ad5, Ad12 and Ad5 ΔE3 for 24 hrs then treated with 300 U/ml IFNγ for a further 24 
hrs before being harvested, stained with mouse anti-human MHC class I and II antibodies, 
and analysed by flow cytometry.  
The results revealed that MHC class I levels remain unaffected after Ad5, Ad12 and Ad5 
ΔE3 infections, regardless of IFNγ treatment. This was seen in A549, HCT116, primary 
tonsil epithelial cells and T47D samples (Figure 4.10A-D) where over 90% of cells were 
positive for MHC class I even after infection. Similarly, MHC class II levels after infection 
was examined in tonsil epithelial cells and the T47D cell line. Both T47D and tonsil 
epithelial cells were used in this study because they highly up-regulate their surface MHC 
class II levels upon IFNγ treatment. The results showed that infection with Ad12 caused 
down-regulation of MHC class II expression in comparison to Ad5 (Figure 4.11A and B). In 
the tonsil cells, MHC class II surface expression was reduced from 65% in mock infected 
cells to approximately 22% in Ad12 infected cells and 45% in Ad5 infected cells. However 
deletion of the E3 gene relieved the inhibition resulting in 66% MHC class II expression 
(Figure 4.11B). In T47D cells, Ad12 infection reduced MHC class II from 76% to 29%, 
whereas Ad5 and Ad5 ΔE3 infections did not affect expression significantly - 69% and 
72% respectively (Figure 4.11B).  
 
4.2.2.2   The effect of AdE1A transfection on MHC Class I and II expression  
Further experiments examining the effect of AdE1A transfection (via mRNA 
electroporation) on MHC class I and II surface expression were also undertaken. mRNA 
was generated from 12SAd5E1A, 13SAd5E1A, 12SAd12E1A, 13SAd12E1A, 12SAd5E1A  
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Figure 4.10 Adenovirus infection has no effect on MHC class I expression. 
A549, HCT116, tonsil epithelial cells and T47D cells were infected with 20 p.f.u. of Ad5, 
Ad12 and Ad5 ΔE3 per cell for 24 hrs, followed by treatment with 300 U/ml IFNγ for 
another 24 hrs. They were then harvested by trypsinisation, washed in cold PBS and 
finally resuspended in 50 µl FACS buffer (1% BSA, 0.02% sodium azide in PBS). They 
were stained with 5 µl of mouse anti-human MHC class I antibody for 30 minutes, washed 
twice with FACS buffer, then resuspended in 400 µl PBS prior to being analysed by flow 
cytometry (left panel). For western blot analysis, the cells were lysed with 9 M urea, 50 
mM Tris (pH 7.3) and 0.15 M β-mercaptoethanol. Thirty microgram of this lysate was 
analysed by Western blotting to determine immunosubunit and E1A levels (right panel). A. 
A549 cells B. HCT116 cells C. Tonsil epithelial cells D. T47D cells   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
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Figure 4.11 Ad12 infection down-regulates MHC class II expression. 
T47D and tonsil epithelial cells were infected with 20 p.f.u. of Ad5, Ad12 and Ad5 ΔE3 per 
cell for 24 hrs, followed by IFNγ treatment for another 24 hrs. They were then harvested 
by trypsinisation, washed in cold PBS and finally resuspended in 50 µl FACS buffer (1% 
BSA, 0.02% sodium azide in PBS). They were stained with 5 µl of mouse anti-human 
MHC class II antibody for 30 minutes, washed twice with FACS buffer, then resuspended 
in 400 µl PBS prior to being analysed by flow cytometry (left panel). For western blot 
analysis, the cells were lysed with 9 M urea, 50 mM Tris (pH 7.3) and 0.15 M β-
mercaptoethanol. Thirty microgram of this lysate was analysed by Western blotting to 
determine immunosubunit and E1A levels (right panel). A. T47D cells B. Tonsil epithelial 
cells.  Data are means +/- SEM from two independent experiments. 
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mutant (L19/20S) and 13SAd5E1A mutant (L19/20S) through in vitro transcription (see 
section 2.3.11). mRNA was electroporated into T47D cells and primary fibroblasts. 
The cells were grown for 12 hrs followed by another 12 hrs of 300 U/ml IFNγ treatment. 
They were then harvested and stained for MHC class I or class II prior to analysis by flow 
cytometry. Electroporation of cells with mRNA yielded high transfection efficiency and high 
cell viability compared to electroporating with DNA (Van Tendeloo et al., 2001). 
Additionally, T47D cells were resistant to transfection using lipofectamine so 
electroporation was seen as a preferable option to achieve maximum transfection 
efficiency. However, the disadvantage lies in achieving equal protein expression between 
the different transfections, so we had to take into account the different levels of AdE1A 
expression when interpreting the data. With regard to the effect of AdE1A transfection on 
MHC class I levels in primary fibroblasts, data showed that surface levels remained 
unaffected after transfection with Ad5 and Ad12 E1A (Figure 4.12); whereas in the case of 
MHC class II, the results (Figure 4.13A) reveal that the transfection of 12S and 13S 
Ad5E1A caused an inhibition of MHC class II induction. The raw data showed 55% MHC 
class II expression in mock electroporated cells compared to 7% and 22% in 12S and 13S 
Ad5E1A expressing cells respectively. Transfection with the double mutants 12S and 13S 
Ad5E1A L19/20S relieved this inhibition with 37% and 40% MHC class II expression 
respectively.  Examining the western blot of the corresponding lysates from each 
transfection, there is unequal expression, with both wild type and mutant 12S Ad5E1A 
being expressed about 3 times more than the mutant and wild type 13S Ad5E1A (Figure 
4.13C).  This may partly explain the added inhibition by 12S Ad5E1A in comparison to 
13SAdE1A. Nevertheless, the double mutations in both cases affected AdE1A’s ability to 
inhibit MHC class II induction in contrast to their wild type counterparts. Similarly, 
transfection with 12S and 13S Ad12E1A reduced MHC class II expression from 55% in 
the mock transfected cells to 33% and 42% in 12S and 13S Ad12 E1A transfected cells 
respectively (Figure 4.13B). However, this was found to be statistically insignificant.  
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Figure 4.12 AdE1A transfection does not affect MHC class I cell surface expression 
Primary fibroblasts cells were electroporated with the appropriate AdE1A mRNA for 12-16 
hrs. They were then harvested by trypsinisation, washed in cold PBS and finally 
resuspended in 50 µl FACS buffer (1% BSA, 0.02% sodium azide in PBS). They were 
stained with 5 µl of mouse anti-human MHC class I antibody for 30 minutes, washed twice 
with FACS buffer, then resuspended in 400 µl PBS prior to being analysed by flow 
cytometry. This data is representative of repeated experiments. 
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Figure 4.13 AdE1A transfection down-regulated MHC class II cell surface 
expression 
T47D cells were electroporated with the appropriate AdE1A mRNA for 12 hrs followed by another 
12 hrs of IFNγ treatment. They were then harvested by trypsinisation, washed in cold PBS and 
finally resuspended in 50 µl FACS buffer (1% BSA, 0.02% sodium azide in PBS). They were 
stained with 5 µl of mouse anti-human MHC class II antibody for 30 minutes, washed twice with 
FACS buffer, then resuspended in 400 µl PBS prior to being analysed by flow cytometry. A. 
Ad5E1A transfected cells. B. Ad12E1A transfected cells. C. Western blot analysis of transfected 
lysates. Data are means +/- SEM from three repeats.  #, ‡ (P >0.05),  * (P<0.05). 
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AdE1A and its effect on MHC class I and class II as well as the immunosubunits is 
summarised in Table 4.2. 
 
4.2.2.3   The effect of AdE1A on MHC Class I and II levels in adenovirus 
transformed cell lines 
An investigation of the effect of AdE1A on the level of surface MHC class I and II in the 
adenovirus transformed human retinoblastoma (HER) cell lines was carried out to 
determine if there is a correlation with the immunosubunit expression. The cell lines were 
either untreated or treated with 600 U/ml of IFNγ for 48 hrs after which they were 
harvested and stained with mouse anti-human MHC class I or II antibodies (Serotec). 
Samples were then analysed by flow cytometry.  It was seen that MHC class I was highly 
expressed on the surface of all the Ad5 transformed cell lines irrespective of IFNγ 
treatment (Figure 4.14A). However, for Ad12 transformed cells, the situation is rather 
more complex (Figure 4.14B).  These responses can be divided into three groups. In the 
first, very low levels of surface MHC class I were expressed irrespective of IFNγ such as 
in cell lines Ad12E1 HER12 (1), Ad12E1 HER2 (14) and Ad12E1 HER10 (15). It was 
especially marked in cell line Ad12E1 HER12 (1), where there is no expression at all prior 
to IFNγ treatment.   In the second group, expression of MHC class I is very low prior to 
IFNγ treatment but drastically increased afterwards - cell lines Ad12E1 HER3 (2), Ad12E1 
HER5 (7) and Ad12E1A HER283 1 (9). Finally in the third group, MHC class I was highly 
expressed regardless of IFNγ treatment - Ad12E1  HER 11 (5), Ad12E1A +N ras HER 414 
B.2 (6) and Ad12E1A HER283 +Ad12E1B 54k (10), as was seen with the Ad5 
transformed cells.  
Considering MHC class II, none of the Ad5 or Ad12 HER transformants showed any 
surface expression with or without IFNγ treatment; however, appreciable MHC class II 
was detected on the surface of certain human tumour cell lines used as a positive control 
(Figure 4.15).  
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Figure 4.14 MHC class I expression in adenovirus transformed HERs 
Adenovirus transformed human embryonic retinoblast cell lines (HER) were treated with 
600 U/ml of IFNγ for 48 hrs. They were then harvested by trypsinisation, washed in cold 
PBS and finally resuspended in 50 µl FACS buffer (1% BSA, 0.02% sodium azide in 
PBS). They were stained with 5 µl of mouse anti-human MHC class I antibody for 30 
minutes, washed twice with FACS buffer, then resuspended in 400 µl PBS prior to being 
analysed by flow cytometry. A. Cell surface MHC class I in Ad5 transformed HERs . B. 
Cell surface MHC class I in Ad12 transformed HERs. For the specific cell lines, refer to 
the legend on figure 4.8. 
A 
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Figure 4.15  MHC class II expression in adenovirus transformed HERs and A549 
cells expressing Ad5E1A 
Adenovirus transformed human embryonic retinoblast cell lines (HER) and A549 cells 
were treated with 600 U/ml of IFNγ for 48 hrs. They were then harvested by trypsinisation, 
washed in cold PBS and finally resuspended in 50 µl FACS buffer (1% BSA, 0.02% 
sodium azide in PBS). They were stained with 5 µl of mouse anti-human for 30 minutes, 
washed twice with FACS buffer, then resuspended in 400 µl PBS prior to being analysed 
by flow cytometry. A549 cell line does not express AdE1A. 
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Table 4.2 Summary of the effect of AdE1A on MHC class I, class II and the 
immunosubunits in transformed, infected and transfected cells. “↓“  signifies down-
regulation, ‘=’ signifies no change.  
 
 
 
 
 
 
 
 
 MHC class I MHC class II 
Ad5 Ad12 Ad5 Ad12 
Adenovirus 
transformation 
= ↓ ↓ ↓ 
Adenovirus 
infection 
= = = ↓ 
AdE1A 
transfection 
= = ↓ ↓ 
 LMP2 LMP7 
MECL-1 
Ad5 Ad12 Ad5 Ad12 Ad5 Ad12 
Adenovirus 
transformation 
= ↓ = ↓ ↓ ↓ 
Adenovirus 
infection 
↓ ↓ ↓ ↓ ↓ ↓ 
AdE1A 
transfection 
↓ ↓ ↓ ↓ ↓ ↓ 
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4.2.3   AdE1A reduces the transcriptional response to IFNγ in human cells 
4.2.3.1  Luciferase assays  
To study the effect of AdE1A on the cellular IFNγ response, a reporter plasmid construct - 
pGAS-luciferase (section 2.3.11) was used. As explained in detail in section 1.5 
(JAK/STAT1 pathway), upon IFNγ stimulation, receptors dimerise at the cell surface 
causing their phosphorylation. This acts as a docking site for STAT1 which, in turn, 
dimerises and translocates to the nucleus where it can activate transcription of IFNγ 
inducible genes by binding to promoters that contain the GAS element. pGAS-luciferase 
reporter constructs can be used to monitor the induction of STAT1 as they possess a 
STAT1 enhancer element upstream of the firefly luciferase reporter gene (luc). Upon 
STAT1 homodimer binding to the promoter, luciferase enzyme is expressed, which upon 
substrate addition, enables the activity levels to be measured via a luminometer. The 
analysis is carried out on cell lysed with passive lysis buffer (PLB, Promega).   
 
4.2.3.1.1   Adenovirus-infected cells 
H1299 cells were first transfected with pGAS-luc for 24hrs followed by 6 hr infection with 
Ad5, Ad12 or Ad5 ΔE3. Cells were then treated with IFNγ for a further 24 hrs. As above, 
cells were lysed in PLB and luciferase activity measured. 
There was very low basal pGAS activity prior to addition of IFNγ.  After treatment, there 
was a massive upregulation of luciferase activity to 210 units in mock infected H1299 
cells. Upon infection with Ad5 and Ad5 ΔE3, luciferase activity remained unaffected, 
however, inhibition of this activity was observed in Ad12 infected cells where it fell by 50% 
to around 100 units (Figure 4.16). 
 
4.2.3.1.2   AdE1A transfected cells 
Finally, the effect of AdE1A transfection on the cellular IFNγ response was studied.  
pGAS-luc constructs were co-transfected with or without 12SAd5E1A, 13SAd5E1A, 
12SAd12E1A, 13SAd12E1A, 12SAd5E1A mutant (L19/20S) and 13SAd5E1A mutant 
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(L19/20S), for 24 hrs followed by another 24 hrs of IFNγ treatment. pcDNA3 was used as 
a negative control. The results revealed that AdE1A strongly inhibited luciferase activity, 
and therefore the IFNγ response, in all cases (Figure 4.17). There was up to 10 fold 
reduction in luciferase activity observed. Double mutations at residues 19 and 20 did not 
significantly affect this repressive activity of AdE1A.  
 
4.2.3.1.3   Adenovirus transformed human cells  
A number of Ad5 and Ad12 transformed cell lines (from 4.2.2.3) as well as A549 
expressing 12SAd5E1A, were transfected with pGAS-luc for 24hrs followed by a further 
24 hrs of IFNγ treatment or they were left untreated. The cells were lysed with PLB 
(Promega). 100 μl of LARII substrate (Promega) was added to this lysate in white 
optiplate wells. The firefly luciferase activity was measured by luminometer. Data was 
optimised using transfection of Renilla as a control.  
The results showed that the cellular response to IFNγ was greatly reduced in all of the 
Ad5 and Ad12 transformed cells as well as 12SAd5E1A expressing A549 cells when 
compared to the original A549 cell line (Figure 4.18). Repression ranged from 85% to 62% 
down-regulation in Ad12E1 HER2 and Ad5 12S 10 A549 cells respectively.    
 
4.2.3.2  The effect of AdE1A on STAT1 phosphorylation 
In light of the above data that showed inhibition of the cellular IFNγ response by AdE1A, 
the effect of AdE1A on the phosphorylation of STAT1, which is a crucial component of the 
JAK/STAT1 signalling pathway, was investigated. Lysates from the transfections and 
infections described above were analysed by western blotting for the expression of 
phosphorylated (on Serine 727) and non- phosphorylated STAT1. Infection with Ad5, 
Ad12 and Ad5ΔE3 significantly reduced the level of phosphorylated STAT1 (phospho-
STAT1) in comparison to the mock infected H1299 cells (Figure 4.19A). The level of total 
STAT1 however remained unchanged. Similarly, transfection with 13SAd5E1A down-
regulated phospho-STAT1 levels after IFNγ treatment compared to pcDNA3 transfected  
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Figure 4.16 Cellular response to IFNγ in adenovirus infected cells. 
H1299 cells were transfected with pGAS-luc for 24 hrs followed by 6 hrs of mock, Ad5, 
Ad12 and Ad5 ΔE3 infection. Cells were then treated with IFNγ for a further 24 hrs. Cells 
were lysed in passive lysis buffer (Promega). LARII substrate was added to 20 µl of this 
lysate and luciferase activity measured. The normalized luciferase activity was 
represented as ratio of Firefly luciferase activity (pGAS-luc) over Renilla luciferase activity 
(pGL3-Renilla). 
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Figure 4.17 Cellular response to IFNγ in AdE1A transfected cells. 
H1299 cells were transfected with 1 µg of pGAS luciferase reporter constructs and 1 µg of 
the appropriate plasmid construct for 24 hrs, followed by a further 24 hrs of IFNγ 
treatment. Cells were lysed in passive lysis buffer (Promega). LARII substrate was added 
to 20 µl of this lysate and luciferase activity measured. The normalized luciferase activity 
was represented as ratio of Firefly luciferase activity (pGAS-luc) over Renilla luciferase 
activity (pGL3-Renilla). 
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Figure 4.18 Cellular response to IFNγ in adenovirus transformed HERs and A549 
cells expressing Ad5E1A 
Cells were transfected with 1 µg of pGAS luciferase reporter constructs for 24 hrs, 
followed by a further 24 hrs of IFNγ treatment. Cells were lysed in passive lysis buffer 
(Promega). LARII substrate was added to 20 µl of this lysate and luciferase activity 
measured by luminometer. The normalized luciferase activity was represented as ratio of 
Firefly luciferase activity (pGAS-luc) over Renilla luciferase activity (pGL3-Renilla). 
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Figure 4.19 AdE1A inhibits the phosphorylation of STAT1 (Serine 727) 
H1299 cells were either A. infected or B. transfected with adenovirus or Ad5E1A 
respectively for 24 hrs, followed by IFNγ treatment for another 24 hrs. Cells were lysed 
with 9 M urea, 50 mM Tris (pH 7.3) and 0.15 M β-mercaptoethanol. Thirty microgram of 
this lysate was analysed by Western blotting to determine proteins levels. 
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cells (Figure 4.19B); and there is a slight up-regulation of STAT1 levels after treatment 
with IFNγ.  
 
 
4.3    Discussion   
In this chapter, the effect of AdE1A on three components of the antigen processing 
machinery: the immunoproteasomes, MHC class I/II and the JAK/STAT1 pathway was 
examined. This was studied in three systems: in adenovirus transformed cells, AdE1A 
transfected cells and following adenovirus infections. AdE1A is already known to target 
various key cellular proteins involved in the regulation of transcription and cell cycle 
progression (Berk 2005; Gallimore and Turnell 2001). There is also well established 
evidence that AdE1A targets the proteasome components of the antigen processing 
machinery (Grand et al., 1999; Turnell et al., 2000; Zhang et al., 2004; Rasti et al., 2000; 
Chatterjee-Kishore et al., 2000). In this chapter, we have expanded on these studies to 
give a further insight into AdE1A interaction with the antigen processing and immune 
evasion mechanisms. 
Adenovirus infection and Immunosubunit expression: Investigations into the effect of 
adenovirus infection on LMP2, LMP7 and MECL1 levels were conducted. Research up to 
now, has focused mainly on adenovirus transformed cells and to a limited extent, in the 
case of AdE1A transfection. It appears that no studies have looked at changes in the 
immunosubunit levels during adenovirus infection. For this study, examining Ad5, Ad12 
and Ad5 ΔE3 infection of H1299 has revealed that all three immunosubunits were strongly 
down-regulated after infection (Figure 4.1). The observation that the same level of 
inhibition was observed during w.t. and Ad5 ΔE3 infection demonstrates that the viral E3 
proteins had little effect (section 1.3.5.3). AdE3 transcription unit encodes at least four 
proteins: E3-gp19K, E3-14.7K, E3-10.4K/14.5K and E3-11.6K. They have various 
immunosubversive functions such as down-regulation of MHC class I (Burgert et al., 1987; 
Wold et al., 1999) and inhibition of tapasin (Bennett et al., 1999), in a manner such that 
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recognition of the infected cell by the immune system is negated. The purpose of the 
inclusion of E3 deletion mutant in this study is to rule out its involvement in the observed 
experimental data. There is also a fifth E3 protein called E3-49K, that has only recently 
been discovered, and only expressed by Ad19a adenovirus of the subgenus D, causing 
epidemic keratoconjunctivitis in AIDS patients (Blusch et al., 2002; Windheim and Burgert 
2002). However, its function is yet to be determined. 
In the experiment shown in Figure 4.1, cells were infected with adenovirus prior to IFNγ 
treatment, or treated with IFNγ prior to adenovirus infection. Interestingly, it was found that 
for IFNγ pre-treated cells, infection with Ad5, Ad12 or Ad5 ΔE3 had no effect on the 
expression of LMP2, LMP7 and MECL-1 at 24hrs (Figure 4.2). The level of infection (as 
indicated by the AdE1A expressed) was significantly reduced. This is consistent with a 
previous study that demonstrated that IFNγ pre-treatment inhibits adenovirus replication 
(Mistchenko and Falcoff 1987). Perhaps, unsurprisingly, treatment with IFNγ increases the 
cell’s defence mechanism making it more resistant to viral replication, hence hindering the 
ability of adenovirus to affect immunosubunit expression. However, prolonged infection to 
48hrs began to inhibit the immunosubunit expression in comparison with mock infected 
cells (Figure 4.3).  
It is well established that adenovirus targets components of the antigen processing 
machinery such as MHC class I, 20S proteasome, TAP proteins and, as it has been 
shown here, also targets the immunoproteasome. A previous study has revealed that the 
immunoproteasome processed the adenovirus early region 1B 19K protein (E1B)-derived 
epitope E1B192-200 with increased efficiency leading to detection of the virus (Sijts et al., 
2000). This group produced a tetracycline-regulated mouse cell line that allowed titratable 
formation of immunoproteasomes. When the immunoproteasomes were highly expressed 
prior to infection, it produced optimal cytotoxic T cell (CTL) activation hence the 
recognition of the infected cell by the immune system. In the light of the above data, one 
can conclude that AdE1A may preemptively target immunoproteasome expression early in 
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infection, affecting its activity and hence avoiding recognition by the immune system. 
Interestingly, in addition to its role in producing epitopes of viral origin for MHC class I 
presentation, recent findings show that immunoproteasomes may also have a role in the 
maintenance of protein homeostasis and preservation of cell viability in response to 
interferon-induced oxidative stress (Seifert et al., 2010). This might be prejudicial to viral 
replication and is a subject for future investigation. 
AdE1A transfection and Immunosubunit expression: The effect of AdE1A on LMP2, LMP7 
and MECL1 expression following transfection into cells was also examined. Data so far 
revealed down-regulation of LMP2 transcription by adenovirus AdE1A (Chatterjee-Kishore 
et al., 2000).  In this study, this was extended to examine LMP7 and MECL1. The non 
small lung carcinoma cell line (H1299) was found to be highly inducible by IFNγ to 
express LMP2, LMP7 and MECL1. Transfection experiments followed by western blotting 
analysis revealed that there was an inhibition of expression of all three immunosubunits in 
all of 12SAd5E1A, 13SAd5E1A, 12SAd12E1A and 13SAd12E1A transfections (Figure 
4.6). Similarly, this inhibition varied in proportion to the amount of AdE1A expressed in the 
cell (Figure 4.7), where the higher the AdE1A expression, the greater the inhibition, 
supporting the proposition that AdE1A was responsible for this down-regulation. 
Furthermore, both 12SAdE1A and 13SAdE1A have caused inhibition, indicating that CR3 
is not solely responsible. As mentioned before, these data contradict the outcome from 
the previous experiment conducted using 12SAdE1A and 13S AdE1A expressing A549 
cells, which showed inhibition in the 13SAd5 expressing cell line only. However, research 
by Routes et al., (1996) has revealed that E1A mutants that do not express CR3 were 
able to impair IFN-stimulated gene expression whereas mutants with deletions in the CR1 
and N-terminal region were unable to block IFN-stimulated gene expression, supporting 
the premise that CR3 is not involved. Later experiments also point towards this inhibition 
being due to AdE1A interfering with the JAK/STAT1 pathway rather than being as a result 
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of direct AdE1A interaction with the immunosubunits; this will be discussed later in this 
chapter. Similarly, Ad5 and Ad12 have also both demonstrated similar levels of inhibition. 
 
Adenovirus transformation and Immunosubunit expression: Prior to this study, research 
on transformed rat cells had suggested down-regulation of LMP2, LMP7 and MECL1 
expression in Ad12 transformed but not in Ad5 transformed cells (Vertegaal et al., 2003, 
Rotem-Yedudar et al., 1996). However, there had been no studies investigating 
immunosubunit expression in human adenovirus transformed cells. To investigate this 
further, a panel of transformed human retinoblast (HER) cell lines with different expression 
profiles of AdE1A, AdE1B and activated (mutant) ras was used (Gallimore et al., 1986; 
Byrd et al., 1982, 1988). Western blot analysis on these lines has shown that LMP2, 
LMP7 and MECL1 expression was down-regulated in the lines that express Ad12E1A but 
not Ad5E1A (Figure 4.8A). The other proteins, namely AdE1B and ras, did not contribute 
to this trend. This observation was consistent with the previous studies on transformed rat 
cells which also showed that Ad12 transformed lines had downregulated immunosubunit 
expression in comparison to Ad5 transformed lines (Vertegaal et al., 2003, Rotem-
Yedudar et al., 1996). A549 cells that constitutively express either 12SAd5E1A (12S 10) 
or 13SAd5E1A (13S and 13S G418) were analysed for immunosubunit expression 
following IFNγ treatment (Figure 4.9). There was an inhibition of immunosubunit 
expression with both 12SAd5E1A and 13SAd5E1A expressing cells. However, this 
contradicts data from the panel of transformed HER cell lines that showed down-
regulation only in the Ad12 E1 transformed cells. The reason for this is not clear. 
However, the 12S 8 and 12S 10 cells used in the present study were of very high passage 
in comparison to the HER cell lines. Long-term culturing of the cells may have altered the 
cellular protein expression profile and clone stability due to potential cumulative mutations 
rather than it being due to the effect of AdE1A. Perhaps earlier passages of these cell 
lines may be used in a future experiment to re-examine immunosubunit expression. 
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Subsequently, our study also looked at the role of AdE1A in the regulation of cell surface 
levels of MHC class I and MHC class II. MHC class I is expressed constitutively on the 
surface of all cells (York and Rock 1996) whereas MHC class II is expressed mostly on 
antigen presenting cells of the immune system (Benoist and Mathis 1990; Steimle et al., 
1994); while it can be induced in other cells by exposure to IFNγ (Steimle et al., 1994). 
Like the immunoproteasome subunits, MHC class II expression is induced via the 
JAK/STAT1 pathway (Gough et al., 2008) (section 1.5, Figure 1.13). Activation of the 
JAK/STAT1 pathway leads to the expression of the master MHC class II regulator CIITA, 
which in turn initiates the transcription of MHC class II with the aid of 19S proteasome 
ATPases and other transcription factors (Bhat and Greer 2011). This transcription is 
illustrated in Figure 1.14.  
Adenovirus infection and MHC class I and II surface expression: The effect of adenovirus 
infection on MHC class I and class II expression was investigated. Past studies have 
indicated that infection of cells with Ad5 down-regulated MHC class I expression (Burget 
et al., 1985, 1987; Wold et al., 1999; Lippe et al., 1991). This has been attributed to 
adenoviral E3-gp19K inhibiting glycosylation and transport of newly synthesized MHC 
class I from the endoplasmic reticulum to the plasma membrane (Burgert et al., 1985, 
1987; Wold et al., 1999; Lippe et al., 1991). In the present study, this was revisited to 
include an Ad5 mutant virus that has the E3 gene deleted in addition to Ad5 and Ad12 w.t. 
virus infections. Infection of A549, HCT116, tonsil epithelial cells and T47D cells (Figures 
4.10 A-D) with Ad5, Ad12 and Ad5 ΔE3 viruses had no effect in the surface levels of MHC 
class I with or without the treatment of IFNγ. This result conflicts with previous data that 
showed down-regulation of MHC class I by w.t. Ad5 (Burget et al., 1987; Wold et al., 
1999; Lippe et al., 1991). However, not all the studies were contradictory; for example, 
work by Routes and Cook (1990), using ten fibroblastic, epithelial (including A549) and 
lymphoid cell lines that have been infected by Ad2/5 adenovirus revealed that, with the 
exception of the Ad5E1A transformed 293, all of the cell lines maintained their surface 
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MHC class I expression until cell death is imminent. The reason for this is still not clear but 
these workers suggest that subclones of certain cell lines may be more sensitive to the 
effects of E3-19K than others. Similarly, in some mouse cells (which are semi-permissive 
for Ad infection), Ad5 infection resulted in an increased transcription rate of MHC class I 
mRNA (Rosenthal et al., 1985) which may mask the inhibitory effect of E3-19K.  
Additionally, infection of mouse cells with mouse adenovirus type 1 (MAV-1) did not affect 
the expression of 10 different mouse class I MHC allotypes (Kring and Spindler 1996). 
The exact role of AdE1A in MHC class I regulation was also studied by looking into 
AdE1A transfection. This will be addressed later in this discussion. 
There appears to have been no previous studies examining the effect of adenovirus 
infection on MHC class II levels on the cell surface. Only one study (that looked at the 
accumulation of HLA class II mRNA in Ad5E1A transfected cells) reported an inhibition in 
the induction of MHC class II genes (Ackrill et al., 1991). In the present study, T47D cells 
and tonsil epithelial cells were mock, Ad5, Ad12 and Ad5 ΔE3 infected and then 
stimulated with IFNγ prior to analysis by flow cytometry. In both cases, a strong reduction 
of cell surface MHC class II expression by Ad12 was observed, compared to Ad5 and Ad5 
ΔE3 (Figure 4.11). T47D cell infection with Ad5 and Ad5 ΔE3 left MHC class II expression 
unaffected.  In tonsil epithelial cells there was a small but significant decrease in cell 
surface MHC class II level upon Ad5 infection. The expression was restored in the Ad5 
ΔE3 infection (Figure 4.11). Tonsil epithelial cells are primary cells so they may be more 
sensitive to the effects of infection compared to the tumour cell line T47D. The restoration 
of MHC class II upon Ad5 ΔE3 may indicate E3 involvement; however, there is no 
research to date implicating E3 in MHC class II down-regulation. Oncogenic Ad12 down-
regulating MHC class II expression during infection may correlate with its capacity to 
inhibit MHC class I expression in the transformed cell lines, however, this result was not in 
agreement with the outcome in the adenovirus transformed and AdE1A transfected cell 
lines, where MHC class II expression was low in all cases.   
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AdE1A transfection and MHC class I and II surface expression: In adenovirus infections 
and Ad transformed cell lines, AdE1A may or may not cooperate with other viral proteins 
to give the observed effect. The involvement of other proteins can be ruled out by 
examining AdE1A transfection in isolation. mRNA electroporation is a technique which is 
highly efficient (with high viability) in gene delivery, and is superior to lipofection or 
electroporation of plasmid cDNA (Van Tendeloo et al., 2001), although it is more labour 
intensive.  Primary fibroblasts and the IFNγ inducible T47D cell line were used to study 
the effect of the electroporation of AdE1A on MHC class I and class II, respectively. 
Previous research has been heavily focused on MHC class I levels in adenovirus 
transformed and infected cells. In the present study, previous findings were 
complemented by examining AdE1A transfection and the effect this may have on MHC 
class I and class II expression. Primary human fibroblasts were electroporated with mRNA 
encoding Ad512SE1A, Ad513SE1A, Ad1212SE1A, Ad1213SE1A, Ad512SE1A mutant 
(L19/20S) and Ad513SE1A mutant (L19/20S). The surface level of MHC class I remained 
unchanged following electroporation (Figure 4.12). With the exception of Ad12 
transformed cells, so far it was observed that AdE1A transfection, infection and Ad5 
transformation had no effect on surface MHC class I levels (summary in Table 4.2). MHC 
class I is expressed constitutively in all somatic cells. This may indicate lack of AdE1A 
involvement in MHC class I repression or it may indicate that AdE1A cannot affect 
expression when MHC is expressed constitutively but may do so in the case of inducible 
expression as evidenced in MHC class II expression in T47D cells.   Electroporation of 
T47D cells gave a different MHC class II profile. AdE1A significantly down-regulated MHC 
class II surface expression in Ad512SE1A and Ad513SE1A transfected cells, although the 
introduction of a double mutant at residues 19 and 20 relieved the inhibition (Figure 
4.13A). Although mRNA electroporation is highly efficient, one disadvantage is that 
obtaining equal expression between the different mRNA contructs is very difficult. RNA is 
highly sensitive to degradation and exhibits different levels of expression depending on its 
stability. So the western blot data (Figure 4.13C) was taken into account when considering 
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the effect of AdE1A on MHC class II levels. No significant down-regulation of MHC class II 
expression was observed in Ad1212SE1A and Ad1213SE1A transfected cells. Perhaps, it 
would be interesting to repeat this experiment using an alternative method of delivering 
the AdE1A genes, so as to ensure this is not due to problems with mRNA quality or 
electroporation efficiency.  
The double mutations in residues 19 and 20 of AdE1A are located in the N-terminal 
region, which is important in mediating the transcriptional regulation effects of AdE1A. 
This region was also found to be involved in binding of AdE1A to STAT1 (Look et al., 
1998) a component of the JAK/STAT1 pathway- see section 1.5, impairing the IFN-
mediated gene expression (Routes et al., 1996). This may suggest that the double 
mutations at the N-terminal region have affected the ability of AdE1A to bind to STAT1 
and hence reduced its repression of MHC class II. The activation of JAK/STAT1 pathway 
leads to the expression of various genes crucial for initiation of immune response and the 
resistance of cells to viral infection. Proteins expressed in response to IFNγ include MHC 
class II and the immunoproteasome subunits LMP2, LMP7 and MECL1. In fact, the down-
regulation of LMP2, LMP7 and MECL1 as well as MHC class II observed in this study may 
be attributed to AdE1A targeting of JAK/STAT1 pathway via STAT1. The effect of AdE1A 
on the phosphorylation of STAT1 will be discussed below. 
AdE1 transformation and MHC class I and  II surface expression:  Prior to this study, there 
has been an extensive research on MHC class I levels in adenovirus transformed rodent 
cell lines, where it was established that Ad12 transformed cells have down-regulated 
surface MHC class I levels in comparison to Ad5 transformed cells (Schrier et al., 1983; 
Ackrill and Blair 1988; Friedmann and Ricciardi 1988). Limited studies on human cells 
transformed with AdE1 have also been presented. They showed similar results with MHC 
class I surface expression greatly reduced in Ad12 transformed cells (Bottley et al., 2005; 
Vasavada et al., 1986). Bottley et al., (2005) utilized three Ad5 and three Ad12 
transformed human retinoblast (HER) cell lines whereas in the study by Vasavada et al., 
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1986, adenovirus transformed human embryonic kidney (HEK) cells were used. In the 
present study, the panel of Ad5 and Ad12 transformed HER cell lines was enlarged to 
include those expressing different combinations of AdE1A, AdE1B or mutant (activated) 
ras.  Consistent with previous data, it was observed that there was no down-regulation of 
MHC class I in any of the Ad5 transformed human cells irrespective of the presence of 
IFNγ (Figure 4.14A). However, in the case of the Ad12 transformed cells, the situation is 
more complex (Figure 4.14B).  The majority of the lines (6 out of 9) expressed very low 
MHC class I levels prior to IFNγ treatment as in the case of cell lines Ad12E1 HER12 (1), 
Ad12E1 HER3 (2), Ad12E1 HER5 (7), Ad12E1A HER283 1 (9), Ad12E1 HER2 (14) and 
Ad12E1 HER10 (15). This was in agreement with past data that showed similar results 
(Bottley et al., 2005; Vasavada et al., 1986). Additionally, three lines had their MHC class I 
fully restored following IFNγ treatment - Ad12E1 HER3 (2), Ad12E1 HER5 (7) and 
Ad12E1A HER283 1 (9) - while the rest showed little or limited induction. This induction by 
IFNγ is consistent with a previous study that showed similar results in transformed rat cell 
lines (Ackrill and Blair 1990, Eager et al., 1989). In the remaining three cell lines MHC 
class I is highly expressed regardless of IFNγ: Ad12E1 HER 11 (5), Ad12E1A +N ras HER 
414 B.2 (6) and Ad12E1A HER283 +Ad12E1B 54k (10). It seems that in these three cell 
lines Ad12E1A did not suppress MHC class I expression. The reason for this is not clear 
but it may be attributed to the differences between the different sub-clones of HER cells in 
terms of sensitivity to AdE1 expression.  
There appears to have been no research so far investigating the effect of adenovirus 
transformation on MHC class II expression. In this study, for the first time, MHC class II 
surface level expression in Ad5 and Ad12 transformed cell lines were addressed. Four 
Ad5E1A expressing, two Ad12 transformed cell lines and the A549 tumour cell line were 
analysed for MHC class II cell surface expression in the absence or presence of IFNγ 
(Figure 4.15). In contrast to MHC class I, MHC class II surface expression levels were 
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very low in both Ad5 and Ad12 transformed lines in comparison to the A549 cell line which 
had high expression of MHC class II, especially after IFNγ treatment.  
Retrospectively examining the effects of AdE1A on the surface MHC class I and class II 
levels against the backgrounds of adenovirus transformation, infection and AdE1A 
transfection have revealed some inconsistencies. Data so far from the present study, with 
regards to the effect of AdE1A on MHC class I, class II and the immunosubunits is 
summarised in Table 4.2. MHC class I levels in Ad12 transformed cells were down-
regulated whereas it remained unchanged in cells infected or transfected by Ad12 virus 
and Ad12E1A respectively. Each of the three systems offer very different settings, and 
thus not strictly comparable. For instance, adenovirus infection involves the co-operation 
of different viral proteins; transfection enables the lone expression of AdE1A within a cell; 
and cell transformation occurs when cells fail to support lytic infection and there is chance 
of integration and expression of the early region AdE1A and AdE1B genes (Ricciardi 
1999). Additionally, in each case, the same set of viral proteins may not be expressed. For 
instance, during Ad5 infection, E3 impairs the transportation of class I molecules to the 
cell surface (Wold and Tollefson 1999; Williams et al., 2004) leading to the down-
regulation of MHC class I, whereas in Ad5 transformants, no E3 is expressed so the levels 
of MHC class I remain unchanged (Williams et al., 2004). Hence, different outcomes on 
MHC levels can be observed with the same serotype. Another study addressing the effect 
of AdE1A on insulin receptor substrate 4 (IRS-4), have shown that IRS-4 was only 
detected in 13SAd5E1A-expressing A549 cells but not  in Ad12E1A and 12SAd5E1A 
expressing cells (Shimwell et al 2009). However, A549s transfected or infected with 
AdE1A and Ad5 w.t. virus respectively had no effect on their IRS-4 expression (Shimwell 
et al 2009). It was found that low passage 13SAd5E1A-expressing A549s do not express 
IRS-4 but over time in culture expression was markedly increased. It was suggested that 
stable but not transient expression of 13SAd5E1A is required for IRS-4 overexpression 
(Shimwell et al 2009). This concept may be applied to this study with regards to MHC 
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class I expression. It can be hypothesized that stable expression of Ad12E1A in the 
transformed cells caused down-regulation of MHC class I surface expression, while it 
remains unchanged in the infected and transfected cells. In addition, certain aspects of 
the experiments may be improved in future work to investigate if the same outcome will be 
observed. For instance, during flow cytometry analysis, dual staining (for AdE1A and MHC 
class I/II) may be suggested in order to examine MHC surface levels in selected AdE1A 
positive cells after infection and transfection. The fact that no change in MHC class I 
levels was observed in all Ad5/Ad12 transfected and infected cells may be due to the fact 
that any significant effect on MHC class I levels is diluted within a whole population of 
AdE1A-negative cells.  Attempts were made, in this study, at dual staining of MHC class I 
and AdE1A for flow cytometry. However, there were problems obtaining optimum cell 
permeabilisation that enabled intracellular staining with anti-AdE1A antibodies. Cell 
permeabilisation methods included using 0.5% saponin and IntraPrep™ Permeabilization 
Reagent kit (Beckman Coulter). 
On the other hand, infection by Ad5 has not caused any effect on MHC class II surface 
expression, whereas there was down-regulation after transfection and transformation.  As 
mentioned above, this may also be attributed to the differences between the three 
backgrounds; however, additional experiments using increasing viral titre may be required 
to investigate this further.  
Comparing Ad5 and Ad12, the latter is highly oncogenic whereas the former is not 
(Trentin et al., 1962; Yabe et al., 1962, 1964). This correlates with Ad12 ability to down-
regulate MHC class I in the adenovirus transformed cells (Schrier et al., 1983; Ackrill and 
Blair 1988; Friedmann and Ricciardi 1988) enabling the cell to escape immune system 
recognition and thus contributing to the induction of tumours in new-born rodents (Trentin 
et al., 1962; Yabe et al., 1962, 1964). In the present study, it was found that Ad12 
transformation also down-regulated LMP2 and LMP7 immunosubunits after transformation 
whereas Ad5 did not have any effect.  Past studies have attributed Ad12 oncogenicity to a 
20 amino acid alanine-rich segment that is unique to the group A viruses (Telling and 
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Williams 1994). This “oncogenic spacer” region in situated between CR2 and CR3 and it 
is missing entirely in Ad5E1A. The group have shown an experiment where they produced 
a chimeric virus where the spacer region in Ad12 is replaced by the equivalent cassette 
from Ad5. This chimeric virus was defective for tumour induction in rats hence showing 
that this spacer region is an oncogenic determinant of Ad12 (Telling and Williams 1994). 
However, it is not entirely clear how this region influences oncogenicity, but it is thought 
that it may not be acting alone; as further studies with chimeric viruses have revealed that, 
though the spacer region is essential for tumourigenicity, it was not responsible for MHC 
class I down-regulation (Williams et al., 2004).  
AdE1A, cellular response to IFNγ and STAT1 phosphorylation: Previous studies have 
shown that STAT1 is reduced in AdE1A expressing cells although this does not appear to 
be the case here (Leonard and Sen 1996).  STAT1 binds to the pGAS promoter and 
associates with CBP/p300 which in turn recruits the basal transcription complex (Zhang et 
al., 1996) to initiate transcription. Through its N-terminal region, AdE1A binds to STAT1 
disrupting its association with CBP/p300 and hence inhibiting transcriptional initiation 
(Look et al., 1998). Another way AdE1A targets STAT1 function is by binding to CBP/p300 
(Zhang et al., 1996). Both AdE1A and STAT1 bind to the same domain of CBP/p300. This 
limits STAT1 from associating with CBP/p300 (Zhang et al., 1996; Look et al., 1998). In 
short, considering that the response to IFNγ via the JAK/STAT1 pathway is what up-
regulates expression of the immunosubunits and MHC class II, and having been shown by 
past studies that AdE1A targets STAT1; one may conclude that the down-regulation of the 
immunosubunit and MHC class II expression observed in the present study may be due to 
AdE1A interference with the progression of the JAK/STAT1 pathway. To test the 
hypothesis that AdE1A affects the cell’s ability to respond to IFNγ, luciferase assays using 
a construct possessing the pGAS promoter were conducted, in transformed, infected and 
transfected cells. In transformed cells (Figure 4.18) there was a large decrease in IFNγ 
response in all of the Ad5 and Ad12 transformed cells compared to the tumour cell line 
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A549. However, in H1299 cells infected with Ad5, Ad12 and Ad5 ΔE3, it was shown that 
pGAS activity was reduced with Ad12 infection while it remained unchanged in mock, Ad5 
and Ad5 ΔE3 infected cells (Figure 4.16). This result seems to correlate with the effect of 
AdE1A on MHC class II surface expression (Figure 4.11), hence it can be concluded that 
the reduction in MHC class II expression observed in that experiment was due to the 
inhibition of the cellular response to IFNγ. This however, contradicted the data from the 
transfected and transformed cells (Figure 4.17 and 4.18) where cellular IFNγ response 
was inhibited with both Ad5 and Ad12E1A (see below). 
H1299 cells that were electroporated with mRNA have shown a large reduction of IFNγ 
response in the presence of Ad512SE1A, Ad513SE1A, Ad1212SE1A, Ad1213SE1A, 
Ad512SE1A mutant (L19/20S) and Ad513SE1A mutant (L19/20S) (Figure 4.17). In 
contrast to the previous data that showed weakening of AdE1A inhibition of MHC class II 
as a result of the double mutations at the N-terminal region, here the same mutants have 
demonstrated equal inhibition as the wild type AdE1A.  This may indicate that AdE1A 
could inhibit MHC class II expression via other mechanisms.  To complement the above 
data, the lysates from the experiments were analysed by Western Blotting to examine the 
effect on STAT1 phosphorylation. The data revealed that in both adenovirus infected and 
Ad5E1A transfected cells, while unphosphorylated STAT1 levels remained constant, there 
was an inhibition of phosphorylation of STAT1 (Figure 4.19 A and B). This is consistent 
with previous research on STAT1 and AdE1A (Look et al., 1998).  
In this chapter, the role of AdE1A in affecting parts of the antigen processing pathway, 
specifically on the expression of immunoproteasomes and MHC class I and II has been 
examined. The data showed that AdE1A down-regulates the expression of the 
immunosubunits LMP2, LMP7 and MECL1 in infected and transformed cells, whereas in 
transformed cells only Ad12 seemed to control expression. MHC class I surface 
expression remained unaffected following transformation, transfection and viral infection, 
except in Ad12 transformed cell lines where there was a down-regulation. MHC class II 
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surface expression was reduced following transformation, infection and transfection with 
both Ad5 and Ad12 AdE1A with the exception of Ad5 infection where MHC class II 
expression remained unchanged.  And finally, AdE1A inhibited the ability of cells to 
respond to IFNγ by targeting STAT1. All this is just further evidence of the role of AdE1A 
in disrupting the antigen processing machinery in order to hinder recognition by the 
immune response.  Data from this chapter is summarized in Table 4.2.  
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5.1     Introduction 
The replacement of the constitutively expressed β1, β2 and β5 of the 20S proteasome by 
the IFNγ-inducible LMP2, MECL-1 and LMP7 protein subunits respectively to form the 
immunoproteasome (Hisamatsu et al., 1996) leads to an adjustment of the cleavage 
preferences leading to a different spectrum of peptides being produced, that may 
potentially enhance antigen presentation to CTLs (Groettrup et al., 2001; Ehring et al., 
1996; Gaczynska et al., 1996; Cascio et al., 2001; Cerundolo et al., 1995). β1, β2 and β5 
possess “caspase-like” activity which cleaves after acidic residues, “trypsin-like” activity 
that cleaves after basic residues and “chymotrypsin-like” activity that cleaves after 
aromatic and hydrophobic amino acids respectively (Groettrup et al., 2001). Replacement 
by the immunosubunits, results in the enhancement of the “chymotrypsin-like” activity and 
the abrogation of the “caspase-like” activity (Groettrup et al., 2001, Gaczynska et al., 
1994; Scmidtke et al., 1998). Immunoproteasomes are more efficient at generating 
epitopes derived mainly from viral proteins (reviewed by Van den Eynde and Morel 2001), 
which may partly explain their expression being only in the presence of IFNγ. However, 
recent research has revealed that immunoproteasome may have other roles. A study by 
Seifert et al., 2010 have shown that immunoproteasomes contributes in the maintenance 
of protein homeostasis and thus preservation of cell viability upon IFN-induced oxidative 
stress. Immunoproteasomes are known be targeted by viruses. Previous research had 
shed light on the various viral proteins that have suppressed individual immunosubunits at 
the transcriptional level, potentially affecting the total immunoproteasome composition and 
activity, as in for instance, HPV type 18 (Georgopoulous et al., 2000) and  HIV-1 p24 
(Steers et al., 2009). Others have targeted immunosubunits by direct binding such as in 
NS3 non-structural protein of the hepatitis C virus, that binds to LMP7 (Yee-Ling Khu et 
al., 2004); and HIV-1 tat protein that can bind directly to LMP7 and MECL-1, as a result 
repressing its catalytic activity (Apcher et al., 2003). 
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AdE1A is a multifunctional viral protein involved in the interaction with multiple cellular 
proteins involved in the regulation of transcription, DNA synthesis, cell differentiation and 
cell cycle progression (Gallimore and Turnell 2001, Frisch and Mymryk 2002) as well as 
aspects of the antigen processing machinery such as the TAP proteins (Proffitt and Blair 
1997; Rotem-Yehudar 1994, 1996)  MHC class I (Bottley et al., 2005; Vasavada et al., 
1986; Schrier et al., 1983; Ackrill and Blair 1988) and the immunoproteasome (Rotem-
Yehudar 1996; Vertegaal et al 2003; Chatterjee-Kishore et al., 2000). In chapter 3, the 
repression of the immunosubunit expression by adenovirus protein AdE1A was observed 
in all of the infected, transfected and adenovirus transformed cells. Subsequently, in 
chapter 4, it was seen that AdE1A binds to the immunoproteasome, specifically to the 
immunosubunit MECL-1. The AdE1A regions as well as the binding sites and residues 
involved in this interaction were mapped. Further to these observations, we have 
attempted to examine the effect of AdE1A’s interaction on the proteolytic activity of 
immunoproteasomes. Research to date on AdE1A and the immunoproteasome was 
mainly focused on its effect on immunosubunit expression at a transcriptional level and 
some limited studies on its direct binding to the immunosubunits. In this study, 
complementary to the  findings in chapter 3 and 4, the effect of AdE1A on the catalytic 
activity of the immunoproteasome will be examined, an area not addressed by previous 
research. The effect of AdE1A on the caspase, trypsin and chymotrypsin-like activities of 
the immunoproteasome will be assessed as well as the effect on the antigen presentation 
to cytotoxic T cells (CTLs). This will be determined using ELISA assays and CD107A 
staining. 
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5.2    Results  
5.2.1 The effect of AdE1A on the proteolytic activities of the 
immunoproteasome 
5.2.1.1 In vitro proteasome assays 
The caspase-like, chymotrypsin-like and trypsin-like activity of the immunoproteasome 
was examined in the presence or absence of AdE1A in vitro using specific fluorogenic 
substrates (refer to protocol on section 2.2.4). Two hundred μM of each substrate in the 
presence or absence of varying amounts of AdE1A was added to 6.25 μg/ml of purified 
human immunoproteasome (obtained from Biomol). Negative controls include: irrelevant 
GST protein and immunoproteasome; as well as substrate solution and assay buffer only 
(50 mM Tris pH 7.5, 25 mM KCl, 10 mM NaCl, 1 mM MgCl2) to test any background 
activity. After 30 minutes at 37°C, the total reaction was transferred to a 96-well 
fluorescence plate where the fluorescence was measured using the Victor plate reader. 
The results show that at high concentrations of GST-Ad5E1A as well as the irrelevant 
GST protein (1 μg, 3 μg and 10 μg), there was no significant change in the trypsin-like 
activity in comparison to the immunoproteasome on its own; whereas there was a strong 
(6-fold) reduction in chymotrypsin activity upon the addition of not only Ad5E1A, but GST 
protein as well (Figure 5.1A). The level of inhibition was generally the same across the 
different quantities of Ad5E1A and GST. Caspase activity was very low in comparison to 
trypsin and chymotrypsin activity in the presence of both Ad5E1A and GST protein (there 
was little or no caspase activity in the presence of 1 μg, 3 μg and 10 μg GST-Ad5E1A). 
The same experiment was repeated, except that smaller amounts of untagged Ad12E1A 
were used (0.5 μg, 2.5 μg and 4 μg). Here, the results have shown that in comparison to 
the lone immunoproteasome, there was no change in trypsin activity upon varying the 
quantity of both GST and Ad12E1A, however, there was about a six-fold reduction in 
chymotrypsin activity across all of the different quantities of Ad12E1A along with the GST 
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proteins (Figure 5.1B). Interestingly, there may be an inhibition of caspase activity 
specifically upon addition of Ad12E1A in comparison to GST (Figure 5.1B). 
A further experiment focusing on only chymotrypsin activity and AdE1A was undertaken. 
Additionally, concern over protein over-saturation causing the inhibition of proteolytic 
activity by even GST was addressed by using smaller amounts of AdE1A and GST (0.01 
μg, 0.05 μg, 0.1 μg and 0.2 μg). With increasing amount of both AdE1A and GST, there 
was a corresponding reduction in the chymotrypsin activity (Figure 5.1C). There was slight 
added reduction in chymotrypsin activity in all of the different amounts of GST protein, 
with the exception of at 0.01 μg, where 13S Ad12E1A caused more reduction in 
chymotrypsin activity at around 21000 compared to 29000 for the same amount of GST. 
The proteolytic inhibition by GST protein alone is difficult to explain, as it was originally 
meant to act as a negative control in the assays. The reason why GST inhibited the 
chymotrypsin activity is not known. Another control protein, for instance bovine serum 
albumin (BSA) was used in place of GST protein, but that too inhibits the proteolytic 
activity of the immunoproteasome (data not shown) 
 
 
 
5.2.1.2 Enzyme-linked immunosorbent assay  (ELISA) 
In the light of the above results, an alternative method to assess the effect of AdE1A on 
the activity of immunoproteasomes was sought. Immunoproteasomes are crucial 
components of the antigen processing machinery as they mediate degradation of antigens 
which are eventually presented by MHC class I to CTLs at the cell surface.  The Epstein 
Barr virus (EBV) system is very well characterised with defined CTL epitopes and 
corresponding antigen specific CD8+ T-cell clones (Lautscam et al., 2001, 2003; Lee at al 
1993, 1997; Houssaint et al., 2001; Khanna and Burrows 2000; Khanna et al., 1996; Meij 
et al., 2002).  
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Figure 5.1 The effect of AdE1A on the catalytic activity of the 
immunoproteasome  
In vitro proteasome assay involved using fluorogenic substrates Z-LLE-AMC, Suc-LLVY-
AMC and Bz-VGR-AMC to examine the caspase, chymotrypsin and trypsin activity of the 
immunoproteasome. Assay was conducted as described in section 2.2.4. Fluorescence 
was measured by “umbelliferone 360 nm/460 nm” on a Victor plate reader. A. GST-13S 
Ad5E1A quantity range 1-10 μg  B. 13S Ad12E1A (untagged) quantity range 0.5-4 μg  C. 
13SAd12E1A (untagged) quantity range 0.01-0.2 μg (chymotrypsin-like activity only). GST 
was included as a control. 
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EBV-derived CTL epitopes with known routes through the antigen processing pathway 
were used in an ELISA testing antigen presentation in the presence or absence of AdE1A. 
For this study, the epitopes are derived from the EBV-encoded latent membrane protein 
2A (LMP2A). LMP2A is a multiple membrane-spanning molecule that is composed of 
short cytosolic NH2- and COOH-terminal domains that flank 12 transmembrane domains 
that are connected by loops that project into the ER (Lautscham et al., 2001; Miller et al., 
1995; Longnecker 2000). The structure of LMP2A and the CTL epitope positions within its 
sequence is demonstrated in Figure 5.2. EBV infects resting B-cells driving them to 
become activated proliferating lymphoblasts (Thorley-Lawson 2001). LMP2A is one of the 
viral proteins that enable EBV to exploit pathways of B-cell differentiation (Thorley-Lawson 
2001). Epitopes derived from LMP2A are either TAP-dependent or independent. This was 
determined using a particular human T2 cell line where TAP1 and TAP2 genes were 
deleted but which still managed to process and present LMP2A protein indicating TAP-
independent pathway (Lee et al., 1996; Khanna et al., 1996). An additional epitope, FLY, 
was found to be TAP-independent and only generated in the presence of 
immunoproteasomes upon IFNγ exposure (Lautscham 2003). 
Primary fibroblasts were transfected or co-transfected with mRNA encoding LMP2A in the 
presence or absence of AdE1A. CTLs specific for the epitope peptides CLGGLLTMV 
(CLG), FLYALALLI (FLY) and IEDPPFNSL (IED) (all being HLA A*0201-restricted 
epitopes) were used (Lautscham et al., 2001, 2003). IED is a TAP-dependent, 
proteasome-dependent epitope, CLG is a TAP-independent, proteasome-dependent 
epitope and finally FLY is a TAP-independent, immunoproteasome-dependent epitope 
(Figure 5.2B). AdE1A mRNAs co-transfected with LMP2A include 12SAd5E1A, 
13SAd5E1A, 12SAd12E1A, 13SAd12E1A, 12SAd5E1A L19/20S and 13SAd5E1A 
L19/20S. Transfected fibroblasts were incubated with the appropriate T-cells, and the 
amount of IFNγ released was measured by ELISA assay (as explained in section 2.5.4). 
In the case of the FLY epitope, the fibroblasts were either pre-treated with 400 U/ml of 
IFNγ for 72 hrs before transfecting with RNA and incubating with CTLs, or transfected first 
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with the appropriate mRNAs for 12 hrs followed by another 12 hrs of IFNγ treatment, 
before exposure to CTLs.  
The results have shown that in comparison to LMP2A alone, there was a significant 
decrease of CTL recognition of both IED and CLG epitopes after 12 hrs (Figure 5.3A). 
IED-specific CTL activity has significantly reduced from 2902 pg/ml IFNγ release 
absorbance units to 952, 1183, 816 and 637 pg/ml in the presence of 12SAd5E1A, 
13SAd5E1A, 12SAd12E1A and 13SAd12E1A respectively, whereas in the 12S and 13S 
L19/20S Ad5E1A mutants, this inhibition was relieved to 1976 and 1399 pg/ml 
respectively (Figure 5.3A). The same pattern was also observed with the CLG-specific 
CTLs where, in comparison to LMP2A alone, there was also a drastic inhibition of CTL 
activity from 1396 pg/ml IFNγ-release to 237, 481, 254, and 145 pg/ml in the presence of 
12SAd5E1A, 13SAd5E1A, 12SAd12E1A and 13SAd12E1A respectively. This inhibition 
was again reduced with the 12S L19/20S Ad5E1A mutants where the value was 766 
pg/ml (Figure 5.3A).  However, the mutation did not affect the inhibition capability of 13S 
L19/20S Ad5E1A mutant. The ELISA data was also expressed relative to actin (Figure 5.3 
C and D). The data pattern however remained unchanged compared to Figure 5.3A. 
With regards to the FLY-specific CTLs, there was difficulty in acquiring recognition of the 
transfected fibroblasts. There was little or no CTL activity observed regardless of whether 
the IFNγ treatment was carried out before or after electroporation.  The FLY-specific CTLs 
were functional as results from incubation with peptide loaded LCLs have shown strong 
CTL activity (Figure 5.4A), which may indicate that the problem is due to fibroblast antigen 
presentation. Interestingly, the efficiency of electroporation was much reduced in the 
event of IFNγ pre-treatment of fibroblasts (Figure  5.4B).  
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                                                                                 Modified from Lautscham et al., 2001 
 
 
 
Epitope Proteasome-dependent 
Immunoproteasome
-dependent TAP-dependent 
CLGGLLTMV (CLG) Yes No No 
IEDPPFNSL (IED) Yes No Yes 
FLYALALLI (FLY) No Yes No 
 
 
 
 
Figure 5.2  Diagrammatic representation of LMP2A in the cell membrane 
A. Shaded boxes represent the positions of the CTL epitopes sequences. Each epitope is 
identified by the first three letters of their amino acid sequence and their corresponding  
HLA class I restricting alleles. B. Table summarizing the proteasome, immunoproteasome 
and TAP dependencies of the epitopes used in the study. 
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Figure 5.3  AdE1A reduces target cell recognition by cytotoxic CD8+ T-cells 
(CTL) 
A. ELISA assay measuring CTL activity by the amount of IFNγ released. ELISA assays 
were undertaken according to protocol in section 2.5.4. Absorbance measured at 450 nm. 
*, ϴ, x, #, ‡ (P<0.05), † (P>0.05). . Data are means +/- SEM from three repeats. B. Western 
blot analysis of 50 μg target cell lysates electroporated with mRNAs encoding the listed 
proteins. C. Densitometric evaluation of the actin blot from B. D. CTL activity relative to 
actin. 
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Figure 5.4  Testing IED and FLY CTL recognition of the appropriate epitopes 
ELISA assay measuring CTL activity by the amount of IFNγ released. ELISA assays were 
undertaken according to protocol in section 2.5.4. A.  FLY T-cells were either incubated 
on their own or in the presence of FLY/control peptide-loaded LCLs in order to test 
specificity. B. Fibroblasts were either electroporated first followed by 12 hrs of 400 U/ml 
IFNγ treatment or treated with IFNγ for 24hrs then electroporated; prior to use in ELISA. . 
Data are means +/- SEM from three repeats. 
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5.2.1.3 CD107a staining of T-cells (CTLs) 
CTL target recognition leads to IFNγ release and cell killing. The ELISA assay described 
above assesses CTL activity by measuring IFNγ release. This, however, is not a 
confirmation of cell killing, which is verified via the widely used chromium release assay. It 
uses the concept of labelling cells with Chromium (51Cr) followed by incubation with the 
appropriate CTLs; in the event of killing, chromium is released into the surrounding 
medium and the amount of radioactivity measured using a gamma counter, hence greater 
cell killing leads to increased radioactivity readings. This procedure was attempted; 
however, it was unsuccessful because the cells were labelled 24 hrs after electroporation 
by which time LMP2A expression was greatly reduced. Additionally, electroporation of the 
fibroblasts following labelling gave rise to high background values as electroporation 
generates pores in the cell membrane; so chromium release assay in this case was not 
feasible.  
Another way to assess cytotoxic killing is by CD107a staining. CD107a is a membrane 
glycoprotein that is a functional marker of CTL degranulation following stimulation (Betts 
and Koup 2004). CTLs degranulate after recognition of a peptide-MHC class I complex on 
a target cell. Hence, for the next experiment, fibroblasts were transfected by mRNA 
electroporation with LMP2A mRNA with or without 12SAd5E1A, 13SAd5E1A, 
12SAd12E1A, 13SAd12E1A, 12SAd5E1A L19/20S and 13SAd5E1A L19/20S mRNAs. 
This experiment was carried out simultaneously with the ELISA experiment described 
above. The results, from the IED-specific CTLs, reveal that there was a reduction in 
CD107a-expressing cells in the presence of AdE1A. CD107a expression was reduced 
from 50.6% (LMP2A on its own) to 31.8%, 22.9%, 18.9% and 8.25% in the presence of  
12SAd5E1A, 13SAd5E1A, 12SAd12E1A and 13SAd12E1A respectively (Figure 5.5). 
Double mutants 12SAd5E1A L19/20S and 13SAd5E1A L19/20S reduced CD107a 
expression to 25.5% and 15.5% respectively. Despite this, the western blot data (Figure 
5.2B) may need to be taken into account when considering the exact effect of AdE1A on 
CD107a expression due to the variability in expression following electroporation with the 
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different constructs of mRNA (refer to discussion below). CD107a staining was intended 
to cover all three CTL clones representing different antigen processing pathways, i.e. IED, 
CLG and FLY-specific CTLs (TAP-dependent, proteasome-dependent, TAP-independent, 
proteasome-dependent and TAP-independent, immunoproteasome-dependent epitopes 
respectively). However, CLG-specific CTLs had very low viability at the outset and not 
enough viable cells remained at the end of the CD107a staining to analyse via flow 
cytometry. Yet, due to the high sensitivity of the ELISA assay, results were obtained from 
as few as 1000 CTLs despite the low viability. As explained previously, no experiments 
could be carried out with the crucial FLY-specific CTLs due to problems with recognition of 
the transfected cells by CTLs.  
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Figure 5.5 AdE1A reduces target cell recognition by CTLs 
One thousand IED-specific T cells were incubated with 50000 fibroblasts electroporated 
with mRNA encoding the listed proteins. They were left at 37°C for 12 hrs after which cells 
were stained for surface CD107a molecules according to protocol in section 2.5.6. For 
Western blot analysis of fibroblast lysates, refer to Figure 5.3B. Experiment undertaken 
once. 
 
 
 
 
 
 
 
 
 
 
Effect of AdE1A on surface expression levels 
of CD107A in cytotoxic CD8+ T-cells (CTLs) 
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5.3    Discussion   
In the previous two chapters, it was shown that AdE1A inhibits immunoproteasome 
expression as well as binding to the MECL-1 immunosubunit. In this chapter, the effect of 
this binding on the catalytic function of the immunoproteasome was addressed, 
investigating the trypsin, chymotrypsin and caspase activity as well as the overall effect on 
the presentation of antigens to CTLs. 
Prior to this study, research into the effect of AdE1A on the immunoproteasome mainly 
focused on the down-regulation of expression of the individual immunosubunits. This was 
seen in adenovirus transformed human and mouse cells (Vertegaal et al., 2003; Rotem-
Yedudar et al., 1996) and in AdE1A transfected cells (Chatterjee-Kishore et al., 2000). 
Results from the present study so far have expanded on both these aspects (chapter 4). 
Subsequently, for the first time, the effect of adenovirus infection on the level of 
immunosubunit expression was also examined (chapter 4). In chapter 3, the direct binding 
of AdE1A to immunoproteasomes and the binding sites involved in this interaction were 
studied. Nevertheless, the effect of AdE1A on the catalytic activity of the 
immunoproteasome and the potential repercussions of this for antigen processing has 
never previously been examined. There is data, however, of other viruses affecting the 
proteolytic activities of the immunoproteasome. For instance, hepatitis C virus NS3 non-
structural protein binds to the LMP7 immunosubunit, as a result repressing its activity and 
that of the immunoproteasome (Yee-Ling Khu et al., 2004). HIV-1 Tat protein binds to 
both MECL-1 and LMP7 and is able to disrupt its proteolytic activity (Apcher et al., 2003). 
It has been hypothesized that the inhibitive effect of various viral proteins either in terms of 
immunosubunit expression at the transcriptional level or by direct binding to any of the 
immunosubunits skews the stoichiometry of the immunoproteasomes leading to 
modulation of overall enzymatic activity. Attempts were made to test this theory in this 
study by examining the direct effect of AdE1A on immunoproteasome activity.  
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In vitro immunoproteasome assays assessing the trypsin, chymotrypsin and caspase 
activity (via appropriate substrates) in the presence or absence of AdE1A were 
undertaken. This experiment, however, had a major setback. Even though there seems to 
be down-regulation of chymotrypsin activity in the presence of AdE1A, the same outcome 
was also observed with control GST protein (Figure 5.1A and B) and BSA that were used 
as negative controls, indicating that this was not an AdE1A-related inhibition. It is not 
known why the negative control proteins also reduced the proteolytic activity.  Attempts 
were made to reduce the amount of AdE1A protein in a titratable manner to address 
concerns of over-saturation, however, the presence of either AdE1A or GST at a 
concentration as low as 0.05 µg also inhibited the chymotrypsin activity (Figure 5.1C). 
To overcome this problem, an in vivo approach was undertaken whereby the effect of 
AdE1A on the presentation of known epitopes (derived from the EBV protein LMP2A) 
(Figure 5.2), to their corresponding antigen specific CD8+ T-cell clones was studied. Three 
EBV-derived CTL epitopes with known pathways through the antigen processing 
machinery were used (Figure 5.2A and B) and these are: CLGGLLTMV (CLG), TAP-
independent, proteasome-dependent epitope; IEDPPFNSL (IED), TAP-dependent, 
proteasome-dependent epitope (Lautscham et al., 2001) and FLYALALLI (FLY), TAP-
independent, immunoproteasome-dependent epitope (Lautscham et al., 2003). Previous 
studies have shown that AdE1A, specifically from Ad12, down-regulates TAP1 and TAP2 
expression in adenovirus transformed cells (Rotem-Yehudar et al., 1994, 1996; Vertegaal 
et al., 2003); hence using EBV-derived epitopes that may be either TAP dependent or 
independent should allow us to identify if any of the experimental outcomes may be due to 
potential inhibition of the TAP proteins rather than an effect on the 
proteasome/immunoproteasome directly. This should also provide further insight into the 
role of the TAP proteins in antigen presentation. Similarly, study of the FLY epitope should 
make it possible to study the effect of AdE1A on the immunoproteasome and antigen 
presentation without the involvement of the TAP proteins.  
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Primary fibroblasts were transfected or co-transfected with mRNA encoding the EBV 
protein LMP2A in the presence or absence of AdE1A. CTL activity was measured by the 
ELISA assay that quantifies the amount of IFNγ released. The data show that the 
presence of 12SAd5E1A, 13SAd5E1A, 12SAd12E1A and 13SAd12E1A reduced IED 
epitope presentation as demonstrated by reduced CTL activity in comparison to when 
LMP2A is transfected alone (Figure 5.3A). Mutations L19/20S of Ad5E1A have relieved 
this inhibition to some extent, suggesting that the N-terminal region of AdE1A is involved 
in this repression. Similar data were also observed with the CLG epitope, indicating that 
this is not due to AdE1A inhibition of TAP protein expression, but rather potentially due to 
AdE1A affecting the 20S proteasome. However, as with the previous experiments in 
chapter 4 studying the effect of AdE1A on surface MHC class II expression, there was 
great difficulty in achieving equal levels of AdE1A protein expression following 
electroporation with the different constructs of mRNA. As mentioned before, although 
mRNA electroporation is highly efficient, it is highly susceptible to degradation and 
exhibits different levels of expression depending on its stability; so again the western blot 
data (Figure 5.3B) was taken into account when considering the effect of AdE1A on 
antigen presentation. The graph (Figure 5.3A) displays the raw data and was thus not 
adjusted according to the expression shown on the Western Blots (Figure 5.3B). The 
above results may be partly due to AdE1A targeting the 20S proteasome. It is already 
known that AdE1A targets 20S and 26S proteasome by binding to the ATPase (S4 and 
S8) and non-ATPase (S2) components of the 19S complex (Grand et al., 1999; Turnell et 
al., 2000; Zhang et al., 2004) as well as several α subunits of the 20S proteasome (Rasti 
et al., 2006). Nevertheless, it may be premature to come to this conclusion without further 
experiments to rule out involvement of other components of the antigen processing 
machinery. Other components that may be targeted by AdE1A; for instance calreticulin, 
calnexin and ERp57, chaperone proteins present in the endoplasmic reticulum that are 
involved in the folding and assembly of MHC class I molecules (Zhang and Williams 
2006), as well as tapasin, a glycoprotein involved in mediating interaction between MHC 
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class I and the TAP complex leading to the loading of peptides onto the newly assembled 
MHC class I molecule (Lankat-Buttgereit and Tampé 2002; Zhang and Williams 2006). 
Tapasin expression was in fact found to be reduced in Ad12 transformed rat cells 
(Vertegaal et al., 2002) so, potentially, affecting CTL recognition. Introduction of minigene 
constructs that express minimal epitopes (Lautscham et al., 2001), hence bypassing the 
role of proteasomes in order to study the proteasome independent, TAP 
dependent/independent pathways, may provide further understanding of other antigen 
processing components involved. 
The double mutations at residues 19 and 20 have affected AdE1A’s ability to repress CTL 
recognition of target cells. These double mutations are located at the N-terminus of 
AdE1A, a region which is important in mediating its transcriptional regulation effects.  In 
chapter 3, it was shown that the same mutations also affected the ability of AdE1A to 
repress surface MHC class II repression. These mutations have also eliminated AdE1A 
binding to CBP, p300, TATA binding protein (TBP), S4, S8, hGcn5, P/CAF and Ran 
proteins (Rasti et al., 2005). This signifies its important role in mediating the interactions of 
the AdE1A N-terminal region. In this study (chapter 4), it was found that the N-terminal 
region was involved in binding to the catalytic subunits of the 20S proteasome. If it was to 
be concluded that reduction in CTL recognition in the presence of AdE1A was due to 20S 
proteasome inhibition then it may be possible to partly relate this to the binding of AdE1A 
to the catalytic β subunits of the 20S proteasome. 
The EBV-derived CTL epitope FLY is immunoproteasome-dependent and TAP-
independent, which makes it ideal to study AdE1A’s effect on immunoproteasome activity 
and the overall antigen presentation. However, there was considerable difficulty in 
acquiring recognition of the transfected fibroblasts. These problems seem to stem from 
the expression of protein or presentation of the epitope as the FLY-specific CTLs were 
found to be functional after incubation with peptide loaded LCLs (Figure 5.4A) Fibroblasts 
were either pre-treated with IFNγ for 48 hrs followed by electroporation with LMP2A 
mRNA, then plated out with T-cells or they were electroporated first then immediately 
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treated with IFNγ for 12 hrs before being washed and incubated with T-cells in culture 
plates. Either way, no CTL activity or IFNγ release was recorded. From optimisation 
experiments, it was found that LMP2A expression declines after 24 hrs, whereas 
immunoproteasome expression and assembly may depend on the cell line, and since 
primary fibroblasts are not natural antigen presenting cells, the expression and assembly 
of immunoproteasomes may take longer. So the issue here may lie with getting optimum 
LMP2A, AdE1A and immunoproteasome expression at about the same time in the cell. 
However, this may be difficult as expression from the very unstable mRNA makes LMP2A 
half-life very short and continuous IFNγ treatment for a longer period may be required to 
replace all the 20S proteasomes with immunoproteasomes; additionally, the half-life of 
immunoproteasomes is known to be shorter than that of 20S proteasomes (Heink et al., 
2005). An alternative way to deliver the LMP2A and AdE1A genes through a recombinant 
vaccinia virus (Lautscham et al., 2001, 2003) was ruled out due to concerns that using a 
virus might produce some side-effects that may affect the accuracy of the data. However, 
on retrospective examination, this may have been a better option, and thus a possibility 
for a future experiment. Interestingly, cells that were pre-treated with IFNγ prior to 
electroporation have reduced presentation of epitopes to CTLs (Figure 5.4B).  This may 
indicate that IFNγ treatment affects electroporation efficiency. 
In order to assess CTL activity, CD107a staining was carried out. CD107a is a functional 
marker of CTL degranulation (Betts and Koup 2004) that occurs after CTLs recognise 
peptide-MHC class I complexes on the target cell and become stimulated. CD107a 
staining was complementary to the ELISA. The same electroporated cells were used for 
both experiments so the release of IFNγ in the ELISA can be linked to CTL degranulation 
or cytotoxic killing. The data revealed that, compared to LMP2A alone, there was a 
significant decrease in CD107a expression in the presence of 12SAd5E1A, 13SAd5E1A, 
12SAd12E1A and 13SAd12E1A (Figure 5.4). As with the ELISA, the western blot data 
(Figure 5.2B) should be taken into account when considering AdE1A’s effect on the 
CD107a expression. There seems to be an increased inhibition of CTL activity by 
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13SAd5E1A and 13SAd12E1A compared to the corresponding 12S proteins. As AdE1A 
binds to the catalytic subunits of the 20S proteasome through its N-terminal and CR3 
regions, and since 12SAdE1A proteins do not contain CR3, this may point to reduced 
interaction, hence weaker impact of the 12S than 13SAdE1A proteins.   
In contrast to the ELISA, the double mutations at residues 19 and 20 did not have an 
effect on the ability of AdE1A to reduce CD107a staining. The double mutants have 
caused a reduction in CD107a expression nearly equal to w.t. AdE1A. This means that 
the double mutations affect IFNγ release from CTLs, preventing the stimulation of an 
immune response, while at the same time not interfering with the CTLs degranulation. 
CD107a staining, unlike the ELISA assay, is less sensitive and requires significant 
numbers of viable T-cells to analyse by flow cytometry. The CLG-specific CTLs had very 
low viability at the outset and unfortunately, at the end of the staining, not enough viable 
cells were acquired for flow cytometry analysis, so data from this was unfortunately not 
obtained.  
Further experiments are still required to study the effect of AdE1A on immunoproteasome 
activity and antigen presentation. With the limited time available for this project, not all 
aspects have been covered in this study, and this may be a topic for a future investigation. 
For instance, the inclusion of the FLY epitope in both ELISA and CD107a staining is 
crucial to understand the effect of AdE1A on an immunoproteasome dependent antigen 
processing pathway. The experiments may be duplicated by using two different CTL 
clones/epitopes for each pathway. This would ensure consistency of the observed data. 
The effect of AdE1A on other components of the antigen processing machinery need to 
be investigated further by including minigenes as mentioned above. The quest for the 
appropriate negative control to equalise mRNA load has involved using mRNA encoding 
GFP and luciferase. However, GFP is a fluorescent protein and this interfered with flow 
cytometry analysis and luciferase protein on the other hand increased CTL background 
activity in the absence of LMP2A. Perhaps in a future experiment, an mRNA control 
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encoding actin may be attempted. Additionally, it would also be of interest to examine the 
effect of AdE1A on the composition of the immunoproteasome. 
In this chapter, the effect of AdE1A on immunoproteasome activity and antigen 
presentation was examined. Results from the ELISA and CD107a assays have shown 
that the presence of AdE1A reduced target cell recognition by CTLs. This may be down to 
AdE1A hindering 20S proteasome activity leading to reduced epitope generation but 
further tests need to be carried out to confirm this observation.       
 
 
~ 187 ~ 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
 
 
 
 
 
 
 
 
 
GENERAL DISCUSSION AND FUTURE 
WORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
~ 188 ~ 
 
AdE1A is the first viral protein to be expressed following infection. It targets multiple 
cellular proteins and pathways, specifically those that are involved in transcription (Frisch 
and Mymryk 2002, Gallimore and Turnell 2001). It has recently been shown that AdE1A 
also targets components of the antigen processing machinery, such as the 20S 
proteasome (Rasti 2005, 2006) which is the source of the major non-lysosomal proteolytic 
activity in the cell; ATPase and non-ATPase components (S4/S8 and S2 respectively) of 
the 19S complex (Grand et al., 1999; Turnell et al., 2000; Zhang et al., 2004;); MHC class 
I surface expression in Ad12 transformed cells (Bottley et al., 2005; Vasavada et al., 1986; 
Schrier et al., 1983; Ackrill and Blair 1988) and tapasin (reviewed by Horwitz 2004; 
Bennett et al., 1999, Vertegaal et al., 2002). In light of these findings, in this study, it was 
decided to expand this further to include an examination of the effect of AdE1A on the 
immunoproteasome as well as MHC class I and class II surface expression in response to 
transfection, viral infection and in adenovirus transformed cells. The cellular response to 
IFNγ and the recognition of target cells by CTLs in the presence of AdE1A was also 
addressed. Additionally, previous research into this area had heavily focused on the use 
of rodent cells so this study was also an opportunity to study such responses in human 
cells. 
 
6.1   Interaction of AdE1A with the immunoproteasome components 
Chapter 3 examined whether AdE1A binds directly to the immunoproteasome. Studies to 
date focused mainly on immunsubunit expression in adenovirus transformed cells and to a 
limited level, in the case of AdE1A transfection, but not on AdE1A binding. It was shown in 
this study that AdE1A binds to the immunoproteasome (Figure 3.1), specifically to MECL-
1, not LMP2 or LMP7 (Figure 3.2). This was followed by a series of pull down assays to 
identify residues within these two regions of AdE1A that are important in the interaction 
(Figure 3.5 and 3.7). Similarly, AdE1A also binds to the 20S proteasome (Figure 3.9), and 
interestingly its interaction was stronger to β1 and β5 (homologues to LMP2 and LMP7 
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respectively) than the MECL-1 homologue β2 (Figure 3.10). In addition, as with MECL-1, 
the β subunits also bind to the N-terminal region and CR3 regions of AdE1A.  The N-
terminal region and CR3 play an important role in mediating the interactions of AdE1A 
with cellular proteins (Gallimore and Turnell 2001). There is already evidence that those 
two regions are involved in the interaction with many components of the antigen 
processing machinery so it is not surprising that this may also include the immunosubunits 
and their constitutive homologues in the proteasome. It has already been established that 
the N-terminal region interacts with STAT1 (Look et al., 1998), S4 and S8 (Turnell et al., 
2000; Zhang et al., 2004) as well as other proteins that are involved in transcription, for 
instance CBP/p300 and TBP (Rasti et al., 2005). On the other hand, the CR3 region is 
involved in the binding to several α subunits of the 20S proteasome (Rasti et al., 2006) as 
well as transcriptional regulators such as Mediator (Wang and Berk 2002; Ablack et al., 
2010). Additionally, the binding sites for MECL-1 have been defined within these AdE1A 
regions to identify specific residues involved in the interaction. The residues identified 
were similar to those studied by Rasti et al., (2004, 2005) that affected binding to several 
other cellular proteins. The study of the point mutations across the N-terminal region has 
provided more information on the interaction with MECL-1 and the β subunits by defining 
the role of each residue, however, the CR3 deletion mutants only defined the role of short 
regions rather than specific amino acids. The data (Figure 3.7 and 3.11) showed that all 
the deletion mutants to varying extent have affected the interaction with MECL-1 and the β 
subunits,  
 
6.2   Regulation of immunoproteasome and MHC expression by AdE1A 
The effect of AdE1A on the expression of the immunoproteasome components LMP2, 
LMP7 and MECL-1 and on cell surface MHC class I and class II expression was studied. 
It was seen that AdE1A down-regulates the expression of all immunosubunits during 
transfection and viral infection (Figure 4.1, 4.6 and 4.7), whereas in adenovirus 
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transformed cells this was more pronounced in Ad12 transformed cells compared to those 
transformed by Ad5 (Figure 4.8). The latter data were in agreement with previous studies 
that indicated down-regulation of the immunosubunits in Ad12 transformed rat cells 
(Vertegaal et al., 2003, Rotem-Yedudar et al., 1996). This study, for the first time, looked 
at the effect of AdE1A transfection and viral infection on immunosubunits levels; there has 
been little research to date examining this, with the exception of one study that found 
repression of LMP2 transcription following AdE1A transfection (Chatterjee-Kishore et al., 
2000). In most somatic cells, the immunoproteasome components and MHC class II are 
expressed in response to IFNγ via the JAK/STAT1 pathway (refer to section 1.5). The 
cellular response to IFNγ was found to be inhibited by AdE1A transfection (figure 4.17), 
during Ad12 infection (figure 4.16) and in adenovirus transformed cells (figure 4.18). This 
may partly be due to AdE1A interfering with the phosphorylation of STAT1 protein (figure 
4.19). Previous finding have revealed that AdE1A targets STAT1 inhibiting its function 
(Zhang et al., 1996; Look et al., 1998; Leonard and Sen 1996). The same reasoning can 
also be applied to the inhibition of MHC class II surface expression by AdE1A (figure 4.11, 
4.13 and 4.15). The fact that AdE1A double mutations at residue positions 19 and 20 in 
the N-terminal region affect the ability of AdE1A to inhibit MHC class II surface expression 
(figure 4.13) indicate this being a case for repression of STAT1 phosphorylation. STAT1 
binds to the N-terminal region of AdE1A (Look et al., 1998), and mutations at those 
residues have proved to abrogate binding to several other cellular proteins (Rasti et al., 
2005), hence indicating their importance in mediating interactions. However, this was not 
consistent with the data from figure 4.17, which showed the same mutants down-
regulating cellular response to IFNγ at a level equal to w.t., hence not corresponding to 
the outcome on MHC class II levels (figure 4.13).  To understand if this down-regulation of 
both immunosubunit and MHC class II is due to interference with STAT1 phosphorylation, 
or AdE1A targeting multiple points of the JAK-STAT pathway or AdE1A binding to other 
transcriptional components at the promoter is a requirement for future study. This may 
also include assessing the binding affinity of the AdE1A double mutant to STAT1. If it is 
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proven not to bind, it would be interesting to investigate if it affects immunosubunit 
expression after transfection into cells. Furthermore, IRF-1 protein is found to be crucial in 
initiating and regulating transcription of LMP2, LMP7 and MECL-1 (White et al., 1996; 
Namiki et al., 2005; Foss and Prydz 1999), so the relationship of AdE1A to this protein 
can also be investigated. MHC class I is constitutively expressed in all somatic cells. 
Results from this study have shown that surface MHC class I expression was unaffected 
following AdE1A transfection and viral infection (Figure 4.10A-D, 4.12), whereas the 
outcome was more complex in adenovirus transformed cells where MHC class I was 
expressed regardless of IFNγ in the Ad5E1A expressing cells. However, in the Ad12 
transformants, MHC class I was generally reduced prior to IFNγ treatment but was 
expressed afterwards (Figure 4.14B). The outcome from the viral infection experiments 
has contradicted previous data that showed down-regulation of MHC class I following Ad5 
infection (Burget et al., 1987; Wold et al., 1999; Lippe et al., 1991). However, it was in 
agreement with one study by Routes and Cook (1990) that showed similar results to this 
study. The exact effect of AdE1A on MHC class I expression has yet to be clarified.  
Retrospectively examining the effects of AdE1A on the surface MHC class I and class II 
levels against the backgrounds of adenovirus transformation, infection and AdE1A 
transfection have revealed some inconsistencies (Table 4.2). In Ad12 transformed cells, 
MHC class I levels were down-regulated while it remained unchanged in cells infected or 
transfected by Ad12 virus and Ad12E1A respectively. Each of the three systems offer very 
different setting, and thus are not strictly comparable. For instance, during Ad5 infection, 
the transportation of class I molecules to the cell surface is impaired by E3 (Wold and 
Tollefson 1999; Williams et al., 2004) leading to the down-regulation of MHC class I, 
whereas in Ad5E1 transformants, no E3 is expressed so the levels of MHC class I remain 
unchanged (Williams et al., 2004). Hence, different outcomes on MHC levels can be 
observed with the same serotype. Additionally, a study addressing the effect of AdE1A on 
insulin receptor substrate 4 (IRS-4), has shown that IRS-4 was only detected in 
13SAd5E1A-expressing A549 cells but not  in Ad12E1A and 12SAd5E1A expressing cells 
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(Shimwell et al., 2009). However, no effect on IRS-4 expression was observed in A549s 
transfected or infected with AdE1A and Ad5 w.t. virus respectively (Shimwell et al., 2009). 
In addition, it was found that early passage 13SAd5E1A-expressing A549s do not express 
IRS-4 but over time in culture expression was markedly increased. It was suggested that 
stable but not transient expression of 13SAd5E1A is required for IRS-4 overexpression 
(Shimwell et al., 2009). This concept may be applied to this study with regard to MHC 
class I expression. It can be hypothesized that stable expression of Ad12E1A in the 
transformed cells caused down-regulation of MHC class I surface expression, whereas 
there was no change in the infected and transfected cells. Furthermore, certain aspects of 
the experiments may need to be improved. For instance, during flow cytometry analysis, 
dual staining (for AdE1A and MHC class I/II) may be suggested in order to examine MHC 
surface levels in selected AdE1A positive cells after infection and transfection. The fact 
that no change in MHC class I levels was observed in all Ad5/Ad12 transfected and 
infected cells may be due to the fact that any significant effect on MHC class I levels is 
diluted within a whole population of non-AdE1A positive cells.  On the other hand, 
infection by Ad5 has not caused any effect on MHC class II surface expression, whereas 
there was down-regulation after transfection and transformation.  An experiment involving 
a viral titration may be required to investigate this further.  
Comparing Ad5 and Ad12, the latter is highly oncogenic whereas the former is not 
(Trentin et al., 1962; Yabe et al., 1962, 1964). This correlates with Ad12 ability to down-
regulate MHC class I in the adenovirus transformed cells (Schrier et al., 1983; Ackrill and 
Blair 1990; Friedmann and Ricciardi 1988) enabling the cell to escape immune system 
recognition and thus contributing to the induction of tumours in new-born rodents (Trentin 
et al., 1962; Yabe et al., 1962, 1964). In the present study, it was found that Ad12 
transformation also down-regulated LMP2 and LMP7 immunosubunits after transformation 
whereas Ad5 did not have any effect.  Past studies have attributed Ad12 oncogenicity on 
a 20 amino acid alanine-rich segment that is unique to the serotype (Telling and Williams 
1994). This “spacer” region in situated between CR2 and CR3 and is missing entirely in 
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Ad5E1A. However, it is not clear how this region influences oncogenicity, but it is thought 
that it may not be acting alone; as other studies have revealed that, though the spacer 
region is essential for tumourigenicity, it was not responsible for MHC class I down-
regulation (Williams et al., 2004).  
 
6.3  The effect of AdE1A on immunoproteasome activity and antigen 
presentation 
In the light of the above, results from chapter 3 and 4 showed that AdE1A down-regulates 
immunosubunit expression as well as being involved in direct binding to MECL-1; the aim 
of chapter 5 was to investigate if this has any repercussions on the catalytic activity of the 
immunoproteasome. Initially, an in vitro experiment, in which purified immunoproteasomes 
were incubated with fluorogenic substrates (that assess the trypsin, caspase and 
chymotrypsin activity), in the absence or presence of AdE1A, was undertaken.  However, 
AdE1A as well as irrelevant proteins used as controls, (namely GST and BSA) all caused 
inhibition of the chymotrypsin activity while the caspase and trypsin activities remain 
unchanged (Figure 5.1A-C). The same outcome was also observed with protein quantities 
as low as 0.05 µg. To overcome this problem, an in vivo approach was undertaken 
whereby the effect of AdE1A on the presentation of known epitopes, from the well-
characterised EBV system, to their corresponding antigen specific CD8+ T-cell clones was 
studied. Three EBV-derived CTL epitopes with known pathways through the antigen 
processing system were used and these are: CLGGLLTMV (CLG), TAP-independent, 
proteasome-dependent epitope; IEDPPFNSL (IED), TAP-dependent, proteasome-
dependent epitope (Lautscham et al., 2001) and FLYALALLI (FLY), TAP-independent, 
immunoproteasome-dependent epitope (Lautscham et al., 2003). Previous studies have 
shown that AdE1A, specifically from Ad12, inhibits TAP1 and TAP2 expression in 
adenovirus transformed cells (Rotem-Yehudar et al., 1994, 1996; Vertegaal et al., 2003); 
hence using EBV-derived epitopes that may be either TAP dependent or independent 
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should allow us to identify if any of the experimental outcomes may be due to inhibition of 
the TAP proteins rather than the effect on the proteasome/immunoproteasome alone, 
additionally this could provide further insight into the role of the TAP proteins in antigen 
presentation. Similarly, study on the FLY epitope will make it possible to study the effect of 
AdE1A on the immunoproteasome and the resulting outcome on antigen presentation 
without the involvement of the TAP proteins. All three epitopes are derived from the EBV 
LMP2A protein.  In ELISA and CD107a staining experiments carried out in the presence 
or absence of AdE1A, it was shown that AdE1A inhibits antigen presentation of IED and 
CLG epitopes (Figure 5.2 and 5.3). The observation that there was also a reduction in the 
TAP-independent CLG recognition by CTLs (ELISA) and that the MHC class I expression 
remains unchanged (Figure 3.14) suggests that this may be as a result of AdE1A 
targeting the 20S proteasome. Nevertheless, it may be premature to come to this 
conclusion without further investigations to rule out involvement of other components of 
the antigen processing machinery (see future work). Attempts were made to study the 
effect of AdE1A on the presentation of the immunoproteasome-dependent FLY epitope, 
but there was difficulty in acquiring recognition of the transfected fibroblasts by CTLs.  An 
alternative way of delivering the LMP2A or AdE1A gene via a recombinant vaccinia virus 
(Lautscham et al., 2001, 2003) was ruled out as there were concerns that the use of a 
virus may have its side-effects and hence affecting the accuracy of the data. However, it 
may have been a better option, and hence an option for a future experiment. 
 
6.4  Role of AdE1A in the context of infection and immune evasion 
Like all successful human viruses, adenoviruses have evolved multiple ways to evade the 
host’s immune system. Soon after infection, the early region genes that code for non-
structural, regulatory proteins (E1A, E1B, E2, E3 and E4) are expressed. These re-
programme host cell transcription to create a favourable environment for virus replication 
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(Shenk 1996, Burgert et al., 2002). Evidence so far shows that AdE1A and AdE3 have 
major roles in immune system invasion.  
In this study, it was found that AdE1A down-regulates immunosubunit expression as well 
as having a profound effect on surface MHC class I and class II levels in at least one of 
the backgrounds of infection, transfection or in adenovirus transformed cells. This may 
affect the recognition of the infected cell by the host immune system. However, another 
adenovirus early protein, AdE3, also plays a primary role in immune evasion. The 
adenovirus early transcription unit 3 (AdE3) encodes at least four proteins: E3-gp19K, E3-
14.7K, E3-10.4K/14.5K and E3-11.6K. They are not essential for viral replication although 
they play an important role in facilitating the establishment and persistence of adenovirus 
infection. They reduce the recognition of infected cells by the host immune system, 
allowing the viability of the cell while viral replication continues. E3-gp19K down-regulates 
surface MHC class I expression by inhibiting its transport from the endoplasmic reticulum 
to the plasma membrane (Burgert et al., 1987; Wold et al., 1999, reviewed by Horwitz 
2004).  E3-gp19K also inhibits the loading of peptides by tapasin, as a result reducing the 
amount of peptide presented by MHC class I in infected cells (reviewed by Horwitz 2004; 
Bennett et al., 1999). AdE3-14.7k is a 128 amino acid protein that inhibits TNF-induced 
apoptosis (Gooding et al., 1988). E3-10.4K/14.5K (RID) is a protein complex, consisting of 
RIDα and RIDβ polypeptides (Tollefson et al., 1991), which was found to downregulate fas 
receptors of the death ligands, FAS-L and TRAIL by internalisation into the cell and 
degradation in lysosomes, thus inhibiting apoptosis (Shisler et al., 1997, Tollefson et al., 
1998). It also inhibits TNF-induced apoptosis (Gooding et al., 1991), degrades the 
epidermal growth factor receptor (EGFR) from the cell surface (Tollefson et al., 1991; 
Carlin et al., 1989) as well as inhibiting TNF-induced NF-Kb signal transduction (Friedman 
and Horwitz 2002). The three E3 proteins prevent the infected cell’s recognition by the 
immune system, although there is an additional Ad E3 protein called the AdE3-11.6K (also 
known as the adenovirus death protein, ADP) (Tollefson et al., 1996). This protein is not 
expressed at the early promoter, at the same time as the other E3 proteins, but 
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synthesized later in infection from the major late promoter, seemingly during the death 
and lysis of the cell when the newly formed virus progeny is released (Tollefson et al., 
1996).    
AdE1A on the other hand, targets different components of the antigen processing 
machinery. Previous studies showed that it binds to the 20S proteasomes (Rasti et al., 
2005; 2006), as well as the ATPase and non-ATPase components (S4 and S8; S2 
respectively) of the 19S complex (Grand et al., 1999; Turnell et al., 2000; Zhang et al., 
2004) and STAT1 proteins (Zhang et al., 1996; Look et al., 1998; Leonard and Sen 1996).  
Research has also found that the levels of MHC class I, TAP1, TAP2, tapasin, PA28α and 
PA28β expression is reduced in Ad12E1 transformed cells in comparison to those 
transformed by Ad5, hence enabling them to escape recognition by CTLs as the 
generation of peptides and loading onto MHC complex requires those components 
(Vertegaal et al., 2002, 2003; Rotem-Yehudar et al., 1994). In this study, this was 
expanded to reveal that AdE1A also inhibited immunoproteasome expression during 
infection, transfection and in Ad12 adenovirus transformed cells. It also down-regulated 
MHC class II cell surface expression in those conditions.  
Evading detection by the host’s immune response is an essential strategy for viruses, if 
they are to persist in host cells, enabling them to manipulate the host cell systems without 
detection by the host immune response. As with many viruses, to tackle this, 
adenoviruses have evolved a strategy to target multiple components of the antigen 
processing machinery. It does this by recruiting both AdE1A and AdE3; both proteins 
targeting a different set of components within the machinery. However, there is an 
overlap, in terms of their effect on MHC class I surface expression. This multiple targeting 
provides adenoviruses with backup proteins that may still disrupt antigen processing in the 
event of either viral protein being inhibited, adding an extra challenge to the host immune 
system. Thus, it can be presumed that both AdE1A and AdE3 complement each other in 
their inhibition of the antigen processing and presentation system (Figure 6.1). This 
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multiple targeting by several viral proteins is not unique to adenoviruses as will be seen 
below. 
Strategies for immune evasion by viruses are very diverse. The processes behind the 
disruption of antigen processing and presentation components such as MHC class I, MHC 
class II, TAP proteins and proteasome vary between viruses, and each of these 
components are targeted in multiple ways. For the purpose of this discussion, we will 
compare and contrast the effect on surface MHC class I and class II expression between 
adenoviruses and other viruses. 
 
 
 
 
 
 
 
 
 
 
 
                                                                         Modified from Hansen and Bouvier 2009 
 
Figure 6.1 MHC class I antigen presentation pathway targeted by adenovirus 
proteins 
Schematic diagram illustrating components of the MHC class I antigen processing 
machinery that are targeted by AdE1A and AdE3. 
 
As already mentioned, adenovirus down-regulates surface MHC class I expression mainly 
through the viral protein AdE3, specifically the E3-gp19K, that down-regulates surface 
MHC class I expression by inhibiting its transport from the endoplasmic reticulum to the 
plasma membrane (Burgert et al., 1987; Wold et al., 1999, reviewed by Horwitz 2004).  It 
also inhibits the loading of peptides by tapasin as a result reducing the amount of peptide 
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presented by MHC class I in infected cells (reviewed by Horwitz 2004; Bennett et al., 
1999).  Previous studies have shown that surface MHC class I expression is repressed in 
Ad12 transformed rodent cells in comparison to Ad5 transformed cells (Schrier et al., 
1983; Ackrill and Blair 1990; Friedmann and Ricciardi 1988).  Limited research on 
transformed human cells also showed similar results (Bottley et al., 2005; Vasavada et al., 
1986), and this was further expanded in this study. Previous research also revealed that 
Ad5 infection down-regulates MHC class I surface expression (Burget et al., 1987; Wold 
et al., 1999; Lippe et al., 1991), however this was contradicted in this study, where no 
effect was observed. Its still unclear whether AdE1A has any direct effect on MHC class I 
levels on its own as transfection experiments in this study showed no disruption to surface 
MHC class I expression. 
Other viruses use different ways to tackle MHC class I expression. HIV-1 recruits at least 
three viral proteins to target surface MHC class I expression. Each of these has a different 
method of disrupting the expression and function of MHC class I. For instance, HIV-1 Nef 
protein co-operates with another protein (phosphofurin acidic cluster sorting protein-1) to 
cause endocytosis and recycling of surface MHC class I back into the Golgi network 
(Schwartz et al., 1996; Piguet et al., 2000; Swann et al., 2001). Similarly, HIV-1 Tat 
protein represses MHC class I promoter activity (Howcroft et al., 1993; 1995; Weissman et 
al., 1998; Carroll et al., 1998). The human pathogen Kaposi’s sarcoma-associated 
herpesvirus (KSHV) encodes two viral proteins, K3 and K5, which are able to down-
regulate surface MHC class I expression by faciltating their endocytosis (Coscoy and 
Ganem 2000; Coscoy et al., 2001; Stevenson et al., 2000), followed by their ubiquitination 
and proteolytic degradation (Coscoy et al., 2001; Lorenzo et al., 2002). On the other hand, 
human cytomegalovirus (HCMV) recruits five viral proteins that all assist in evading MHC 
class I presentation: US2, US3, US6, US11 and UL18.  UL18 is a MHC class I homolog 
that is capable of binding to β2m and peptide hence competing with MHC class I (Beck 
and Barrell 1988; Browne et al., 1990; Fahnestock et al., 1995). US2 and US11 cause the 
ejection into the cytoplasm and proteasomal degradation of MHC class I H chains (Wiertz 
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et al., 1996). US3 possesses an ER retention sequence and thus binds to MHC class I 
and prevents its transport to the cell surface (Jones et al., 1996; Lee et al., 2003; Ahn et 
al., 1996). And finally US6 inhibits TAP, therefore inhibiting loading onto MHC class I (Ahn 
et al., 1997; Hengel et al., 1997; Lehner et al., 1997). A summary of the different ways 
MHC class I is targeted by viruses is presented in Table 6.1. 
Viral proteins can be processed and presented to CD4+ T-cells via MHC class II 
molecules. There were no reports studying the effect of adenovirus on MHC class II.  This 
was addressed for the first time in this study, where we found that AdE1A did down-
regulate surface MHC class II expression during transfection, infection and in adenovirus 
transformed cells. However, it has previously been shown that adenovirus disrupts the 
JAK/STAT1 pathway, which is responsible for the induction on MHC class II expression 
(and other proteins involved in immune response) following cellular exposure to IFNγ, and 
specifically targeting STAT1 function (Look et al., 1998; Leonard and Sen 1996; Zhang et 
al., 1996); all this potentially affecting surface MHC class II expression. Various other 
viruses also seem to target the JAK/STAT1 pathway, and a higher proportion of those 
disrupting STAT1 protein (Hegde et al., 2003). Table 6.2  shows different viruses and their 
respective proteins. 
Infection of mouse embryonic cells with adenovirus and analysis of antigen presentation 
with Ad5-specific CTL have revealed that immunoproteasome-containing cells processed 
the adenovirus early 19k 1B protein (E1B)-derived epitope E1B192-200 with increased 
efficiency leading to detection of the virus (Sijts et al., 2000). This group produced a 
tetracycline-regulated mouse cell line that allowed titratable formation of 
immunoproteasomes. When the immunoproteasomes were highly expressed prior to 
infection, it produced optimal cytotoxic T cell (CTL) activation hence the recognition of the 
infected cell by the immune system. In the light of the above data, one can conclude that 
AdE1A may preemptively target immunoproteasome expression early in infection,  
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Table 6.1 Selected viral proteins that interfere with antigen presentation (Petersen 
et al., 2003) 
 
Mechanism Virus Protein 
Down-regulates MHC class I β2m transcription HIV-1 Tat 
Reduces the MHC class I mRNA level 
Bovine 
papillomavirus 
E5 
Inhibits phagocytosis by DCs and thereby interferes with cross-
presentation, but also induces DC maturation and surface MHC 
class I up-regulation 
HIV-1 Secreted Tat 
Blocks 11S regulator association with the proteasome HIV-1 Tat 
Binds TAP in the ER an inhibits peptide translocation HCMV US6 
Prevents TAP transport of peptides into the ER HIV-1 Unknown 
Prevents TAP association with tapasin Adenovirus E3/19K 
Competes for β2m and peptide HCMV UL18 
Reduce level lessens the availability of epitopes from other 
viral proteins 
HIV-1 Rev 
Delays MHC class I egress from the ER HCMV US10 
Retains MHC class I molecules in the ER Adenovirus E3/19K 
Binds MHC class I in the ER and prevents its egress HCMV US3 
Blocks the transport of MHC class I molecules from the ER 
into the Golgi 
MCMV 
gp40 (m152 
product) 
Lowers the surface level of MHC class I by facilitating MHC 
class I/APLP-2 interaction 
Adenovirus E3/19K 
Reduces the quantity of MHC class I protein 
Bovine 
papillomavirus 
E5 
Binds MHC class I in the assembly complex and causes rapid 
turnover of MHC class I 
Murine γ-
herpesvirus 68 
mK3 
Increases MHC class I turnover HIV-1 Vpu 
Ejects MHC class I molecules into the cytoplasm HCMV US2 and US11 
Redirects MHC class I molecules to lysosomes MCMV 
gp48 (m06 
product) 
Retains MHC class I in the Golgi 
Bovine 
papillomavirus 
E5 
Increases endocytosis of MHC class I from the cell surface via 
an allele-specific mechanism 
HIV-1 Nef 
Facilitates MHC class I in the ER and remains associated with 
it at the cell surface 
KSHV K3 and K5 
Complexes with MHC class I in the ER and remains associated 
with it at the cell surface 
MCMV 
gp34 (m04 
product) 
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Table 6.2: Viral inhibition of the JAK/STAT signal transduction, expression of CIITA 
or induction of MHC class II gene expression (Hegde et al., 2003) 
 
Virus Protein Mechanism 
Poxviruses   
Several species e.g. T7, B8-R Soluble homologs of IFN-gR that sequester immune IFN-γ 
Vaccinia VH1 Dephosphorylation of activated STAT1 
Herpesviruses   
Herpes simplex virus 1 Unknown Phosphorylation of Jaks and STAT1 affected 
Human cytomegalovirus Unknown 
Loss of Jak1; inhibition subsequent to nuclear translocation 
of STAT1 dimer 
Murine cytomegalovirus Unknown 
Inhibition subsequent to nuclear translocation of STAT1 
dimer 
Epstein-Barr virus BZLF-1 Reduction in transcription of IFN-gR1 
Varicella zoster virus Unknown Reduction in Jak2 and STAT1 levels 
Paramyxoviruses   
Simian virus 5 V Proteasome-mediated degradation of STAT1 
Mumps virus V? Destabilization of STAT1 
Sendai virus C 
Reduced synthesis and phosphorylation of STAT1; 
destabilization of STAT1 
Human parainfluenzavirus 
3 
Unknown STAT1 phosphorylation affected? 
Nipah virus V 
Complex formation with STAT1 and sequestration in the 
cytoplasm 
Adenoviruses 
E1A or E1A-
dependent events 
Reduction in IFN-gR2 levels; inhibition of function of 
STAT1when bound by E1A; decrease in STAT1 levels; 
inhibition of general transcription 
Other viruses   
HIV Unknown Reduced transcription of NF-YA 
HIV Tat Binds cyclin T1 to inhibit CIITA–pTEFb interactions 
Hepatitis C virus Core Decrease in STAT1 expression 
Murine polyoma virus Large T Binds to Jak1 
Ebola virus Unknown Inhibition before STAT1 dimer formation 
Hepatitis B virus Polymerase? Effects on transactivation function of STAT1? 
 
 
 
Abbreviations: CIITA, class II transactivator; IFN-gR, interferon-g receptor; Jak, Janus kinase; NF-YA, 
nuclear factor-Y subunit A; pTEFb, positive transcription elongation factor-b; STAT1, signal 
transducer and activator of transcription 1. 
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inhibiting its activity and hence avoiding recognition by the immune system. However, it is 
important to note that efficient production of MHC class I antigens of viral origin may not 
be the main function of immunoproteasomes. It was recently revealed that they may also 
have a major role in the maintenance of protein homeostasis and preservation of cell 
viability under conditions of IFN-induced oxidative stress by rapidly degrading nascent 
oxidant-damaged proteins (Seifer et al., 2010). It would be interesting to investigate the 
effect of AdE1A on this aspect of immunoproteasome function in the future. 
 
6.5   Future work 
 Future experiments may include studying if AdE1A associates with components of 
MHC class I molecules or its chaperones. This can be done by Native Band Shift 
assay that analyses shifts by new bands in the event of complex formation, as 
described by Fu et al., (2011). Alternatively, GST-tagged AdE1A can be used in a 
pull-down assay with cell lysates followed by blotting for constitutents of MHC 
class I molecule.   
 Binding sites of MECL-1 within the CR3 region of AdE1A can be investigated by 
generating point mutations across the CR3 in order to obtain further insight into the 
role of each residue. Another future experiment may also include a pull-down 
assay using the N-terminal point mutants and the catalytic β subunits to identify 
their binding sites and comparing it to that of MECL-1. 
 Other components of the antigen processing machinery that may be targeted by 
AdE1A need to be investigated. AdE1A’s effect on chaperone proteins present in 
the endoplasmic reticulum that are involved in the folding and assembly of MHC 
class I molecules such as calreticulin, calnexin and ERp57, (Zhang and Williams 
2006) can be studied. Additionally, association of AdE1A with tapasin, a 
glycoprotein involved in mediating interaction between MHC class I and the TAP 
complex leading to the loading of peptides onto the newly assembled MHC class I 
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molecule (Lankat-Buttgereit and Tampé 2002; Zhang and Williams 2006) can also 
be addressed. Tapasin expression was in fact found to be reduced in Ad12 
transformed rat cells (Vertegaal et al., 2002), so potentially affecting CTL 
recognition.  
 With regard to antigen presentation to CTLs, introduction of minigene constructs 
that express minimal epitope (Lautscham et al., 2001) hence bypassing the role of 
proteasomes in order to study the proteasome independent, TAP 
dependent/independent pathways may provide further understanding of other 
antigen processing components involved if applied to the adenovirus system.  
 Further experiments are still required to study the effect of AdE1A on 
immunoproteasome activity and antigen presentation. With the limited time 
available for this project, a number of aspects have not been covered, which may 
be a topic for future investigation. For instance, the inclusion of the FLY epitope in 
both ELISA and CD107a staining is crucial to understand the effect of AdE1A on 
an immunoproteasome dependent antigen processing pathway. Furthermore, the 
experiments may be duplicated by using two different CTL clones/epitopes for 
each pathway. The quest for the appropriate negative control to equalise mRNA 
load have involved using mRNA encoding GFP and luciferase enzyme. However, 
GFP is a fluorescent protein and this interfered with flow cytometry analysis and 
luciferase protein on the other hand increased CTL background activity in the 
absence of LMP2A. Perhaps, in the future, mRNA encoding for actin could be 
attempted as the negative control. 
 An alternative way of delivering LMP2A and AdE1A genes using a recombinant 
vaccinia virus (Lautscham et al., 2001, 2003) may be attempted in a future 
experiment. This will avoid using the highly unstable and laborious mRNA. 
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6.6   Summary 
Summarising the findings of this PhD project, it was found that AdE1A targets the 
immunoproteasome. AdE1A was shown to bind to the immunoproteasome as well as the 
20S proteasome directly, preferentially binding to MECL-1 (in the immunoproteasome) 
and β1 and β5 (of the 20S proteasome). The binding sites of these subunits were in the 
N-terminual and CR3 regions of AdE1A, and through a series of pull-down assays, the 
binding sites within these two regions have been determined. AdE1A also down-regulates 
the expression of the immunosubunits LMP2, LMP7 and MECL-1 during infection and 
transfection. In adenovirus transformed cell lines, the immunosubunit expression was 
reduced more in Ad12 transformed cells than in the Ad5 transformants. Additionally, MHC 
class I expression was not affected following transfection and infection, however in 
adenovirus transformed cells, it was generally down-regulated to a greater extent in Ad12 
expressing cells prior to IFNγ treatment; MHC class I expression was however restored in 
most of the cell lines following IFNγ treatment. With regards to MHC class II, there was 
little or no expression in adenovirus transformed as well as in Ad5 and Ad12 E1A 
expressing A549 cells; nevertheless, there was significant down-regulation upon 
transfection with AdE1A and during viral infection with Ad12. The phosphorylation of 
STAT1 and cell’s ability to respond to IFNγ was also inhibited. ELISA assay and CD107a 
staining to measure CTL activity in response to target cells have revealed that the 
presence of AdE1A significantly reduced T-cell recognition, hinting at the interference with 
proteasomal activity. 
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